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19F Fluorine
1H Proton
2-HG 2-HydroxyGlutarate
31P Phosphorus
Act Acetate
Ala Alanine
Asp Aspertate
ATP Adenosine TriPhosphate
BALB Bagg ALBino
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DNP Dynamic Nuclear Polarization
EMA European Medicines Agency
FDA Food Drug Administration
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GSH Glutathione
Gua Guanidinoacetate
H&E Hematoxylin & Eosin
HIF Hypoxia Inducible Factor
HR-MAS High Resolution - Magic Angle Spinning
i.p. intra peritonial
IC50 half maximal Inhibitory Concentration
IDH Isocitrate DeHydrogenase 
IR Inversion Recovery
Lac Lactate
Lip Lipids
MCT MonoCarboxylate Transformer
mI Myo-inositol
MM Macro molecules
MR Magnetic Resonance
MRI Magnetic Resonance Imaging
MRS Magnetic Resonance Spectroscopy
MRSI Magnetic Resonance Spectroscopic Imaging
NAA N-acetyl-aspartate
NAAG N-Acetylaspartateglutamate
NADP+ Nicotinamide Adenine Dinucleotide Phosphate
NADPH Reduced Nicotinamide Adenine Dinucleotide Phosphate
p.p.m. parts per million
PBS Phosphate Buffered Saline
PCh Phosphocholine
PCr Phosphocreatine
PE PhosphoEthanolamine
PET Positron Emission Tomography
PFS Progression Free Survival
PHIP ParaHydrogen Induced Polarization
Pi Inorganic Phosphate
Pyr Pyruvate
SABRE Signal Amplification By Reversible Exchange
Scyllo Scyllo-inositol
SD Standard Deviation
SE Spin Echo
Suc Succinate
SWI Susceptibility Weighted Imaging
Tau Taurine
TE Echo Time
TI Inversion Time
TKI Tyrosine Kinase Inhibitor
TR Repetition Time
TSE Turbo Spin Echo
VEGF Vascular Endothelial Growth Factor
WT Wild Type
αKG αKetoGlutarate

General Introduction
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Cancer
The cellular content of normal tissue is controlled by keeping a tight balance 
between proliferation and cell death (apoptosis). In cancerous tissue this steady 
state is lost because of uncontrolled division and growth of cells [1]. The origin of 
cancer lies in the acquired ability of these cells to escape from the control of the 
rate of division [2]. Cells become cancerous by the accumulation of mutations in 
various genes that control cell proliferation. These mutations are predominantly 
inherited, but also may be introduced by external factors like smoking, ionizing 
radiation, small particles like asbestos, or due to diet (e.g. alcohol, fat) or to chemical 
exposure (e.g. arsenic) [3]. Viral infections such as by human papillomavirus can 
inactivate products of tumor suppressor genes like p53 and pRB that result in a 
deregulated cell cycle checkpoint control [4].
 Tumors may be benign or malignant depending on their growth rate and 
behavior. Cells of benign tumors do not have the tendency to spread to other 
parts of the body or invade neighboring tissues. Most commonly these tumors 
exhibit a relatively low metabolic activity and limited local growth. Malignant 
tumors have the tendency to grow fast, possibly even infiltrating neighboring 
tissues and the blood- and/or lymphatic systems leading to new centers of cancer 
growth called metastasis. Malignant tumors are commonly metabolically more 
active when compared to healthy tissue of the same origin. These tumors rely on 
readily available amounts of nutrients and oxygen to maintain their high level of 
metabolism. 
Tumor characteristics
Tumors start as small clusters of cells that exchange oxygen, nutrients and waste 
products with their surroundings by diffusion [5]. If the cell cluster grows beyond 
a diffusion distance of approximately 1 mm in diameter the cells in the core of the 
lesion cannot be supplied with nutrients and oxygen via diffusion anymore. This 
creates a hypoxic micro-environment in these cores that promotes cells which 
have evolved into a state that can handle these conditions [6]. A major event is the 
stabilization at low oxygen levels of hypoxia inducible factor-1alpha (HIF-1alpha), 
a transcription factor that is responsible for activation of hypoxia-sensitive genes. 
This molecular ‘switch’ compound stimulates a range of processes including the 
synthesis of compounds like platelet-derived growth factors (PDGF) and vascular 
endothelial growth factors (VEGF). These are the key actors in the formation of new 
blood vessels via a process called angiogenesis [7]. The VEGF and PDGF signaling 
pathways are a common target for anti-angiogenic cancer therapy. If, in fast 
growing tumors, the rate of vessel formation nevertheless cannot keep up with 
tumor growth this will lead to a chronic  state of hypoxia and, eventually, central 
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necrosis [8]. In addition, hypoxia in tumors is caused by poor supply due to an 
immature, dysfunctional state of the vascular bed. 
 Another hallmark of tumor cells is an adaptation of metabolism to meet the 
requirements of rapid ATP synthesis and biosynthesis of nucleic acids, proteins 
and lipids. Besides aerobic glucose oxidation tumors also, or even preferably, make 
use of glycolysis in which glucose is broken-down into lactate (lactic acid) without 
the use of oxygen even in its presence, a phenomenon called the Warburg Effect [9]. 
It is argued that enhanced aerobic glycolysis is needed to provide substrates for the 
formation of biomass for new tumor cells and simultaneously contributes to a 
sufficient amount of ATP for these cells [10]. The proliferation of tumor cells is 
accompanied by a rise of compounds needed for cell membrane synthesis such as 
choline, myo-inositol and lipids.  
Brain tumors 
Brain tumors are classified based on morphology, genetics and immunologic 
markers in an attempt to construct a cellular classification that is universally 
applicable and prognostically valid [11]. Glioma is a broad category of brain tumors 
Figure 1  Schematic overview of different diffuse astrocytoma grades. A: normal brain, 
B: low-grade astrocytoma (WHO grade II), C: anaplastic astrocytoma (WHO grade III) and 
D: Glioblastoma multiforme (WHO grade IV). Diffuse infiltrative growth is characteristic for 
all grades. In addition, microvascular proliferation and necrosis (dark grey area) emerge in 
the most malignant tumors (D).
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that originate from glial cells. Next to neurons the brain consists of four types of 
glial cells, namely astrocytes, oligodendrocytes, ependymal cells and microglia. 
As such gliomas are also differentiated in to astrocytomas and oligodendrogliomas. 
 Gliomas tend to grow and infiltrate into the normal brain tissue, which makes 
surgical removal very difficult and complicates treatment.
 Next to the general tumor characteristics, described above, gliomas have some 
specific properties.  These tumors may have a compact part with a necrotic core 
(especially high grade tumors), but most characteristic is the (co-)occurrence of an 
infiltrative growth pattern where the tumor invades into pre-existing brain 
structures [12], mostly along blood vessels or white matter tracts.
 This invasive growth pattern makes the tumors hard to visualize and treat. 
A distinctive feature of brain capillaries is the blood brain barrier (BBB), a highly 
selective impermeable cell layer that separates circulating blood from the 
interstitial fluid of the brain. In the angiogenic  part of gliomas this BBB is 
disturbed, which enables local access of therapeutic compounds and MR contrast 
agents via the blood stream. However, in invasive parts where the BBB is intact, 
distribution of systemically delivered compounds to the tumor cells is severely 
compromised.
 Brain tumors also have some specific metabolic features. Most remarkable are 
the recent findings of mutations in the genes encoding the enzymes isocitrate 
dehydrogenase 1 and 2 (IDH1, IDH2). These enzymes catalyze conversions between 
isocitrate and α-ketoglutarate (αKG) within respectively the cytosol and the 
mitochondria. A single mutation from arginine 132 to histidine (R132H) in one 
allele of the gene equips the enzyme with the capability to convert αKG into 
 2-hydroxyglutarate (2-HG). This so-called onco-metabolite accumulates to high 
concentrations (several mM) in cells with the mutated gene. The mutation occurs 
at a high frequency in low grade gliomas and in secondary glioblastomas. Patients 
with this mutation have a better prognosis than patients without [13]. This makes 
detection of the mutation of clinical interest. 
Magnetic Resonance 
Most of the (brain) tumor characteristics described above can only be studied in an 
undisturbed way if the tumors are in their natural environment. Thus for both 
diagnostic and research purposes it is important to have non-invasive methods 
available to image or map these characteristics. This can be achieved with several 
techniques, among which Magnetic Resonance (MR) is one of the most used. As MR 
is also the central technique applied in the work for this thesis a brief description 
of some principles of MR is given below.    
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Zeeman and Boltzmann 
Magnetic Resonance makes use of a nuclear property called spin. Depending on 
the number of neutrons and protons in a nucleus the net total spin can be zero or 
non-zero. For atoms with non-zero spin (e.g. 1H) the spinning motion of the electric 
charge of neutrons and protons inside a nucleus cause it to have a magnetic 
moment. When not subjected to a magnetic field the magnetic moments of spins 
are randomly orientated. 
Figure 2  Isocitrate dehydrogenase 1 (IDH1) and IDH2 are common mutations in glioma. 
Instead of isocitrate being converted to α-ketoglutarate (αKG) with the production of reduced 
nicotinamide adenine dinucleotide phosphate (NADPH), αKG is converted to 2-hydroxyglu-
tarate (2-HG) with the consumption of NADPH. 2-HG builds up to high levels in tumor cells 
and with the mutation.
Figure 3  Representation of a collection of spins in the absence of a magnetic field. The 
vector sum of these spins is zero.
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When placed in a magnetic field the nuclear magnetic moments lose their 
orientation and align parallel (up, spin +1/2) or anti-parallel (down, spin -1/2) with 
respect to the main magnetic field. Due to the Zeeman effect, the energy level of 
the up state in a strong magnetic field is slightly lower (-1/2 E) than the energy level 
of the down state (+1/2 E). 
Depending on the magnitude of the applied magnetic field and sample temperature 
there is a small difference in the population of the up and down states. The 
distribution between both states is governed by the Boltzmann distribution:
Where ΔE is the energy difference between the up and down states, k is the Boltzmann 
constant and T is the temperature in K, h = Plancks constant and ν is the frequency 
of the nucleus in Hz. (e.g. 300 MHz at an applied field strength of 7 T). 
 Suppose we have a sample with 2 million spins with spin quantum number 
1/2. If we place this in a 7 T magnet the spins will be distributed over 2 energy 
levels with a population difference of only 92 spins at 37 °C. This relatively small 
spin population difference is exploited to obtain an MR signal. As can be derived 
from the above equation, the spin distribution difference and thus MR sensitivity 
can only be enhanced by either increasing the main magnetic field strength B0 or 
Figure 4  In the absence of a magnetic field (left side of the figure) spins will have a random 
orientation (similar to figure 1) resulting close to the same amount having a component in 
the up or down orientation. In the presence of a magnetic field (right side of the figure) 
alignment to the magnetic field starts to occur with a slightly larger part of the spin 
population in the up or parallel orientation as compared to the down or anti-parallel 
orientation. The difference in the energy levels, ΔE, between both orientations is proportional 
to the magnetic field B0.
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by lowering the temperature T. There are nevertheless other methods of increasing 
the population difference that do not rely on Boltzmann statistics. Methods relying 
on chemistry include Para-Hydrogen Induced Polarization (PHIP) [14] or Chemically 
Induced Dynamic Nuclear Polarization (CIDNP) [15] where internal molecular 
order or the influence of radicals are exploited to enhance populated states beyond 
the thermal equilibrium. Another method simply called Dynamic Nuclear 
Polarization (DNP) relies on transferring spin polarization from electrons to nuclei 
[16]. These approaches can enhance MR sensitivity by several orders of magnitude. 
The refinement of the DNP technique by using a fast dissolution step allows for a 
variety of in vitro and in vivo applications [17].
Precession 
When placed in a magnetic field the magnetic moments of the nuclear spins 
precess around the direction of the applied magnetic field. The frequency at which 
this precession takes place is called the Larmor frequency (ω) and is the nucleus 
specific gyromagnetic ratio (γ) times the applied field strength (B).
The difference in energy between the two Zeeman energy levels corresponds to the 
energy in the radiofrequency band of the electromagnetic spectrum. If a nucleus 
is subjected to a radiofrequent (RF) pulse with the correct energy E = hν the nucleus 
can flip to the other energy level (from spin up to down or from down to up).  
Figure 5  The difference in the energy levels ΔE between both orientations is proportional 
to the magnetic field B0 and precession frequency ω0. When energy at this frequency is 
applied, a spin from the lower energy state is promoted to the upper energy state, following, 
a spin from the upper energy state will release its energy and relax to the lower state.
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MR experiment and relaxation
Only changing the population of energy levels does not lead to an observable 
situation. It is only when there are transitions from energy levels to other levels 
that a signal can be observed. This can be rigorously described by quantum 
mechanics, but it is easier to describe this in a classical way looking at the total 
magnetic moment of all spins. When spins have quantum number ½ there are 
more spins aligned with the main magnetic field, which results in a macroscopic 
magnetization along the direction of the main field (z) called M. The precessing 
spins have no phase coherence. 
 By applying an RF pulse at the Larmor frequency for a certain duration 
perpendicular to the main field, the macroscopic magnetization M can be rotated 
from the z-direction to the x-y plane (so-called 90° pulse). An RF pulse can also be 
called B1 field. A 90° pulse represents the situation in which the spins are equally 
distributed over the up and down energy levels and have acquired phase coherence 
in the x-y plane in the direction perpendicular to the B1 field.
 The macroscopic magnetization M now precesses in the x-y plane around B0 
and induces an oscillating current in a receiver coil (Faraday’s law). This observable 
signal is called the free induction decay (FID). This principle forms the basis of 
NMR, MRI and MRS [18], [19].
 Due to interactions with each other and energy exchange with the ‘lattice’ the 
spin system will return to its original energy levels and M to its orientation along 
the z-direction (Mz), (a process called T1 relaxation.
Figure 6  (a) A collection of spins in the presence of a magnetic field (analog to the right side 
of figure 3). Each spin precesses around the magnetic field with frequency ω0. (b) When 
summing up all vectors a summed vector M is aligned with the applied magnetic field. 
The orientation of this vector is defined as direction z.
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The signal in the x-z plane is only observable when all spins show precession with 
a similar phase. Due to the different local environment of individual spins the 
phase coherence is lost leading to a faster decay of the signal. This is called T2 
relaxation. If T2 dephasing is caused by effects that cannot be undone by rephasing 
the spins it is called  T2* [20]. 
Both T1, T2 and T2* are characteristic for specific molecules and their surroundings. 
By adjusting MR sequence timings contrast in images can be optimized. 
Magnetic Resonance Imaging (MRI)
In MRI the main nucleus of interest is 1H, which is abundantly present in water 
(H2O) molecules in the body.  The distribution of proton spins of water and their 
relaxation properties are used to create an image. The water concentration of 
tissue is approximately 50 M which results in concentration of 100 M 1H. Thanks 
to this high amount a strong MR signal can be received and high resolution images 
are possible. To produce an image it is necessary to label the water spins spatially. 
This is conventionally done by (transient) magnetic field gradients in the x, y or z 
direction. With such a gradient each location in a particular direction gets its own 
Larmor frequency or phase, which can be encoded in different ways  [21], [22].  In 
MRI only the protons of water, and occasionally of fat, are depicted. The specific 
relaxation of these spin systems in various tissues can be employed to obtain 
images with variable contrast between normal anatomical structures or between 
diseased and normal tissue. 
Figure 7  A 90° RF pulse or B1-field resulting in rotation of M from z to x.
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Contrast agents 
By using so called MR contrast agents the relaxation properties of the 1H spins in 
water can be influenced leading to shorter characteristic relaxation times. This 
concept is exploited to generate contrast between anatomical or cellular structures 
throughout the body. 
 These exogenous agents either predominantly have an effect on T1 relaxation 
or on T2* relaxation. A longitudinal or T1 relaxation effect occurs due to a magnetic 
exchange with water proton spins. T1-shortening contrast agents are mostly based 
on lanthanide series metals (mostly Gadolinium-based). T2*-shortening contrast 
agents disturb the local magnetic field, e.g. (ultra-small) super paramagnetic 
particles of iron-oxide that cause more rapid T2* dephasing. A lot of biological 
information derived from contrast agents is obtained by looking at the distribution 
of the contrast agent. By choosing the appropriate size of the agent particular 
properties of tissues such as perfusion or vascular density can be visualized and 
quantified. The tissue uptake of the contrast agent also depends on the permeability 
of the vascular wall. A particular case is the brain as routinely used contrast agents 
do not efficiently pass the blood brain barrier [23].
Magnetic Resonance Spectroscopy (MRS)
In magnetic resonance spectroscopy (MRS) the same basic principles of signal 
generation as in MR imaging are applied. However, MRS involves an additional 
parameter called chemical shift. This concerns differences in resonance frequency 
between nuclei within a molecule due to interactions with neighboring nuclei. 
Figure 8  T2-weighted MR image of a healthy mouse brain at 7 T. Slice thickness of 0.7 mm, 
matrix of 256 x 256 in a field of view of 25.6 x 25.6 mm.
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Often MR of all non-water or fat protons and of all non-proton MR sensitive nuclei 
are considered to be part of MRS. Non-water protons may be those present in 
metabolites such as in lactate. The relative contributions to the signal of the 
various atoms in different molecules is plotted in a spectrum in which the x-axis 
represents the chemical shift difference. Non-proton or X-nuclei are for example 
31P, which occurs in molecules like ATP, and 19F which is often used as a label in 
exogenously administered contrast agents, as there is no natural 19F in the body. 
As all non-water and fat compounds occur at much lower concentrations than 
water and fat in the body the sensitivity of MRS is lower than MRI and therefore 
spatial resolution is also lower. A lower sensitivity can also be caused by a lower 
gyromagnetic constant or lower natural abundance of a nuclear spin. For instance 
13C, present in most biochemical molecules occurs only at 1.1% in the body and has 
a lower γ than 1H. 
Chemical shift
As explained above the resonance frequency of a particular nucleus in a molecule 
depends on the local magnetic field. This local experienced magnetic field depends 
on the shielding of the electron cloud surrounding the nucleus, of the neighboring 
molecular structure and of the solvent or macroscopic environment of an 
individual atom. Altogether this is expressed in a shielding constant σ that changes 
the individual spins’ Larmor frequency. 
By expressing the chemical shift, Δν, relative to the main magnetic field the value 
gets field independent. The relative shift in frequency is expressed in parts per 
million (ppm). This is because the chemical shift is usually in the order of Hz and 
the main magnetic field B0 in MHz. As different nuclei in a molecule will have a 
different shielding this will result in a specific signal pattern that allows for a 
unique identification of the molecule in the spectrum. 
J-coupling
In addition to the chemical shift the resonance frequency of a nucleus may be 
influenced by interactions with nearby spins, called J-coupling. An example of 
chemical shift is the instance where 1H’s are unequivalently attached to a 13C 
atom. In J-coupling new transitions through combined energy levels are possible. 
This can only be described properly in quantum mechanical terminology. Instead 
of only up and down states the spins can also populate two unequal intermediate 
states with a energy separation J.  The transitions to and from these energy levels 
lead to a splitting of the resonance frequency of the J-coupled spin systems. 
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Single voxel MR spectroscopy and spectroscopic imaging.
The most simple form of localization of MR spectra is by selecting a single voxel 
with slice selection. A slice in a particular direction can be selected by combining 
a frequency selective pulse with a gradient in that direction. Popular single voxel 
methods are STEAM [24], PRESS [25] and ISIS [26]. In magnetic resonance spectroscopic 
imaging (MRSI), also called chemical shift imaging (CSI), the principles of MRI and 
MRS are combined to create images or maps of the relative distributions of various 
molecules [27]. By applying phase encoding steps, spectra for different spatial 
positions are combined to form a two or three dimensional grid with MR spectra 
in each voxel of the grid. In 1H MRSI often a spatial pre-selection of a large single 
voxel is performed to exclude unwanted signal from e.g. fat from the skin 
surrounding the skull. If the frequency dispersion of the slice selection is 
comparable to the spectral frequency dispersion this may cause a so-called 
chemical shift artifact in which different MRS signals may be encoded at different 
positions.  To avoid this problem special selective refocusing pulses with a large 
bandwidth can be used that limit the chemical shift displacement  [28], [29]. 
 By fitting signals in the acquired spectra using a model based system [30] 
metabolic maps can be made. In these maps individual metabolites or ratios of 
metabolites can be displayed in an image like fashion optionally overlaid on a 
conventional proton MR image. 
Figure 9  1H MR spectrum of a 1 µl voxel central in a healthy mouse brain, TE 144ms, 7T.
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MR in brain cancer
As is obvious from the above explanation, MR is a very versatile technique that 
allows for in-depth characterization of the morphology and physiology of gliomas. 
By using MR imaging and MR spectroscopy not only the anatomy of the tumor can 
be visualized but also a host of functional parameters can be gathered. 
 By looking at diffusion of water in tissue by diffusion weighted imaging (DWI) 
a measure of tumor cellularity can be obtained [31]. High cellularity in tumors 
impedes free water diffusion, resulting in a reduction of apparent diffusion 
coefficient (ADC) values. 
 Malignant gliomas are characterized by high degree of angiogenesis, one of 
the major therapeutic targets in the development of novel treatments. The abnormal 
caliber and number of tumor vessels resulting from angiogenesis can be measured 
using dynamic susceptibility-weighted contrast-enhanced (DSC) MR imaging, 
which measures changes in tumor T2* following injection of contrast agent. 
 Often in the compact part of brain tumors the blood brain barrier (BBB) has 
become leaky. By using a small T1-affecting contrast agent like Gd-DTPA this 
leakage may be visualized. The local accumulation of extravasated contrast agent 
can be visualized using T1-weighted MR imaging. Infiltrating tumor areas with a 
Figure 10  Metabolic map of tCho over tNAA overlayed on an anatomical T2w image of a 
glioma bearing mouse.
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relatively intact BBB may show no enhancement. A known side-effect of anti-angio-
genic therapy is restoration of the BBB leading to an underestimation of tumor 
extent using this technique [32]. Signal enhancement by T2 contrast in a fluid 
attenuated inversion recovery type (FLAIR) MRI can be used as a measure for the area 
of (infiltrative) tumor spread, although this type of measurement may also represent 
peri-tumoral edema. 
 In addition to MRI, MR spectroscopy or MR spectroscopic imaging have been 
extensively used to characterize different types and grades of brain tumors. With 
1H or 31P MRS or MRSI it is possible to obtain information on metabolism or the 
energetic state of tumors. 1H MRS of brain (tumor) metabolites like N-acetyl 
aspartate (NAA), choline (Cho), creatine and phosphocreatine (Cr), lactate (Lac), 
lipids (Lip), and myoinositol (mI) are often used for charecterization [33]. 
Upregulated choline metabolism is a hallmark of all cancers [34]. The choline to 
NAA signal ratio or index (CNI) is often used as a biomarker for the presence of a 
brain tumor [35]. An important new glioma metabolite that can be detected in vivo 
in the brain 2-hydroxyglutarate [36].
 Although 31P MRS is much less sensitive than 1H MRS it provides more insight 
into the role of a number of interesting phosphorus containing brain metabolites. 
These are adenosine triphosphate (ATP), phosphocreatine (PCr), inorganic phosphate 
(Pi), phosphoethanolamine (PE), phosphocholine (PC), glycerophophoethanolamine 
(GPE) and glycerophosphocholine (GPC). Where ATP resonances, PCr and Pi give 
insight into energy metabolism, PE, PC and GPE, GPC reveal more information on 
phospolipid metabolism necessary for cell membrane synthesis [37].
 As a result of the lack of endogenous fluorine, background free imaging of 
exogenous compounds containing fluorine using 19F MRS or 19F MRSI has some 
interesting possibilities in oncological studies. For instance, the distribution of 
19F labeled anti-cancer drugs or markers can be assessed in vivo which may allow 
to predict response to therapy. It is also possible to apply 19F labeled compound of 
which the T1 relaxation properties are sensitive to partial oxygen pressure (pO2) 
[38] or compounds that accumulate in hypoxic tissues [39]. 
Aim of the research
The aim of the work presented in this thesis is to establish and evaluate novel MR 
methods to assess tumor perfusion, hypoxia and metabolism in preclinical models 
of cancer. These methods can be applied in the diagnosis of tumors, in the research 
to understand the physiology of tumors and to evaluate cancer therapy. This thesis 
focuses on clinically relevant tumor models of diffuse infiltrative glioma of human 
origin, growing in the mouse brain.
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Outline of the thesis
In chapter 2 a novel method for assessing mouse brain and brain tumor perfusion 
is proposed using a technique called contrast enhanced susceptibility weighted 
imaging (CE-SWI). The method relies on the use of additional exogenous contrast 
to enhance the susceptibility effect. 
 In chapter 3 contrast enhanced magnetic resonance imaging (CE-MRI) is 
applied to show the lack of an additive effect of targeting multiple angiogenic 
pathways in the treatment of gliomas. In addition the applied method is evaluated. 
 In chapter 4 magnetic resonance spectroscopic imaging is used to visualize 
the metabolic state of  gliomas before and during anti-angiogenic treatment. In 
contrast to conventional contrast enhanced magnetic resonance imaging the 
technique is insensitive to restoration of the blood brain barrier occurring during 
treatment. 
 In chapter 5 phosphorus 31P magnetic resonance spectroscopic imaging is 
used to characterize the genetic alterations, relating IDH1 to tumor aggressiveness. 
An 31P biomarker, complementary to 2-HG in 1H MRSI, was established.
 In chapter 6 the hypoxic state of a glioma and a colon carcinoma xenograft is 
evaluated by 19F MRSI using a newly synthesized MR compatible hypoxia marker: 
trifluoro-pimonidazole. 
 In chapter 7 an approach to address the inherent low sensitivity of MR using 
hyperpolarization techniques based on parahydrogen is described. 
 Chapter 8 concludes this thesis with a general summary and a discussion about 
the role of magnetic resonance imaging and magnetic resonance spectroscopy in 
preclinical cancer research. 
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Abstract
Susceptibility weighted imaging (SWI) has been introduced as a novel approach to 
visualize the venous vasculature in the human brain. With SWI, small veins in the 
brain are depicted based on the susceptibility difference between deoxyhaemoglobin 
in the veins and surrounding tissue, which is further enhanced by the use of 
MR phase information. In this study we applied SWI in the mouse brain using 
an exogenous iron-based blood-pool contrast agent, with the aims of further 
enhancing the susceptibility effect and allowing the visualization of individual 
veins and arteries. Contrast enhanced (CE-) SWI of the brain was performed on 
healthy mice and mice carrying intracerebral glioma xenografts. This study 
demonstrates that detailed vascular information in the mouse brain can be 
obtained by using CE-SWI and is substantially enhanced compared to native SWI 
(i.e. without contrast agent). CE-SWI images of tumour-bearing mice were directly 
compared to histology, confirming that CE-SWI depicts the vessels supplying and 
draining the tumour. We propose that CE-SWI is a very promising tool for the 
characterization of tumour vasculature.
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Introduction
Based on the blood oxygenation level dependent (BOLD) effect, which was found in 
rats by Ogawa et al. [1], T2* weighted MRI can depict veins in the brain with high 
detail. One can further enhance this effect by using susceptibility weighted 
imaging (SWI) which additionally enhances the T2* effect by using the phase 
information [2, 3]. A more detailed description of the technique can be found in 
the following recent reviews: [4–6]. Compared to other more common MRI 
techniques, like T1 and T2 weighted imaging, SWI allows to depict the veins with 
higher spatial resolution, especially at higher field strengths [7, 8]. However, the 
phase images which commonly show undesired phase wraps have to be unwrapped 
sometimes by using more sophisticated phase unwrapping techniques than 
homodyne demodulation [9], such as techniques based on region growing [10]. 
Current research using susceptibility phenomena also focuses on a more 
quantitative assessment of physiological parameters using this or a multi-echo 
variation of this technique [11–15]. Contrast-enhanced (CE-) SWI relies on the 
additional effect of contrast agents injected into the blood, which allows 
enhancement of this effect and shorter scan times [16]. When using Gd-DTPA as 
contrast agent this enhancement is achieved by an additional T1 effect of the 
venous blood compartment [17, 18]. Recently, truly intravascular (blood pool) 
contrast agents based on ultrasmall superparamagnetic ironoxide particles 
(USPIO) have been introduced which cause a huge additional effect on local 
magnetic field inhomogeneities, resulting in both a reduction of T2* in blood and 
higher susceptibility differences between all vessels (both veins and arteries) and 
their surrounding tissues than just caused by venous deoxyhaemoglobin. CE-SWI 
using a blood pool contrast agent has been introduced in cats [19] as a novel 
approach to depict the whole brain vasculature as only large veins could be 
depicted in native SWI. In this paper we used USPIOs for (additional) enhancement 
of local susceptibility effects. A detailed characterization of the vasculature in 
brain tumours is extremely important for the evaluation of anti-tumour therapies. 
For instance, we have recently reported that anti-angiogenic therapy precluded 
tumour detection by Gd-DTPA enhanced MRI due to restoration of the blood brain 
barrier [20]. Visualization of the tumour, based on an aberrant blood volume, is 
obviously important to establish the efficacy of therapy. Common approaches to 
estimate tumour blood volume or vessels size index rely on mapping DR2 and DR2* 
[21, 22]. The aim of this study was to perform both native SWI and CE-SWI in the 
mouse brain to assess the potential and the sensitivity of these methods in 
depicting the brain vasculature of the mouse as a promising method to follow 
treatment of brain tumours. We hypothesized that CE-SWI may reveal blood vessel 
structures in greater detail than by using common T2* weighted imaging and 
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native SWI. To test this hypothesis T2* and susceptibility weighted imaging was 
performed on the mouse brain before and after USPIO injection. 
Material and Methods
Animals
SWI and CE-SWI was performed on two healthy C57Bl6 mice (25–26 g) and two 
BALB/c nu/nu mice (22–23 g) carrying intracerebral xenografts of the human 
glioma line E98 [23]. All mice were anaesthetized using 1.5–2% isoflurane in a 
70:30 N2 O/O2 mixture. The mice were positioned in prone position in an animal 
cradle with integrated waterbed and temperature and respiration monitoring 
options. Throughout the experiment body temperature and respiration rate were 
monitored and kept constant.
MRI
Experiments were performed on a 7 T/12 cm horizontal-bore magnet (MR Research 
Systems, UK) equipped with a gradient insert of gradient strength 150 mT/m and 
rise time 150 µs (Magnex, UK). A home built 16 mm diameter 1H brain surface coil 
was positioned over the mouse skull and used as a transmit-receive coil. For all 
mice three orthogonal slices were acquired as a navigational scan using a fast 
gradient echo sequence (TR = 140 ms, TE = 6 ms, α = 20 ,˚ FOV = 7,5 cm ×× 7,5 cm, 
matrix = 256 × 192). Using this scan the actual (CE-) SWI volumes were positioned 
minimizing aliasing within the field of view. To obtain the (CE-) SWI data a 3D, T2* 
weighted gradient echo sequence with flow compensation in all three directions 
was acquired. Scan parameters were as follows: TR = 30 ms, TE = 15 ms, FOV = 1.28 
× 1.28 × 1.28 cm 3 , matrix = 128 × 96 × 128, α = 20º. Total scan time for a single 
acquisition was 6 min 9 sec. For the CE-SWI ultrasmall superparamagnetic iron 
oxide particles (USPIO) (Sinerem, Guerbet, France) were injected as a bolus via the 
tail vein just before acquisition. A dosage of 12.5 mg/kg was used.
Post-processing
Reconstruction and post-processing of the CE-SWI data was performed using 
Matlab (The Mathworks, USA). The data were unwrapped and filtered using 
homodyne filtering [9]. A 3D Hamming window with a width of 64 × 48 × 64 was 
applied to the k-space data. From the unwrapped phase data phase masks were 
created by setting all positive phases to 1 and by scaling negative phases linearly 
between 0 and 1. These masks were then multiplied four times with the 
corresponding magnitude image to create susceptibility weighted images. To 
allow for better visualization of the data 5 slices (500 µm) were combined to form 
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a minimum intensity projection (mIP). Histology - After CE-SWI experiments the 
animals were sacrificed and brains were removed and fixed in formalin. The 
brains were cut in 4 to 5 coronal slices with a slice thickness of 3–4 mm, which 
were embedded in paraffin, allowing later correlation of the MR images with 
histology. Haematoxilin/eosin staining was performed on 4 µm sections, and blood 
vessels were highlighted by immunostaining with antibodies against CD34 
(Hycult, The Netherlands). 
Results
SWI C57Bl6
In the regular T2* weighted magnitude image (Fig. 2.a) hardly any brain vasculature 
could be discriminated. Also, after processing the data with the previously 
described SWI post processing methods, i.e. multiplication with the phase mask, 
still little brain vasculature could be discerned (Fig. 2.b). The susceptibility 
difference caused by endogenous deoxyhaemoglobin proved to be too small to 
allow visualization of individual veins using this setup. 
Figure 1  Magnitude image (a), the displayed plane is perpendicular to the main magnetic 
field B0, the raw phase image (b), the homodyne filtered unwrapped phase image (c), the 
phase mask (d) and the SWI image (e) of a single brain slice of a healthy mouse.
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CE-SWI C57Bl6
In the data set acquired after application of the USPIO contrast agent, brain 
vasculature could be distinguished easily already in the T2* weighted image. A 
significant decrease of signal intensity clearly outlined the major vascular 
architecture (Fig. 2.c). When the SWI post processing algorithm was applied, 
substantially more details could be observed in comparison to the regular T2* 
weighted image (Fig. 2.d). This is caused by the additional USPIO-induced 
susceptibility weighting using the phase information that further enhanced the 
contrast between vessels and its surroundings. 
CE-SWI BALB/c nu/nu E98 Glioma
We also performed CE-SWI on a brain tumour model of BALB/c nu/nu mice carrying 
the human E98 glioma line. The CE-SWI showed a large vessel clearly supplying or 
draining the intracerebral tumour (Fig. 3.a and a zoomed version in Fig. 3.b). 
Histological matching confirmed the presence of this vessel (Fig. 3.c) that was 
identified as an artery feeding the tumour with nutrients and oxygen. 
Figure 2  Pre-contrast T2* weighted magnitude image (a) and the corresponding native 
(pre-contrast) SWI (b). The signal loss in the deep nuclei is caused by their relatively high iron 
content making them susceptible to the  SWI  post  processing  (green arrows). Post contrast 
T2* weighted magnitude image (c) outlining the major vascular architecture. The contrast 
enhanced SWI (d) shows even more vascular details (blue arrows)
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Discussion / Conclusion
USPIO CE-SWI demonstrates that by using a blood pool contrast agent the vascular 
information provided by SWI is substantially enhanced. Not only veins but also 
arteries can be outlined using this technique. Due to the size of the mouse brain, 
intrinsic susceptibility differences were generally too small to provide enough 
phase differences to allow visible effects on susceptibility weighted images, 
however with USPIO CE-SWI this is dramatically improved allowing extensive 
visualization of mouse brain vasculature at 7 T. Despite the preliminary nature of 
the results several important findings for the application of CE-SWI in brain 
tumour research are presented in this study. A direct comparison between SWI 
findings and histology was performed. This confirmed – as has already been 
estimated from the image appearance of the low intensity tubular structures in 
SWI data sets in previous studies – that these structures directly correspond to 
vessels carrying particles or molecules that cause a local disturbance of the 
magnetic field (paramagnetic deoxyhaemoglobin/ ultra-small super paramagnetic 
iron oxide particles) To our knowledge CE-SWI was performed for the first time in 
the mouse brain indicating that with the parameters used even at a field strength 
of 7 T no clear endogenous vessel (vein) contrast could be achieved in a reasonable 
measurement time (6 min) which is compatible with a standard MRI protocol for 
studies of mouse brain tumours. Changing certain MRI parameters (higher spatial 
resolution, longer echo time) might lead to a depiction of veins also without using 
CA, but this would inevitably cause much longer measurement times to compensate 
for low SNR, which is most often not an option in standard tumour studies in 
mice. In a study in rats and cats presented at the ISMRM 2005 [24] a higher spatial 
Figure 3  CE-SWI of BALB/c nu/nu mouse with E98 glioma (green arrows) in the upper right 
hemisphere (a). Zoomed section of the glioma region (b) clearly showing a large vessel 
(blue arrow) supplying the tumour. Histological matched H&E stained slice of this region (c).
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resolution at a higher field strength (9.4 T) lead to the depiction of veins, but a 
measurement time of 35 minutes was necessary. Clearly, the application of USPIOs 
solved the issue of the visualization of brain vasculature within the given 
measurement time restraints. In a recent study Bolan et al. [19] performed high 
resolution T2* weighted MRI in the cat brain and could depict the venous 
vasculature based on the endogenous magnetic properties but again only by using 
a very long measurement time (35 min) at a field strength of 9.4 T which gave 
sufficient sensitivity for the (much larger) cat brain. However, they did not use a 
phase mask to enhance the venous visibility. They also used a higher spatial 
resolution that decreased partial volume effects thereby increasing the blood 
volume per voxel. Using higher resolution might also have led to a better vein 
conspicuity, however, also leading to much longer measurement times. CE-SWI 
using USPIOs made it possible to depict veins as well as arteries therefore providing 
information on both the feeding and draining vessels in tumour supply 
independent of the blood flow. Blood flow is often used in MRI to depict brain 
vasculature. However, only fast flowing spins can be depicted in time-of-flight and 
phase contrast angiography. Therefore these methods are less sensitive to depict 
small veins [25]. SWI based on the paramagnetic properties of deoxyhaemoglobin 
in the (venous) blood and USPIO CE- SWI based on the magnetic properties of the 
contrast agent also depicts slow flowing blood. In the study of Bolan et al. [19] the 
authors also made use of a similar approach by using MION as a contrast agent 
thus also depicting veins and arteries in a second scan. By subtracting the first 
(pre-contrast) scan they could also depict the arteries only, resulting in the 
visualization of the whole brain vasculature. These results indicate the potential 
of SWI to depict the brain vasculature in both healthy and tumour bearing mice. 
In a next step it would be important to validate if SWI can also depict microvascular 
density, for example in mice carrying solid tumours. This would be a very 
important step to be able to follow anti-angiogenic therapies in animal models 
next to the already more common methods of dynamic susceptibility contrast and 
time of flight angiography. In another step, a translation of the diagnostic abilities 
of USPIO CE-SWI from mouse studies to humans would be important for the 
assessment of therapies in brain tumours. The big advantage of MRI here is that 
follow-up studies during and after treatment can be performed minimally invasive 
(only CA has to be applied) and can be repeated easily. 
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Abstract 
Currently available compounds that interfere with VEGF-A signalling effectively 
inhibit angiogenesis in gliomas, but influence diffuse infiltrative growth to a 
much lesser extent. Development of a functional tumour vascular bed not only 
involves VEGF-A but also requires platelet-derived growth factor receptor-β 
(PDGFRβ), which induces maturation of tumour blood vessels. Therefore, we tested 
whether combined inhibition of VEGFR and PDGFRβ increases therapeutic benefit 
in the orthotopic glioma xenograft models E98 and E473, both displaying the 
diffuse infiltrative growth that is characteristically observed in most human 
gliomas. We used bevacizumab and vandetanib as VEGF(R) inhibitors, and sunitinib 
to additionally target PDGFRβ. We show that combination therapy of sunitinib 
and vandetanib does not improve therapeutic efficacy compared to treatment 
with sunitinib, vandetanib or bevacizumab alone. Furthermore, all compounds 
induced reduction of vessel leakage in compact E98 tumour areas, resulting in 
decreased detectability of these mostly infiltrative xenografts in Gd-DTPA- 
enhanced MRI scans. These data show that inhibition of VEGF signalling cannot be 
optimized by additional PDGFR inhibition and support the concept that diffuse 
infiltrative areas in gliomas are resistant to anti-angiogenic therapy.
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Introduction 
Glioblastoma is a primary brain tumour that is characterized by angiogenic 
tumour areas, but also extensive diffuse infiltrative dispersion in the brain [1]. 
Treatment consists of surgery when possible, followed by radiotherapy and 
chemotherapy. Curative treatment is rare as complete removal of tumour cells is 
very difficult to achieve [2–4]. The majority of patients therefore die within 15 
months after initial diagnosis. In the angiogenic areas of glioblastoma, the 
vasculature is leaky, allowing contrast-enhanced magnetic resonance imaging 
(CE-MRI)-based detection. In contrast, in the diffuse infiltrative tumour regions, 
pre-existing blood vessels with an intact blood–brain barrier (BBB) are involved, 
preventing extravasation of contrast agents and thereby hampering radiological 
delineation of tumour areas in T1 -weighted Gd-DTPA MRI [4,5]. Many compounds 
have been developed that effectively inhibit the angiogenic factor vascular 
endothelial growth factor-A (VEGF-A). The anti-VEGF-A antibody bevacizumab and 
tyrosine kinase inhibitors (TKIs) of angiogenic receptors are now used for the 
clinical management of a number of tumour types [6–9]. The presence of angiogenic 
areas in glioblastomas suggests that these tumours may also be candidates for 
 anti-angiogenic therapies. Bevacizumab treatment of patients with recurrent 
glioblastoma indeed results in radiological responses and improved progression- 
free survival (PFS) [10]. However, the efficacy of anti-angiogenic treatment on 
glioma outgrowth is still an issue of active debate, culminating in FDA approval of 
bevacizumab for the treatment of patients with recurrent glioma in the United 
States, while the European Medicines Agency (EMA) declined bevacizumab for this 
condition. We previously showed that vandetanib, a potent TKI directed against 
VEGFR2 and epidermal growth factor receptor (EGFR) (IC50 = 40 and 500 nM, 
respectively) [11], affected angiogenesis-dependent tumour growth in brain models 
of metastatic melanoma and different orthotopic glioma xenograft models, but at 
the same time did not improve survival of the tumour-bearing animals [5,12–14]. 
This could be attributed to a lack of inhibition of diffuse infiltrative or perivascular 
growth. Vandetanib caused a significant reduction of vessel leakage, resulting in 
difficulties with CE-MRI-based detection [5,12,13]. The diminished extravasation of 
contrast agent due to reduced vessel leakage may indeed result in an overestimation 
of drug efficacy in clinical studies (‘pseudo-response’), not only with respect to 
glioma but also with respect to metastatic tumours in the brain [10,15]. In the 
Rip-Tag mouse model of pancreatic carcinoma, the efficacy of anti-angiogenic 
therapy is greatly improved by the simultaneous targeting of VEGF and platelet- 
derived growth factor (PDGF) receptors [16]. This can be explained by the presence 
of tumour vessels in early stages of development which are susceptible to VEGFR 
inhibition only, and vessels in later stages of maturation, which are solely 
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responsive to PDGFR inhibition. The prominent vessel heterogeneity in gliomas 
suggests that similar mechanisms may be operative in these tumours as well. 
Blood vessels with a mature phenotype may not be susceptible to anti-VEGF 
treatment, but additional targeting of these vessels via inhibition of PDGFR may be 
of benefit. A recent phase II clinical study supports this proposition, as cediranib 
(RECENTIN, AZD2171), an inhibitor of VEGFR, c-KIT, and PDGFR, improves PFS 
in patients with recurrent glioblastoma [17]. These results warrant further 
investigations in relevant preclinical glioma models. Here we performed an 
in-depth analysis of the effects of bevacizumab and sunitinib (a TKI with high 
affinity for VEGFR and PDGFRβ) (IC50 = 10 nM for both receptors [18]), either alone 
or in combination with vandetanib, in two orthotopic xenograft models of glioma, 
E98 and E473. One of the morphological key features of both xenograft models is 
the presence of large areas with diffusely infiltrating tumour cells, whereas the 
E98 model also presents more compact angiogenesis-dependent areas. The diffuse 
infiltrative phenotype closely mimics the growth pattern in large areas of human 
gliomas, distinguishing these xenografts from many other orthotopic glioma models. 
Since this phenotype may be an important determinant for the susceptibility to 
anti-angiogenic compounds, it is of paramount importance to investigate the 
effects of these therapies in such relevant models. We show that in E98 xenografts, 
(partial) restoration of the BBB is a result of anti-angiogenic treatment and that 
additional targeting of the PDGFR pathway does not exert a beneficial effect on the 
infiltrative part of the tumour and therefore does not improve the outcome for 
either xenograft model.
Materials and methods 
Animal tumour models 
All experiments were approved by the Animal Experimental Committee of the 
Radboud University Nijmegen Medical Centre and were carried out in accordance 
with national and international guidelines. Balb/c nude mice (6 to 8 weeks old, 
weighing 18–25 g) were kept under specific pathogen-free conditions and received 
food and water ad libitum. Orthotopic E98 and E473 gliomas were xenografted as 
described previously [19]. Both lines consistently produced intracerebral tumours 
displaying diffuse infiltrative and, in the case of the E98 line, additional angio-
genesis-dependent growth in the brain parenchyma. 
Anti-angiogenic treatment 
Mice carrying orthotopic E98 xenografts were randomly divided into groups of 
five, except for the control group (P), which consisted of seven animals. Three 
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different anti-angiogenic agents were used in four treatment groups: bevacizumab 
(B), sunitinib (S), vandetanib (V), and vandetanib plus sunitinib (VS). Treatments 
started on day 8 after intracerebral injection of tumour cells. On that day, two 
mice from the control group were sacrificed to check tumour burden. Bevacizumab 
(Avastin, Genentech, San Francisco, CA, USA) was administered four times (days 8, 
10, 12, and 14 after intracerebral injection) by intraperitoneal injection in a volume 
of 100 µl (5 mg/kg in phosphate buffered saline). Mice received vandetanib 
(ZACTIMA™, AstraZeneca, Macclesfield, UK) (50 mg/kg as a suspension in 1% 
polysorbate-80) or sunitinib (Sutent, Pfizer, New York, USA) (30 mg/kg as a 
suspension in 12.5% cremaphor–12.5% ethanol in water) once daily by oral gavage 
in a volume of 100 µl. At these concentrations, the therapeutic agents have shown 
in vivo efficacy in preclinical models [13]. Mice were treated from day 8 until day 
21 after tumour injection. A fourth group (VS) was treated with a combination of 
vandetanib and sunitinib using the dosage scheme as described for the individual 
compounds. The control group (n = 5) received 1% polysorbate80 vehicle only. To 
limit the number of animals in this study, we relied on historical controls, which 
showed that intraperitoneal injection of PBS did not affect mouse welfare or 
tumour behaviour. A similar protocol was applied to mice carrying orthotopic 
E473 xenografts. Mice were left untreated (n = 6), treated twice weekly with 
bevacizumab (n = 5), or treated daily with the combination vandetanib and 
sunitinib (n = 6) as described above. Treatment in these groups started at day 29, 
when signs of tumour development were observed in MRI (data not shown). 
Figure 1  Percentage of hypoxia in E98 xenografts in the different treatment groups. All 
anti-angiogenic treatments cause an increase in hypoxia in the compact tumour compartments. 
Hypoxia in compact tumour areas in mice treated with vandetanib (V) or combination 
vandetanib–sunitinib (VS) was significantly higher than in compact tumours in placebo- 
treated mice (P) ( * p < 0.01). A similar increase, although not significant, was present in 
compact tumour areas of mice treated with bevacizumab (B) and sunitinib (S).
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CE-MRI 
Throughout the experiments, mice were monitored closely by visual inspection. 
After 16–20 days, when tumour-related symptoms became apparent for the E98 
model (weight loss and neurological defects), imaging was performed on a 7 T 
preclinical MR setup (MR Research Systems, Guildford, UK) as described previously 
[5], using a 12 mm diameter transmit/receive head coil. In short, 16 T-weighted 
coronal images (TE = 8 ms; TR = 100 ms; flip angle = 90°  ; number of averages = 1; 
field of view = 25 × 25 mm 2 ; matrix size = 256 × 256; slice thickness = 1 mm) were 
acquired. A bolus of 0.2 ml of Gd-DTPA (20 mmol/l; Magnevist , Schering, Germany) was 
injected intravenously, and additional sets of T-weighted images were acquired 
immediately following injection and at 2 and 10 min after administration. CE-MRI 
was carried out on at least two mice per treatment group (P: n = 2; B: n = 2; S: n = 4; 
V: n = 3; and VS: n = 3). For mice receiving daily doses of sunitinib and/or vandetanib, 
CE-MRI was performed on the same day as the last dose. Mice in the bevacizumab 
group received the last dose on day 14, and CE-MRI was performed 5–7 days later. 
With a half-life of approximately 20 days [20], significant levels of bevacizumab are 
still expected in the circulation at the time of imaging. 
Immunohistochemistry 
Mice were sacrificed when the effects of tumour development were apparent, and 
their brains were removed, formalin-fixed, and cut in five to six coronal slices of 
approximately 2 mm before embedding in paraffin blocks, allowing simultaneous 
analyses of tissue on five to six levels. Sections of 4 µm were subjected to 
haema toxylin and eosin (H&E) or immunohistochemical staining using antibodies 
against Ki-67 (Clone SP6; Lab Vision Corporation, Fremont, CA, USA) for 
proliferating cells, CD34 (MEC14.7; Hycult Biotechnology, Uden, The Netherlands) 
to detect mouse brain capillary endothelial cells, mouse IgG (DakoCytomation, 
Glostrup, Denmark) to detect vessel leakage, and GLUT1 (DakoCytomation) to 
highlight brain vasculature with an intact BBB. GLUT1 was simultaneously used 
as a marker to detect hypoxic tumour cells [21]. Glomeruloid microvascular 
proliferations were detected in CD34 stains. The fraction of hypoxic cells in E98 
tumours was quantified as described previously [5] and expressed as percentage 
hypoxic tumour area (GLUT1 staining area)/total tumour area × 100. Proliferation 
indices were measured in four random, nonoverlapping microscopic fields 
(magnification ×200) in both compact and diffuse infiltrative growth areas. A 
proliferation index of 50% or more was considered high; 20% or less was considered low. 
Measurements were performed in tumours of all placebotreated and anti-angio-
genesis-treated E98 and E473 mice. Hypoxia data (percentages) were subjected to a 
one-way ANOVA, with treatment as a factor. A posthoc T-test (two-sided) was performed 
where appropriate, and a p value less than 0.05 was considered significant. 
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Results 
Anti-angiogenic treatment 
Mice bearing E98 tumours were treated with bevacizumab, sunitinib, vandetanib, 
or a combination of sunitinib and vandetanib. All treatments were well tolerated. 
Mice were sacrificed when obvious signs of tumour growth (evident weight loss, 
neurological defects) were present (P: day 22 ± 9; B: day 22 ± 3; S: day 18 ± 2; V: day 
19 ± 3; VS: day 19 ± 3, p = ns). Although none of the therapies delayed the development 
of tumour-related symptoms, the treatments did cause anti-tumour effects in the 
expansive, compact growing tumour areas which, in E98 xenografts, are 
reproducibly found in ventricles and leptomeningeal spaces [19]. Mice from groups 
V and VS showed a significantly higher percentage of hypoxia in the compact 
tumour areas compared with the vehicletreated mice (Figure 1, one-way ANOVA: 
treatment effect: p < 0.05; 13.4% in P versus 32.7% in V and 29.9% in VS groups, p < 
0.01). In mice treated with bevacizumab or sunitinib alone, there was a similar 
trend, although significance was not reached [Figure 1; 13.4% in placebo versus 
22.4% in B (p = 0.1) and 22.9% in S groups (p = 0.2)]. A prominent effect of all the 
therapies was the near absence of florid microvascular proliferations [1], which 
were found in 80% of the vehicle-treated animals (Figures 2C and 2D). Importantly, 
although inhibition of VEGF signalling resulted in an increase of hypoxia in the 
compact tumour areas and a concomitant reduced size, tumour growth was still 
possible here to some extent (Figure 3A, asterisk), presumably due to diffusion of 
nutrients from the surroundings. This hypothesis is supported by a high 
proliferation index in the tumour rim, whereas the proliferation was strongly 
decreased in hypoxic areas (50–60% in non-hypoxic tumour parts versus 10% in 
hypoxic areas; Ki67 staining in Figure 3B). In sharp contrast, none of the anti- 
angiogenic treatments notably affected diffuse infiltrative tumour areas (Figure 
2B and H&E staining in Figure 4), similar to previous observations with vandetanib 
treatment alone [13]. No hypoxia was detected in the diffuse infiltrative tumour 
areas (Figure 3A, arrowhead) and the proliferation index remained high in these 
areas (±70%; Figure 3B, arrowhead). To rule out tumour-specific features that cause 
resistance to anti-angiogenic compounds, we performed similar experiments in 
orthotopic E473 xenografts, characterized by only diffuse infiltrative growth 
(Figure 5A). E473-bearing mice were left untreated (P) or were treated with 
bevacizumab (B) or the combination vandetanib and sunitinib (VS). Again, 
treatment did not notably prolong time until tumour-related symptoms became 
evident (P: day 42 ± 8; B: day 44 ± 9; VS: day 35 ± 2, p = ns). Mice in the VS group had 
to be sacrificed earlier than the other groups, due to extensive weight loss. The 
reason for the early deterioration is unknown. Examination of liver and kidney 
showed no obvious signs of toxicity. Histological analysis of E473 mouse brains 
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Figure 2  Effect of anti-angiogenic treatment on mice carrying intracerebral E98 tumours. 
Representative H&E staining of vehicle-treated mice (A, C) and vandetanib + sunitinib-treat-
ed mice (B) is shown. Panels C and D show an example of a glomeruloid microvascular 
proliferation in a vehicle-treated mouse in H&E and CD34 immunohistochemical staining, 
respectively. Whereas this phenotype was observed in 80% of vehicle-treated mice, it was 
only occasionally observed in the sunitinib group and was absent in all the other treatment 
groups (G). Panels E and F show immunostaining for mouse IgG in vehicle-treated and van-
detanib-treated mice, respectively. Note the extravascular deposition in the control tumour, 
whereas IgG is confined to the blood vessels in the treated mouse. The diffuse infiltrative 
areas in, for example, the corpus callosum (A, B, arrowheads) were not notably affected by 
the treatment. Original magnifications: (A, B) ×12; (C, D) ×400; (E, F) ×200.
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revealed no treatment-induced alterations in the infiltrative growth pattern 
(Figure 5A). Proliferation indices were not significantly influenced by the treatment 
(Figure 5A; control group: 34%, treatment groups 37%, p = 0.13). Thus, targeting 
VEGF or its receptors, either in combination with inhibition of PDGFRβ or not, 
does not interfere with the invasive growth of E473 glioma cells. 
Figure 3   Effect of anti-angiogenic treatment on hypoxia and proliferation index in the 
tumour. Representative GLUT1 (A) and Ki67 (B) immunohistochemical staining of 
intracerebral E98 lesions of a bevacizumab-treated mouse (serial sections are shown). The 
compact tumour areas show a striking increase in hypoxia (A, asterisk). The proliferation 
index of tumour cells remains high in both diffuse infiltrative (A, B, arrowheads) and 
compact (A, B, arrows) tumour areas, despite anti-angiogenic treatment. Only in hypoxic 
tumour regions in the compact tumour areas (A, asterisk, GLUT1) is there a strong decrease 
in proliferation index (B, asterisk, Ki67). There is no hypoxia detectable in the diffuse 
infiltrative areas (A, B, arrowheads). (C) The graph shows that there is no difference in the 
proliferation indices when comparing placebo-treated and anti-angiogenic-treated mice. 
Original magnifications: (A, B) ×100.
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Effect of anti-angiogenic treatment on the blood–brain barrier (BBB) 
The angiogenic areas in E98 tumours allow CE-MRI based detection. In diffuse 
infiltrative areas, leakage is lower than in the compact tumour parts, consistent 
with a predominantly intact BBB in these regions [13]. Bevacizumab, sunitinib, and 
the combination of sunitinib and vandetanib all resulted in (partial) restoration of the 
Figure 4  Correlation between CE-MRI and histopathology of intracerebral E98 glioma 
lesions. For each treatment group, a representative image is shown of the intracerebral 
lesion before (pre) and after (post) injection of Gd-DTPA contrast agent. Maps of the relative 
signal enhancement upon contrast agent injection, (Spost – Spre )/Spost, are displayed in the 
third column. All post images were taken immediately after the contrast agent injection. 
H&E staining of the corresponding slices are shown on the right. Tumours in vehicle-treated 
mice (P) were readily detectable using Gd-enhanced MRI. No tumour was detected in the 
MRI of mice treated with the anti-angiogenic compounds bevacizumab (B), sunitinib (S), or 
vandetanib (V), or with the combination vandetanib–sunitinib (VS). H&E staining of the 
corresponding brain slice, however, shows extensive tumours. Original magnification of 
H&E staining: 12×.
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BBB and consequently decreased visibility in CE-MRI, despite the presence of large 
tumours. Characteristic examples of MR images and the corresponding histology 
of tumour-bearing brains are presented in Figure 4. The CE-MRI results were in 
agreement with the lack of IgG extravasation in treated mice (Figures 2F and 2E). 
The unresponsiveness of E473 tumours to antiangiogenic compounds strongly 
suggests that for growth, these tumours do not need angiogenesis. Indeed, these 
tumours have incorporated pre-existent vessels with an intact BBB, as illustrated 
by GLUT1 expression (Figure 5B) and the lack of extravasation of plasma IgG 
proteins (Figure 5C). The intact BBB in E473 tumours hampers detection in 
Gd-DTPA contrastenhanced (CE) MRI scans and, as expected, this does not change 
upon treatment with bevacizumab or sunitinib/vandetanib (data not shown). 
Figure 5  Anti-angiogenic treatment of highly diffuse infiltrative E473 glioblastoma 
xenografts. Representative H&E and Ki-67 images (A) of E473 brain slices of mice left 
untreated (P), treated with bevacizumab (B), or treated with the combination vandetanib 
and sunitinib (VS) are shown. Neither the mainly diffuse infiltrative phenotype nor the 
proliferation index is notably affected by anti-angiogenic therapy. Regions of which Ki67 
images are shown are indicated in the H&E staining. The presence of vasculature with an 
intact BBB is illustrated by Glut1-positive vessels in the tumour regions of an untreated E473 
mouse (B) and the absence of IgG vessel leakage in these regions (C). Original magnifications: 
(A) H&E 20×, Ki67 400×; (B) 400×; (C) 20×/400×.
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Discussion 
Glioblastoma is a highly malignant brain tumour characterized by the presence of 
areas with highly cellular and more compact, angiogenesis-dependent growth, as 
well as large diffuse infiltrative areas which up to now have left these tumours 
essentially incurable [2]. Characteristically, in the more compact tumour 
components, prominent angiogenesis occurs, suggesting that gliomas may be 
good candidates for anti-angiogenic therapies [22]. However, the effectiveness of 
anti-angiogenesis for glioma is still a matter of debate, as the angiogenesis 
dependency of gliomas is not as clear-cut as in many other tumour types. This is 
mainly due to the extensive diffuse infiltrative growth of glioma cells in the 
pre-existent brain parenchyma and to the very high density of pre-existent blood 
vessels in the brain which can be co-opted by infiltrating glioma cells [23,24]. Still, 
the improved PFS seen with anti-angiogenic therapies in other tumour types, 
together with a disturbing lack of effective treatment options for glioma patients, 
has resulted in the implementation of anti-angiogenic compounds, in combination 
with chemotherapy, in the clinical management of these patients. We have shown 
here that anti-angiogenic treatment (bevacizumab, sunitinib, and/or vandetanib) 
results in at least a partial restoration of the disrupted BBB and reduced vessel 
permeability in orthotopic glioma xenografts. This phenomenon may lead to 
overestimation of the response to treatment on Gd-DTPA enhanced MR images [5]. 
It is important to take this knowledge into account when evaluating the treatment 
response based on standard CE-MRI. There is now increasing awareness of this 
pitfall, which has recently also led to a proposition of updated criteria for the 
assessment of therapeutic response in high-grade glioma patients [25]. In previous 
work, we showed that normalization of brain tumour vasculature and concomitant 
closure of the BBB may have an antagonizing effect on the distribution of 
chemotherapy to tumour cells [13]. The current data show that antagonism of 
chemotherapies could also be anticipated when other VEGFR/PDGFR targeting 
compounds are used that result in BBB restoration. However, it has to be realized 
that (partial) BBB closure and the resulting reduction of oedema and intracranial 
pressure have a clear clinical benefit [17,26]. Clinically, this may be misinterpreted 
as tumour regression, and this effect may also account for improved PFS. Anti- 
angiogenic therapies in gliomas do not result in tumour regression, but rather 
induce a shift from angiogenic to infiltrative, but progressive growth [14]. This is 
in agreement with recent studies showing that anti-angiogenic TKIs can increase 
the invasiveness of tumour cells in pancreatic carcinoma, breast carcinoma, 
melanoma, and glioblastoma, and may even accelerate metastatic tumour growth 
[27,28]. We have shown here that anti-angiogenic therapies do not affect progression 
of the diffuse tumour areas, whereas angiogenesis in the compact growing 
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components in gliomas is potently inhibited, resulting in increased hypoxia. 
Conversion to an exclusively co-opting phenotype may provide gliomas with a 
mechanism of escape from antiangiogenic therapy [29]. It was recently published 
that diminishing oedema by anti-angiogenic compounds in mice with intracerebral 
glioma xenografts prolonged survival [30]. Why the survival of tumour bearing 
mice in our study was not elongated is not clear but it may be related to the 
extensive diffuse infiltration in our models. Mice carrying E473 xenografts 
receiving the TKI combination had to be sacrificed earlier than the other groups, 
due to illness and weight loss. We cannot explain this phenomenon. Investigation 
of the livers of treated mice did not reveal signs of hepatotoxicity. We cannot, 
however, exclude that other toxicities may exist. Whereas PDGFR inhibition is 
effective in preventing the maturation process during later stages of angiogenesis 
[16], it does not affect the vasculature in diffuse growth areas in our tumour 
models. This provides further evidence that these co-opted vessels are pre-existing, 
incorporated vessels and are not newly formed. It must be noted that stromal 
cell-derived mouse VEGF-A is not neutralized by bevacizumab [31]. We consider it 
unlikely that mouse VEGF-A contributes to angiogenesis in E98 xenografts as 
VEGF-A is expressed solely by hypoxic tumour cells in angiogenic regions [19]. The 
role of the BBB in the treatment of glioma is an important issue. Presumably, in 
order to neutralize VEGF-A, bevacizumab should be able to diffuse freely through 
the tumour to reach hypoxic cells. In angiogenic areas, this diffusion is initially 
facilitated by leaky vessels, but this will be a selflimiting process due to vessel 
normalization. This may not be an issue with TKIs as these directly target 
endothelial cells. Furthermore, sunitinib is not a substrate for ABC transporters 
and is efficiently transported over the BBB [32]. Several recent clinical studies 
using bevacizumab or cediranib (AZD2171, AstraZeneca) revealed reduced contrast 
enhancement in half of the glioblastoma patients [10,17,26], without prolonged 
overall survival. The difficulties in obtaining post-therapy glioblastoma material 
for histopathological analysis make it difficult to determine whether radiological 
reduction is the result of true tumour regression or whether therapeutic efficacy 
is overestimated due to restoration of the BBB. Recent clinical data are in favour of 
the second hypothesis [4]. In conclusion, our data show that the incorporation of 
pre-existing brain vasculature in diffuse infiltrative growth parts of glioblastomas 
prohibits effective curative therapy using approaches targeting VEGF. These 
results suggest that anti-angiogenic therapies need to be used in combination with 
compounds that can target the diffuse infiltrative parts of these devastating 
tumours. 
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Abstract
Background Anti-angiogenic treatment of glioblastoma characteristically results 
in therapy resistance and tumor progression via diffuse infiltration. Monitoring 
tumor progression in these patients is thwarted because therapy results in tumor 
invisibility in contrast-enhanced (CE) MRI. To address this problem, we examined 
whether tumor progression could be monitored by metabolic mapping using 1H 
MR spectroscopic imaging (MRSI). 
Methods We treated groups of BALB/c nu/nu mice carrying different orthotopic 
diffuse-infiltrative glioblastoma xenografts with bevacizumab (anti–vascular 
endothelial growth factor [VEGF] antibody, n = 13), cabozantinib (combined VEGF 
receptor 2/c-Met tyrosine kinase inhibitor, n = 11), or placebo (n = 15) and compared 
CE-MRI with MRS-derived metabolic maps before, during, and after treatment. 
Metabolic maps and CE-MRIs were subsequently correlated to histology and immu-
nohistochemistry. 
Results In vivo imaging of choline/N -acetyl aspartate ratios via multivoxel MRS is 
better able to evaluate response to therapy than CE-MRI. Lactate imaging revealed 
that diffuse infiltrative areas in glioblastoma xenografts did not present with 
excessive glycolysis. In contrast, glycolysis was observed in hypoxic areas in angio-
genesis-dependent compact regions of glioma only, especially after anti-angiogen-
ic treatment.
Conclusion Our data present MRSI as a powerful and feasible approach that is 
superior to CE-MRI and may provide handles for optimizing treatment of glioma. 
Furthermore, we show that glycolysis is more prominent in hypoxic areas than in 
areas of diffuse infiltrative growth. The Warburg hypothesis of persisting glycolysis 
in tumors under normoxic conditions may thus not be valid for diffuse glioma.
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Introduction
Glioblastoma is a highly aggressive primary brain tumor with dismal prognosis. 
Current therapy consists of surgery to the maximum feasible extent, followed by 
local irradiation and chemotherapy with temozolomide. These treatments are, 
however, palliative rather than curative: almost without exception, glioblastomas 
eventually recur with fatal outcome, and median survival is currently still 
only 14.6 months[1]. Glioblastomas characteristically contain areas of necrosis, 
surrounded by regions of active angiogenesis[2]. The lack of curative treatment 
options results from the presence of additional tumor zones in which cells 
infiltrate in a spiderlike pattern over considerable distances in the brain, often 
using white matter tracts or blood vessels as a scaffold and preventing radical 
surgery and radiotherapy. Diffuse infiltrative tumor growth does not strictly rely 
on neovascularization, as incorporated preexistent vasculature in these areas 
suffices to comply to the tumors’ metabolic demands[3]. As the blood–brain barrier 
in these incorporated vessels is mostly intact, regions of diffuse tumor growth go 
largely unnoticed on contrast-enhanced (CE) MRI scans, which might result in an 
underestimation of tumor burden[4–8]. Also, the blood–brain barrier in diffuse 
infiltrative tumor areas complicates treatment with intravenously administered 
therapies[9]. In the absence of curative treatment options, the presence of 
angiogenic areas in glioblastomas has made these tumors candidates for anti- 
angiogenic therapy[10–12]. Bevacizumab, a neutralizing antibody of vascular 
endothelial growth factor (VEGF) A, induces a radiological response in the majority 
of patients and may considerably improve quality of life[5,13,14]. Bevacizumab 
was FDA approved for treatment of recurrent glioma in 2009. In the past years we 
have generated a number of orthotopic human glioma xenograft models by direct 
implantation of surgically obtained glioblastoma specimens in nude mice[15]. 
Unlike most cultured glioma cell lines that develop to circumscribed and 
angiogenic tumors upon intracerebral implantation (eg, U87 [16]), our xenograft 
models have retained the capacity to grow via diffuse infiltration, sometimes 
concomitantly with local angiogenesis. It is increasingly recognized that these 
models that recapitulate the heterogeneous phenotypes of clinical glioma, 
including intact blood–brain barrier in diffuse areas, are of high value for 
preclinical investigations of antiglioma therapies[17]. We previously reported that 
treatment of diffuse glioma xenograft models with angiogenesis inhibitors 
(bevacizumab, vandetanib, sunitinib, and combinations thereof) affects compactly 
growing, angiogenesisdependent regions in glioma but does not have an impact 
on the diffuse infiltrative phenotype[4,7,9]. These treatments did not improve 
overall survival in our models. Whereas the perinecrotic angiogenic areas in 
clinical glioblastoma can be readily visualized in CE-MRI scans, this visibility 
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drops rapidly when VEGF-targeted therapies are applied[5,18]. In our orthotopic 
glioma models, this effect is also observed, and it is well established that this does 
not represent an antitumor effect but is rather due to vascular normalization and 
(partial) restoration of the blood–brain barrier[4,7,9,19], making it difficult to 
evaluate response to therapy via routine CE-MRI. We argued that noninvasive in 
vivo measurement of tumor metabolic characteristics is a better method to detect 
diffuse infiltrative glioma, as tumor metabolism does not depend on the status of 
the blood–brain barrier. Here, we investigated whether metabolic mapping via 
multi-voxel in vivo 1H MR spectroscopic imaging (MRSI) is more appropriate to 
detect glioma progression under anti-angiogenic therapies and we examined the 
effects of these therapies on tumor metabolism. 
Materials and Methods
Animals 
Athymic female Bagg albino (BALB)/c nu/nu mice (18–25 g, age 6–8 wk) were kept 
under specified pathogen free conditions and received food and water ad libitum. 
The local Animal Experimental Committee of the Radboud University Nijmegen 
Medical Centre (RUNMC) approved all experiments. E98 or E473 glioblastoma cells 
were injected orthotopically as described previously (300 000 tumor cells per 
mouse). 15 Animals were closely monitored and subjected to MRS and MRI followed 
by sacrifice when evident signs of tumor burden (e.g. 15% weight loss in 2 d, severe 
neurological abnormalities) were observed. In some cases, tumor-bearing animals 
were subjected to longitudinal measurements (T2-weighted imaging and MRSI). 
Brains were harvested and formalin fixed and paraffin embedded for further 
analysis.
Therapy 
Animals carrying E98 tumors were randomly divided into 3 groups. Treatment 
was started when signs of tumor growth became apparent, evidenced by the presence 
of edema in T2-weighted MRI (characteristically at day 13 post-implantation, not 
shown). Bevacizumab (Avastin, Genentech) was administered twice a week at a 
dose of 5 mg/kg in 100 mL phosphate buffered saline (PBS) via i.p. injection (n = 13). 
XL184 (cabozantinib, a combined VEGF receptor 2/c-Met tyrosine kinase inhibitor; 
Exelixis) was given by oral gavage by daily dosing at 100 mg/kg (n = 11). Placebo- 
treated mice (oral administration of PBS) were used as the control group (n = 15). 
Previous studies already showed that i.p. injection of PBS did not affect tumor 
growth, allowing us to use this control group for both treatment regimens. 
Treatment of mice carrying E473 human glioma xenografts, which grow in a 
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highly diffuse fashion, has been described before. [7] E473-carrying mice, both 
controls and bevacizumab treated, were also subjected to the MRSI protocol to be 
described here (n = 4 or 5).  
MRI and MR Spectroscopy 
Animals (n = 4 for each group) were anesthetized using 1% –2% isoflurane in a 
70%/30% N2O/O2 mixture and placed in a prone position in an MR cradle. Breathing 
was monitored throughout the MR experi- ment, and the animals’ core temperature 
was maintained at 37.5 °C using a continuous flow of warm air (SA Instruments). MR 
investigations were performed on a 7 T animal MR system (ClinScan, Bruker BioSpin) 
equipped with a clinical user interface (syngo MR, Siemens). All used MR sequences 
were adopted from their clinical counterparts and received minor modifications to 
allow for optimal usage of the available gradient and radiofrequency power without 
compromising compatibility with the clinical (postprocessing) platform. After 
acquisition, data were fitted in LCModel software, and choline (Cho), N-acetyl 
aspartate (NAA), and lactate (having 1H resonances at 3.5 and 3.19 ppm; 2.01, 2.49, 
and 2.67 ppm; and 1.31 ppm, respectively) in 0.85mm3 voxels were quantified. Cho/
NAA ratios were projected as 2D heat maps superimposed on T2-weighted MR maps. 
Similarly, absolute lactate levels were depicted in heat maps. Cho/NAA ratios in sets 
of 4 independent voxels, chosen in CE or non-CE areas (as identified on hematoxylin 
and eosin [H&E] staining of corresponding sections), as well as in normal brain, were 
compared using a Mann–Whitney U-test. CE-MRI was performed as described 
previously [4]. In short, after acquiring MRS data, T1-weighted images were acquired, 
followed by an intravenous bolus injection of 0.2 mL of gadolinium–diethylene-
triamine pentaacetic acid (Gd-DTPA; 20 mMol/L; Magnevist, Schering). Additional 
sets of T1-weighted images were acquired 2 min after injection. 
Immunohistochemistry 
Immunohistochemical stainings were performed as described before [7] with 
antibodies against glucose transporter 1 (GLUT1; a constitutive marker for normal 
brain capillary endothelial cells and for hypoxic tumor cells; Neomarkers), mono-
carboxylate transformer 1 (MCT1; a lactate importer, expressed near and in 
glycolytic cells) and MCT4 (a lactate exporter, expressed by glycolytic cells; both 
MCTs from Santa Cruz Biotech), and hypoxia-inducible factor 1-alpha (HIF1a; clone 
54, BD Biosciences Pharmingen). Anti–carbonic anhydrase (CA)–IX (M75) antibody 
was a generous gift from Dr E. Oosterwijk (RUNMC). For HIF1a staining, the signal 
was additionally amplified using catalyzed reporter deposition [20]. In some cases, 
tumor-bearing animals were injected with pimonidazole prior to sacrifice, after 
which the accumulated pimonidazole in hypoxic tumor areas was visualized 
using a specific rabbit antiserum (Hydroxyprobe Omni kit) [21]. 
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Results
Detectability of Glioma by MRSI
The poor visibility in CE-MRI of diffuse infiltrative areas in clinical and preclinical 
models of glioblastoma, a phenotype that is characteristically present in untreated 
tumors and is increased upon treatment with angiogenesis inhibitors [4,9,22], led 
us to investigate whether the metabolic profile of tumor cells in these areas allows 
visualization via multivoxel MRSI. NAA is a metabolite that is synthesized by 
neurons in abundant amounts, whereas Cho compounds are precursors of cell 
membrane components that increase in cells after malignant transformation [23]. 
Both NAA and Cho-containing compounds (total choline, tCho) can be detected by 
chemical shift imaging in 1H MRSI. Increased tCho and decreased NAA tissue 
levels are hallmarks of brain tumor growth, and tCho over NAA ratios (Cho/NAA) 
are increased in gliomas, discriminating tumor from normal brain tissue with a 
specificity of 86% and a sensitivity of 90% [24–26]. E98 xenografts present with the 
heterogeneous phenotypes that are also present in clinical gliomas and respond 
similarly to anti-angiogenic treatment with respect to loss of MRI visualization 
[4,7,9]. Compared with normal mouse brain (Fig. 1A), E98 xenografts present with 
highly elevated tCho/NAA, both in compactly growing (Fig. 1B) and diffuse 
infiltrative E98 areas (Fig. 1C). Panels D – F in Fig. 1 show spectra corresponding to 
the respective encircled voxels in panels A –C. Voxels with elevated ratios colocalize 
with tumor, as established by Gd-DTPA–enhanced T1-weighted MRI (see the post/
pre subtraction image in Fig. 1G) and H&E staining of corresponding brain sections 
(Fig. 1I and J). Note that the diffuse tumor in panel J is hardly detectable on CE-MRI 
(panel H) but results in elevated Cho/NAA ratios (panels C –F).
MRSI of Glioma Under Anti-angiogenic Treatment 
To investigate whether the tCho/NAA ratios could be utilized for detection of 
diffuse infiltrative glioma under antiangiogenic treatment, we treated E98- and 
E473-bearing mice with bevacizumab. Treated animals were sequentially subjected 
to MRSI and CE-MRI. Whereas Gd-DTPA– enhanced imaging showed a greatly 
diminished signal compared with that in nontreated E98 mice (Fig. 2B, compare 
with Fig. 1G), MRS mapping of the tCho/NAA ratio revealed extensive presence of 
tumor (Fig. 2A and D). Comparison with corresponding H&E-stained brain sections 
(Fig. 2C) showed that despite the relatively low resolution, the tumor was far better 
delineated by 1H MRS than by CE-MRI. To exclude that these findings were somehow 
specific to E98 xenografts, we performed similar experiments with the E473 
xenograft model. E473 tumors grow in a diffuse infiltrative manner without 
evidence of an angiogenic response [15]. We previously showed that the apparent 
absence of angiogenesis coincides with a lack of response to bevacizumab [7]. 
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Figure 1  MRSI visualizes the diffuse infiltrative E98 tumor component better than CE-MRI. 
Representative in vivo tCho/NAA (scaled 0–1.5) MRSI metabolic maps of (A) 1 non-tumor-bearing 
control brain and (B and C) 2 untreated brains infiltrated with E98 xenografts. E98 tumors 
characteristically display compact, angiogenic growth as well as diffuse infiltrative growth, 
the ratio of these being variable. For clarity, a tumor with profound compact growth and 
relatively small areas of infiltrative growth (B, E, G, I) and one with the converse ratio 
(C, F, H, J) are shown. Panels D–F show spectra (TE = 24 ms) of the respective white encircled 
voxels in panels A–C. Cho, creatine (Cre), NAA, lipid, and lactate peaks are indicated. Panels 
G and H show contrast enhanced (Gd-DTPA) MRI delta map (Spost-Spre)/Spre of corresponding 
slices of the tumor-bearing animals. Note that contrast agent entered the brain in panels 
G and H, indicated by the high signal intensity in the skull and skin. Panels I and J show matched 
endpoint H&E histology. Size bars correspond to 2 mm. Abbreviations: T, tumor; N, normal.
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Figure 2  MRSI visualization of bevacizumab-treated E98 xenografts. Cho/NAA (scaled 
0–1.5) MRSI metabolic map of representative mouse brains with (A and I) E98 tumor or (E) 
E473 tumor after treatment with (A, E) bevacizumab and (I) cabozantinib. The short echo 
time (24 ms) spectrum of the white encircled voxel in panel A is depicted in D. Note that the 
MRSI correlates better with histology (H&E staining in C, G, K) than contrast enhanced 
(Gd-DTPA) MRI; see delta map (Spost-Spre)/Spre in B, F, and J. The inset in panel B shows a red 
and a green area (corresponding to enhancing and non-enhancing tumor) in which Cho/
NAA ratios were quantified. These data, together with Cho/NAA ratios from non-neoplastic 
brain, are presented in H. Size bars in C – K correspond to 2 mm. Note that only the central 
part of the brain is included in the metabolic maps, as the boundaries between brain and 
other tissues severely compromise the quality of spectra collected from these regions.
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Similar to the results obtained with E98 tumors, CE-MRI was not able to delineate 
tumor in E473 xenografts (Fig. 2F) [7], whereas MRSI revealed extensive tumor 
involvement (Fig. 2E) consistent with histology (Fig. 2G). The ratio of tCho/NAA in 
the CE area in Fig. 2B was 2.9 + 0.84 (mean + SD of 4 voxels in the red boxed area in 
inset) and did not differ from tCho/NAA ratios outside the CE area (2.64 + 0.83; 
mean + SD of 4 voxels in green boxed area; P 1 ⁄4 .69). These numbers were 
significantly higher than tCho/NAA ratios in voxels outside the tumor area and in 
nonneoplastic mouse brain (0.45 + 0.38 and 0.49 + 0.12, respectively; P = .03 for 
both comparisons; see Fig. 2H). In our experience, tyrosine kinase inhibitors of 
VEGF receptor 2 can be more effective in normalizing tumor blood vessels in 
glioma xenografts than can bevacizumab [4,7]. We have previously published that 
cabozantinib, a tyrosine kinase inhibitor with specificity for VEGF receptor 2, Met, 
and Ret, fully reduces blood vessel leakage in E98 xenografts, resulting in tumors 
that are invisible in CE-MRI (Fig. 2J) [27]. In agreement with the E98 and E473 data, 
MRSI heat maps of tCho/NAA were indicative of extensive tumor presence (Fig. 2I, 
compare with H&E staining in Fig. 2K). 
Glycolysis in E98 Xenografts Is Limited to Focal Areas of Hypoxia 
Inhibition of angiogenesis has been shown to result in hypoxia and an increase of 
glycolysis in glioma [28]. Based on the observed lack of hypoxia in diffuse areas of 
glioma, also after anti-angiogenic treatment [7,29], we evaluated the extent of 
glycolysis during development of E98 xenografts by directly measuring tissue 
lactate levels in treated and nontreated E98 xenografts. In addition to MRSI at 
short echo time (TE = 24 ms), we acquired data at TE = 144 ms, allowing 
quantification of tissue lactate concentrations (representative examples shown in 
Fig. 3N). At this long echo time, the lactate peak at 1.3 ppm shows a characteristic 
inversion due to the strong J-coupling of the lactate CH3 and CH proton spins. 
Furthermore, at long echo times, the contribution of overlapping lipids (as is 
present at TE = 24 ms) is minimized by their short T2 relaxation time. Lactate 
levels were low in control-treated E98-bearing mice (Fig. 3B and E, compare with 
panels A, C, D, and F, which show elevated Cho/NAA levels in tumor containing 
voxels; note that this is the same mouse presented in Fig. 1). Bevacizumab treatment 
clearly induced glycolysis, as reflected by gradually increasing lactate levels at D13, 
D20, and D26, representing days 0, 7, and 13 after start of treatment (Fig. 3H, J, L, 
mean concentration at D26: 9.9 + 2.2 mM in compact tumor areas, as established 
by corresponding histology [n = 76 voxels] vs 2.6 mM in control mice [n = 495 
voxels], P < .0001). In the tumor periphery, however, large areas of highly elevated 
Cho/NAA ratios were detected (Fig. 3I and K), with relatively low lactate (Fig. 3J 
and L). Tumor heterogeneity with respect to lactate production stresses the 
importance of performing multivoxel instead of single voxel MRSI. Importantly, 
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Figure 3  Bevacizumab treatment results in a highly localized increase in lactate production 
in E98 xenografts. Panels A and D show maps of Cho/NAA metabolite ratios (range 0–1.5, 
values obtained using TE = 24 ms); in panels B and E, absolute lactate concentrations are 
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after cabozantinib treatment, a number of mice showed only diffuse infiltrative 
growth with no detectable hypoxia markers [27]. Whereas tumor was readily 
detected by tCho/NAA mapping (Fig. 3N), lactate levels were even lower than after 
bevacizumab treatment in these mice (Fig. 3O, compare with 3P). The diffuse 
infiltrative tumor that remains after antiangiogenic therapy takes advantage of 
the high cerebral vascular density for its blood supply. As these areas are well 
perfused (as indicated by the absence of hypoxia), lactate may be rapidly drained 
from the tumor, resulting in underestimation of lactate levels. In this scenario, 
glycolytic cells should express MCTs to facilitate efficient lactate secretion, and 
CA-IX to prevent intracellular acidosis [30]. GLUT1 and MCT4 were absent in 
diffusely growing tumor cells (Fig. 4A, arrows point to diffuse infiltrative cells), 
and this was also true for MCT1, HIF1a, and CA-IX (data not shown). Similar results 
were previously obtained with diffuse E473 xenografts [7]. This contrasted with 
the situation in compact tumor regions where significant areas stained positive 
for GLUT1 and MCT4 proteins in a pattern that was reminiscent of central hypoxia 
(arrowheads in Fig. 4A). Hypoxia was far more pronounced in compact areas in 
response to bevacizumab treatment (lower panels in Fig. 4A), and this is in 
agreement with previous data [7]. To further prove that excessive glycolysis in our 
models was confined to areas of hypoxia, we injected mice just before sacrifice 
with pimonidazole, accumulation of which is the gold standard for hypoxia [31], 
and stained serial sections of treated E98 xenografts for GLUT1, MCT4, and 
pimonidazole. As shown in Fig. 4B, MCT4 especially had a strong colocalization 
with pimonidazole, and this staining pattern largely colocalized with GLUT1 (data 
not shown). In conclusion, comparison of the lactate map in Fig. 3L with histological 
analysis in Fig. 3M and immunohistochemical data from Fig. 4 strongly suggests 
that elevated lactate levels concentrate in areas of hypoxia. The absence of glycoly-
depicted (range 0–15 mM, values obtained using TE = 144 ms). C and F represent H&E stained 
corresponding coronal sections (same animals as shown in Fig. 1). (A – F) untreated; (G – M) 
bevacizumab-treated. Panels G – H, I – J, and K – L represent MRS maps at days 13, 20, and 26 
post tumor implantation, which corresponds to days 0, 7, and 13 of bevacizumab treatment. 
Note in panels J and L that lactate levels gradually increase after treatment with bevacizumab, 
but predominantly in compact tumor areas. Panel N shows a representative short (24 ms) 
and long (144 ms) echo time MR spectrum of a selected voxel of the bevacizumab-treated 
animal (day 26, white encircled voxel in panel L). Panels O – Q represent mouse brains with 
E98 xenografts after treatment with cabozantinib. Note that only low levels of lactate are 
observed (P), whereas high Cho/NAA ratios are detected throughout the tumor (O). All 
metabolite values were obtained using LCModel and plotted regardless of the Cramér–Rao 
lower bound value of the fits. Voxels in which one of the metabolites could not be fitted by 
LCModel are omitted. Size bars correspond to 2 mm.
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sis-related proteins in diffuse tumor areas, together with the absence of elevated 
lactate levels, suggests that tumor cells in these areas do not excessively depend on 
glycolysis for their growth.
Discussion 
The lack of reliable modalities to visualize the diffuse infiltrative component of 
glioblastoma, especially after treatment with anti-angiogenic compounds, is a 
serious problem in neurooncology. The necessity for novel imaging modalities is 
emphasized by the recent finding from randomized clinical trials that despite 
dramatic radiological responses upon bevacizumab treatment, overall survival of 
glioblastoma patients was not improved [32,33]. CE-MRI is the common standard 
Figure 4  Hypoxia levels in E98 xenografts upon treatment. Representative immunohisto-
chemistry of the hypoxia markers GLUT1 and MCT4 in (A) untreated and bevacizumab-treated 
tumor-bearing animals. (B) MCT4 expression correlates well with pimonidazole accumulation 
and further demonstrates that hypoxia is limited to foci in central compact tumor areas 
only. Size bars: 1 mm.
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in routine examinations of brain tumors, but it is not able to delineate the entire 
tumor volume, and detectability is even more decreased upon VEGF inhibition, a 
phenomenon that was confirmed in multiple orthotopic glioma xenograft models 
after treatment with different anti-angiogenic compounds [4,7]. Recently, new 
guidelines for response assessment of high-grade gliomas were proposed by the 
Revised Assessment in Neuro-Oncology consortium, in which T2-weighted and 
 fluid-attenuated inversion recovery (FLAIR) imaging is used to detect invasive 
nonenhancing tumor areas [34]. T2-FLAIR imaging visualizes tumors to some 
extent but has a number of limitations as well. Again, therapy may complicate 
T2-based tumor detection [18] due to vessel normalization and resulting edema 
reduction. We routinely performed T2-weighted imaging of the mice in the current 
study and indeed found that T2-weighted imaging in general was a less reliable 
measure of tumor volume (not shown). Thus, novel diagnostic modalities that 
properly visualize tumor extent and provide patients with realistic information 
on therapeutic effects and prognosis are urgently needed. In recent years, specific 
physiological and metabolic MR methods have been implemented to assess 
response to brain tumor treatment, such as imaging relative cerebral blood 
volume, water diffusion in tissue (diffusion weighted imaging), and MRSI of 
metabolites [26,35–39]. The potential of these approaches to reliably detect tumor 
load and spread and thus to circumvent the registration of mainly pseudoresponses 
in anti-angiogenic treatments is currently a topic of intense research. As proper 
validation of this potential may be difficult in patients, studies of orthotopically 
growing human brain tumors in animals is important for validation. We show 
here in 2 independent orthotopic glioma xenograft models, both displaying the 
characteristic diffuse infiltrative growth of glioma, that 1H MRSI of tCho/NAA 
ratios identifies the presence of infiltrative tumor tissue better than CE-MRI. This 
metabolism-based visualization is not hampered by vessel-normalizing effects (ie, 
functional restoration of blood–brain barrier) of antiangiogenic compounds. With 
increasing accessibility of high-field MR equipment and robust spectroscopic 
imaging acquisition software also in the clinic [40,41], inclusion of 1H MRSI–based 
visualization of glioblastoma growth becomes feasible and an attractive and 
promising modality. Of importance, this technology may also yield further 
information on the metabolic status of tumors that could aid in tumor classification 
[42]. Whereas bevacizumab treatment resulted in increased hypoxia in E98 
xenografts, corroborating a previous report [28], our multivoxel analysis revealed 
that lactate levels were increased in areas of hypoxia only. Cabozantinib treatment 
resulted in predominantly diffuse infiltrative tumors, often without any sign of 
hypoxia, and this was corroborated by the absence of significantly elevated levels 
of lactate. The combined findings suggest that anti-angiogenic treatment induces 
glycolysis only in compactly growing areas in which a rapid shutdown of blood 
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supply may result in local hypoxic conditions. Possibly, the local shutdown of 
blood supply and the resulting poor washout in glycolytic areas contributes to 
even higher accumulation of lactate. Also in E473 glioma xenografts, no glycolysis 
markers could be detected, even after treatment with bevacizumab [7]. Our finding 
of limited glycolysis in glioma is therefore not a one-model artifact. Furthermore, 
since glycolysis markers cannot be found in diffuse infiltrating tumor cells in 
clinical samples [43], these findings seem to have clinical relevance. Recent studies 
in glioma patients and in mice carrying orthotopic patient-derived glioma 
xenografts revealed that in glioma, mitochondrial oxidative phosphorylation 
predominates over glycolysis [44,45]. This is in line with our findings and does not 
conform to the Warburg hypothesis that tumor cells depend more on glycolysis 
than on mitochondrial oxidative phosphorylation [46]. It is likely that the potential 
for extensive vessel co-option by glioma cells, a result of the dense vascular bed in 
the brain, equips the diffusely infiltrating glioma cells with sufficient oxygen and 
nutrients to allow mitochondrial metabolism to proceed. Only in highly proliferative 
tumor areas that outgrow the local blood supply may hypoxia develop, resulting in 
a shift of the glycolysis/oxidative phosphorylation equilibrium toward glycolysis. 
In a previous report, a symbiotic relationship was suggested between hypoxic and 
normoxic tumor areas [47]. In this paper it is suggested that lactate, produced by 
hypoxic cells, is taken up by normoxic cells via MCT1. As we did not find increased 
MCT1 expression in diffuse infiltrative tumor cells in our models, it is not clear to 
what extent this phenomenon applies to our xenografts. Glycolysis is gaining 
interest as a therapeutic target— for instance, with inhibitors like dichloroacetate 
[48]. This pyruvate dehydrogenase kinase inhibitor has been proposed as a 
potential adjuvant treatment to bevacizumab [28]. Indeed, cells that shifted their 
metabolism to glycolysis as a result of bevacizumab treatment would be forced to 
turn to mitochondrial oxidative phosphorylation and this would result in cell 
death in the absence of oxygen [49–53]. Our data show that the effects of glycolysis 
inhibition on E98 tumor growth would be limited to hypoxic tumor areas, leaving 
the larger volume of diffuse infiltrative tumor unaffected. Yet, the highly 
heterogeneous nature of clinical glioblastoma makes it worthwhile to generate 1H 
MRS – based maps of Cho/NAA and lactate. Patients in whom a significant fraction 
of the tumor is glycolytic (as determined by the total voxel volume with elevated 
lactate/ total voxel volume with elevated Cho/NAA) may indeed significantly 
benefit from therapy with dichloroacetic acid. In this way MRSI can help in 
selecting patients who are eligible for antiglycolytic treatment. Besides pruning of 
newly formed vessels, bevacizumab treatment has been proposed to normalize 
tumor blood vessels and improve tumor perfusion and oxygenation, thereby 
increasing susceptibility to radioand chemotherapy [54]. In our study, treatment 
with bevacizumab increased the hypoxic tumor cell fraction in compact E98 areas, 
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an effect that was also seen previously with vandetanib [9]. This is in agreement 
with a model in which bevacizumab rapidly decreases blood flow to compact 
growing tumor areas, rather than improving perfusion. We propose that anti-an-
giogenic treatment of tumor areas that have undergone the angiogenic switch [55] 
will result in consolidation of vasculature in these areas. Continuing tumor 
expansion in the absence of novel vascularization (initially via vascular co-option 
[3] ) will result in increased hypoxia. On the other hand, in earlier-stage tumors in 
which the angiogenic switch did not yet occur, treatment would prevent development 
of these areas, resulting in diffuse tumor growth exclusively. In conclusion, we 
have shown that MRSI is superior to CE-MRI for a reliable noninvasive evaluation 
of therapeutic effects in the anti-angiogenic treatment of gliomas and yields 
additional information about tumor metabolism that may be exploited for 
individualized treatment. We further showed that infiltrating glioma cells in our 
models did not display the glycolytic phenotype that has been suggested to be a 
hallmark of tumors (ie, the Warburg effect). 
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MR Sequence settings
T1w TSE
A turbo spin echo sequence with following settings were used, repetition time (TR) 
3880 ms, echo time (TE) 43 ms and a turbo factor of 7. The scans had a resolution 
of 98 µm inplane and a thickness of 0.7 mm per slice.
MRSI
For all time points anatomical references using a multi-slice localizer with slices 
in the three main orthogonal directions were acquired. Subsequently multi-slice 
fat-suppressed T1-weighted anatomical reference scans (GRE) were made in the 
three directions parallel to the main orientations of the MRSI grid. Before 
acquiring the MRSI the magnetic field homogeneity was optimized using a 
standard 3D stimulated echo shimming routine. For the MRSI a 3D short echo 
time (TE 24 ms) semi-LASER [1] sequence followed by a long echo time (TE 144 ms) 
semi-LASER was acquired. Prior to sacrificing the animal, additional T1 MPRAGE, 
spin echo T2, and T1 time of flight data were acquired before and after injection of 
the contrast agent Gd-DTPA (Magnevist, Bayer Schering Pharma, Germany). MR 
spectra were processed by LCModel [2] to obtain tissue concentrations of metabolites 
which are reported as absolute values for the treated and control animal groups. 
The output of the LCModel fitting routine was re-gridded to a 3D grid representing 
the volume of interest (VOI) using MATLAB (Mathworks, Natick, MA, USA). For 2D 
projections of relative or absolute metabolite concentrations, maps with linear 
color intensities overlaying the corresponding reference T2w MR image were 
made. For MRSI a semi-LASER sequence was used. Common settings between short 
(24ms) and long echo time (144 ms) measurements were: TR 1500 ms, a scan matrix 
of 12 × 12 × 16 which was interpolated after Fourier reconstruction to 16 × 16 × 16. 
The field of view (FOV) was 11 × 11 × 16 mm with a VOI 8 × 6 × 8 mm resulting in a 
nominal voxel size of 0.92 × 0.92 × 1.00 mm (0.85 mm3). Using a 3D elliptical 
weighted phase encoding scheme the total acquisition time per scan was reduced 
to 27 m 54 s. By using accumulation / acquisition weighted (AW) k-space sampling 
( NA (k=0) = 4 ) only 1674/13824 of the time needed for full spatial phase encoding 
was needed. To eliminate high frequency noise after weighted k-space acquisition 
an additional Hamming filter with a width of 100 Hz was applied to k-space 
resulting in a spherical voxel with a true size of 1.48 mm3. The water signal was 
suppressed using WET over a bandwidth of 120 Hz. Six saturation slices of 1 mm 
thickness were positioned to suppress any residual signals from tissues surrounding 
the VOI, mainly fat and bone. Saturation was positioned at -3.40 ppm relative to 
water. For subsequent absolute metabolic quantification a non-water suppressed 
short echo time semi-LASER was acquired. The sequence is similar to the regular 
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short echo time semi-LASER but with the water suppression pulses set to 0 and the 
carrier at -2.20 ppm relative to water. 
Metabolic quantification using LCModel
The raw 1H MR spectra as obtained by the short-echo time semi-LASER were 
used for LCModel analysis. No time-domain filtering was applied to the spectral 
time-domain data before LCModel analysis. The LCModel basis data set simulated 
for 7 T and using the semi-LASER with either TE = 24  ms or TE = 144 ms included 
the following metabolites: alanine, aspartate, creatine (Cr), phosphocreatine, 
γ-amino butyric acid, Glc, glutamine, Glu, glycerophosphorylcholine (GPC), 
 phosphorylcholine (PCh), glycine, myoinositol, scyllo- inositol, Lactate, N-acetyl-
aspartate (NAA), N-acetylaspartylglutamate, and taurine. In addition an inversion 
recovery nulled macromolecular base line was included for the TE = 24 ms basis 
set. The LCModel analysis was performed on each of the spectra from the chemical 
shift range of 0.0 to 4.0 p.p.m. The Cramer–Rao lower bounds (CRLBs) were used 
to eliminate statistically unreliable values. A detailed description of the metabolic 
fitting is available in the support information After MR acquisition the data was 
fitted with the LCmodel 6.2-1 software package [2]. LCModel uses a linear 
combination of in vitro metabolite model spectra to fit the in vivo measured 
spectra. Zero- and first-order phase correction and reference shift correction are 
included in the model. The non-water suppressed semi-LASER [1] data was used by 
LCModel as an internal reference for quantification and for eddy current correction 
of the metabolite data. A water concentration of 65% was assumed as an average 
value for the white and gray matter areas in the mouse brain. Input for LCModel 
was the time domain data of each metabolite FID in the data set, also referred 
to as the basis set. The individual metabolites used for the basis set are listed in 
table S1 using chemical shift information from [3]. The basis set was extended 
with a macromolecular basis line acquired on 3 healthy control mice by using an 
inversion recovery metabolite CH3-nulling semiLASER sequence. Settings were 
similar to the short echo time semi-LASER sequence but the sequence started with 
a 180° inversion pulse with an additional inversion time (TI) of 570 ms. Before 
adding this macromolecular basis line to the basis set some residual CH2 
resonances where filtered by using a HLSVD filter [4]. For quality control in vitro 
metabolite spectra were obtained under similar experimental conditions to the 
in vivo measurements. 
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Table S1   Metabolites used for fitting in vivo spectra with LCModel. 
Metabolite Abbreviation PPM range (between 4.00-0.20)
Creatine Cre 3.9 / 3.03 
N-acetyl-aspartate NAA 2.49 / 2.67 / 2.01
Phosphocreatine PCr 3.9 / 3.03
Lactate Lac 1.31
Glucose Glc 3.88-3.2 
Choline Cho 3.50 / 3.19 
Glycerophosphorylcholine GPC 3.95-3.61 / 3.21
Phosphorylcholine PCh 3.64 / 3.21
Myo-inositol mI 3.61-3.52 / 3.27
Taurine Tau 3.42 / 3.25
Aspertate Asp 3.89 / 2.80 / 2.65
Glutamate Glu 3.74 / 2.35-2.04
Alanine Ala 3.77 / 1.47
Glutamine Gln 3.75 / 2.46-2.12
Glutathione GSH 3.77 / 2.98-2.93 / 2.55 / 2.15
γ-Aminobutyric acid GABA 3.01 / 2.28 / 1.89
N-Acetylaspartateglutamate NAAG 2.75 / 2.55 / 2.04
Acetate Act 1.90
Scyllo-inositol Scyllo 3.34
Glycine Gly 3.55
Pyruvate Pyr 2.36
Succinate Suc 2.39
Macro molecular base line MM 4.00-0.20
Creatine CH2 correction term  
(not a metabolite!)
-CrCH2 3.94
Guanidinoacetate position Gua 3.78
Lipid signal at 1.3 ppm Lip13 1.30
Lipid signal at 0.9 ppm Lip09 0.90
Lipid signal at 2.0 ppm Lip20 2.00
Abbreviation and ppm positions of major resonances. Derived from [3].
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Abstract 
Many patients with glioma harbor specific mutations in the isocitrate 
dehydrogenase gene IDH1 that associate with a relatively better prognosis. 
IDH1-mutated tumors produce the oncometabolite 2-hydroxyglutarate. Because 
IDH1 also regulates several pathways leading to lipid synthesis, we hypothesized 
that IDH1-mutant tumors have an altered phospholipid metabolite profile that 
would impinge on tumor pathobiology. To investigate this hypothesis, we 
performed 31P MRS imaging in mouse xenograft models of four human gliomas, 
one of which harbored the IDH1-R132H mutation. 31P-MR spectra from the 
IDH1-mutant tumor displayed a pattern distinct from that of the three IDH1 
wild-type tumors, characterized by decreased levels of phosphoethanolamine and 
increased levels of glycerophosphocholine. This spectral profile was confirmed by 
ex vivo analysis of tumor extracts, and it was also observed in human surgical 
biopsies of IDH1-mutated tumors by 31P high-resolution magic angle spinning 
spectroscopy. The specificity of this profile for the IDH1-R132H mutation was 
established by in vitro 31P NMR of extracts of cells overexpressing IDH1 or 
IDH1-R132H. Overall, our results provide evidence that the IDH1-R132H mutation 
alters phospholipid metabolism in gliomas involving phosphoethanolamine and 
glycerophosphocholine. These new noninvasive biomarkers can assist in the 
identification of the mutation and in research toward novel treatments that target 
aberrant metabolism in IDH1-mutant glioma.
587
Introduction 
Diffuse gliomas are the most common malignant brain-born tumors and are 
incurable with present therapeutic strategies (1). These tumors are classified by the 
World Health Organization (WHO) as grade 2, 3, and 4 of which grade 4 glioma 
(glioblastoma, GBM) is the most malignant type. The current median survival 
from the time of diagnosis for GBMs is only 14.6 months and for lower grades 
between 4 and 15 years (2, 3). This highly variable survival calls for reliable 
prognostic biomarkers for rational decision making in clinical management. Such 
biomarkers have become available with the discovery that in more than 70% of 
grade 2 and 3 gliomas and in secondary GBMs, one of the genes for isocitrate 
dehydrogenase (IDH1 and IDH2) carry specific mutations, which are associated 
with prolonged overall survival (4–8). IDH1, the predominantly affected enzyme 
(>95%), catalyzes the conversion of isocitrate into α-ketoglutarate (αKG) in the 
cytosol, using NADP as electron acceptor to generate NADPH (Fig. 1A). IDH1 can 
also catalyze the reductive carboxylation of αKG to isocitrate that can be further 
processed to citrate and acetyl- and succinyl-CoA, important anabolic precursors 
for lipid synthesis (9). The mutation in IDH1, almost always affecting arginine 
R132, confers a neomorphic activity to the enzyme, which results in NADPH-de-
pendent conversion of αKG to 2-hydroxyglutarate (2-HG; Fig. 1A; ref. 10). The 
mutant enzyme lacks the capacity of reductive carboxylation (11). As 2-HG 
accumulates in mutated tumor cells and tissues (12–14), it has attracted attention 
as a potential biomarker in the diagnosis and prognosis of gliomas, in particular 
as the high levels of 2-HG can be detected noninvasively by 1H MR spectroscopy 
(MRS) in humans (8, 15–19). 
 1H MRS has been explored extensively in the diagnosis and treatment 
evaluation of brain tumors in humans (20, 21). MR spectra of the brain show a 
single spectral peak for the methyl protons of small choline compounds, which 
are involved in the Kennedy pathway of membrane lipid synthesis and breakdown 
(Fig. 1B). In brain tumors, choline metabolism is adapted to the needs of higher 
proliferation and to the physiologic microenvironment (such as acidic extracellular 
pH; refs. 22, 23), and the intensity of this peak (labeled as total choline or tCho) is 
often increased (24). Another prominent spectral change is a decrease of the peak 
for the methyl protons of N-acetyl aspartate (NAA), a neuronal marker compound, 
reflecting replacement of neurons by glial tumor cells (25). The tCho/NAA ratio is, 
therefore, often used as a biomarker for tumor load and malignancy in gliomas 
(26–28). The intensity of the tCho peak also correlates with cell density, and may be 
related to gliosis (29, 30). To understand in more detail what determines the tCho 
peak intensity, an analysis of each contributing component is needed. This is 
possible with 1H MRS of ex vivo biopsy material, which has a better spectral 
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Figure 1  Schemes of metabolism involved in 2-HG biosynthesis (A), and of choline and 
ethanolamine phospholipid metabolism (B). Arrows, metabolic pathways. A, IDH1/2 catalyze 
oxidative decarboxylation of isocitrate to αKG using NADP+ as a cofactor to generate NADPH 
and CO2. Mutations in these genes generate the oncometabolite 2-HG by consuming NADPH, 
and have an impact on intracellular signaling and epigenetics. The citrate generated via the 
TCA cycle contributes to the lipid synthesis. This pathway can be interrupted by mutations 
in IDH1 and/or IDH2 genes. Subsequent metabolism of citrate produces acetyl-CoA for fatty 
acid and/or lipid synthesis, and other intermediates such as oxaloacetate and malate in TCA cycle. 
B, metabolic pathways of PtdCho and PtdEtn. Acyl-CoA, acyl-coenzyme A; Etn, ethanolamine; 
CDP-Etn, cytidinediphosphate ethanolamine; PtdSer, phosphatidylserine; ChoK, choline 
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resolution than in vivo MRS and allows the separation of tCho into peaks for 
phosphocholine (PC), glycerophosphocholine (GPC), and free choline (24). Ex vivo 
1H MRS or high-resolution magic angle spinning (HR-MAS) spectroscopy has 
revealed that PC and GPC contribute importantly to the increase of tCho in brain 
tumors and also uncovered more subtle relationships of choline compounds with 
tumor features, in particular with tumor grade (31–34). Direct in vivo detection of 
PC and GPC is possible by 31P MRS, which also enables detection of phosphoetha-
nolamine (PE) and glycerophosphoethanolamine (GPE), thereby providing a more 
complete picture of in vivo phospholipid metabolism (35). Because 31P MRS is less 
sensitive than 1H MRS and requires dedicated radiofrequency probes, it has been 
less used to examine phospholipid metabolites in vivo in brain tumors (36, 37). 
However, the increased access to high-field (pre-) clinical MR scanners, which 
improves 31P MRS sensitivity and resolution, invigorates its further exploration in 
studies of tumor phospholipid metabolism. As α-KG and NADPH are important 
components for lipogenesis (38, 39) and as the mutated IDH enzyme consumes 
both compounds and lacks reductive carboxylation capacity, we hypothesized that 
phospholipid metabolism is altered in IDH1-mutated glioma. To test this hypothesis, 
we applied in vivo 31P MR spectroscopic imaging (MRSI) to four unique and representative 
human glioma models growing orthotopically in mice (40), one carrying the 
IDH1-R132H mutation (41). The spectral findings were verified by 31P NMR analyses 
of tumor tissue extracts. To examine the causal relationship of the spectral profiles 
to expression of the mutated enzyme, we also performed 31P NMR on extracts of 
glioma cell lines, stably expressing wild-type or mutated IDH1. Finally, we tested if 
similar phospholipid profiles occur in human gliomas by performing 31P HR-MAS 
MRS of biopsies of gliomas in patients with and without IDH1 mutation.
Materials and Methods 
Animals 
Balb/c nu/nu mice were obtained from Janvier and housed in filter-top cages under 
specific pathogen-free conditions. Animals were fed a standard diet with food and 
water ad libitum. A 12-hour light, 12-hour dark day–night regimen was applied. 
All procedures and experiments involving animals were approved by The National 
kinase (EC 2.7.1.32); ETNK, ethanolamine kinase (EC 2.7.1.82); cPLA2, cytosolic phospholipase 
A2 (EC 3.1.1.4); PLC, phospholipase C (EC 3.1.4.3); PSD, phosphatidylserine decarboxylase (EC 
4.1.1.65); PSS1, phosphatidylserine synthase I (EC Ptdss1); PSS2, phosphatidylserine synthase 
II (EC Ptdss2); PEMT, phosphatidylethanolamine N-methyltransferase (EC 2.7.8.29).
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Animal Research Authority, and carried out according to the European Convention 
for the Protection of Vertebrates used for scientific purposes.
Glioma xenografts 
Glioma xenografts were injected in the brain of female Balb/c nu/nu mice (6–10 
weeks of age, n > 4 for each individual xenograft line), as described previously (40). 
Two xenograft lines, labeled E468 and E473, were originally derived from human 
GBM biopsies, whereas E434 and E478 were established from high-grade oligoden-
droglioma specimens. The E478 xenograft model contains the heterozygous 
IDH1-R132H mutation (41). All xenografts grow via diffuse infiltration, whereas 
the E434 model additionally presents with some compact growth (40).
Development of IDH1 (-R132H)–expressing cell lines 
To generate IDH1 and IDH1-R132H–expressing U251MG glioma cell lines, human 
IDH1 cDNA (accession number, BC093020, ImaGenes) in pBluescript plasmid was 
used for site-directed mutagenesis using the QuickChange Site-Directed 
Mutagenesis Kit (Stratagene/Agilent). Primers containing the critical IDH1-G395A 
mutation were 5'-CCT ATC ATC ATA GGT CAT CAT GCT TAT GGG GAT CAA TAC 
AGA GC-3' (forward) and 5'-GC TCT GTA TTG ATC CCC ATA AGC ATG ATG ACC TAT 
GAT GAT AGG-3' (reverse, mutated bases are underlined). After mutant strand 
synthesis, DNA of both wild-type and mutant IDH1 was amplified using primers 
5'-GAA TTC ATG TCC AAA AAA ATC AGT GGC GG-3' (forward) and 5'-GGA TCC TTA 
AAG TTT GGC CTG AGC-3' (reverse) and cloned into the EcoR1 and BamH1 sites of 
a customized pENTR/U6 vector (Invitrogen). Both pENTRY/U6 plasmids were 
recombined with pLenti/DEST (Invitrogen) using LR clonase-II for 6 hours at 25°C, 
proteinase-K treated for 10 minutes at 37°C and transformed into One Shot Stbl3 E. 
coli. Plasmids from overnight grown colony cultures were isolated using the 
Plasmid Midi Kit from Qiagen. To produce lentivirus, 293FT cells were transfected 
using Lipofectamine 2000 (Invitrogen) and the pLenti/DEST DNA was mixed with 
ViraPower Packaging mix (Invitrogen). After overnight incubation, medium was 
replaced and lentivirus-containing medium was harvested after 72 hours, filtered, 
and used to infect U251MG glioma cells for 6 hours with addition of polybrene 
(5 µg/mL). After 48 hours, medium was replaced with medium containing blasticidin 
(10 µg/mL; Invitrogen) and cells were kept under selection for at least 2 weeks. IDH1 
expression in U251-IDH1 and U251-IDH1R132H cells was analyzed by Western 
blotting using a specific antibody recognizing the mutation (42). Cells were grown 
in DMEM containing high glucose, supplemented with 10% FCS and penicillin/
streptomycin (100 U/mL). 31P MRS was performed on extracts of U251 cells 
(parental, IDH-WT and IDH1-R132H; n = 5 per cell line, >1.5 × 107 cells per sample) 
as described below.
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Surgical specimens of glioma patients 
Surgical specimens were collected from 6 IDH-wild-type (IDH-WT) glioma patients 
(4 GBM, 1 anaplastic astrocytoma, and 1 diffuse astrocytoma), and from 5 
IDH1-R132H tumors (3 GBM, 1 anaplastic astrocytoma, and 1 diffuse astrocytoma). 
IDH mutation was identified by anti-IDH1-R132H immunostaining as described 
previously (34). Directly after surgical excision, samples were snap frozen and 
stored for later analysis
In vivo 31P 3D MRSI acquisition and analysis 
All in vivo MR experiments were performed on a preclinical 7 T MR system (Bruker 
ClinScan) operating at 121.7 MHz for 31P MRS. The phosphorus spectra were 
acquired using a homebuilt 16-mm transmit/receive quadrature coil in 
combination with a solenoid 1H surface coil (20 mm in diameter). The animals 
were subjected to MRSI when evident signs of tumor burden (especially evident 
weight loss, neurologic defects) were present. A control group consisting of healthy 
Balb/c nu/nu animals (n = 3) was also included. Animals were placed in prone 
position and anesthetized by 1.5% isoflurane (Abott) and a mixture of O2 and N2O 
inhalation. The animal’s body temperature was maintained at 37.5°C applying 
warm air circulation and physiologic monitoring (Small Animal Instrument Inc.) 
to assess respiration and temperature. After obtaining a localizer image, 
T2-weighted multi spin-echo images in three orthogonal orientations of the brain 
were acquired. First- and second-order shimming was performed using FASTMAP 
(43). The MRSI field of view (FOV) and matrix size were then selected carefully 
reviewing T2-weighted images to cover hyperintense areas within the tumor 
tissues (Fig. 2). Three-dimensional 31P MR spectroscopy was performed using a 3D 
MRSI pulse acquire sequence with an adiabatic BIR-4 45° excitation pulse (44), a 
repetition time (TR) of 1500 milliseconds, Hanning-weighted cartesian k-space 
sampling with 196 signal averages at the centre of k-space, 2,048 data points over 
a spectral width of 4,868 Hz and a total acquisition time of 2 hours. The FOV of 24 
mm × 24 mm × 24 mm with an 8 × 8 × 8 data matrix and Hamming filtering 
resulted in a nominal voxel size of about 5 mm3. After the MR exams, the animals 
were sacrificed by cervical dislocation, the brains removed and separated in two 
halves, which were frozen in liquid nitrogen for subsequent in vitro MRS analyses. 
Remaining brain tissue was formalin fixed and paraffin embedded for further 
histopathology analysis. All in vivo MR spectra were analyzed using the jMRUI 
software (45) and signals fitted with a Lorentzian lineshape, except the J-coupled 
signals of ATP, which were fitted with a Gaussian shape, using the Advanced 
Method for Accurate, Robust and Efficient Spectral fitting method (46). Before 
fitting, spectral processing was performed, including manual phase correction, 
zero-filling (4,096 points), and line-broadening of 20 Hz.
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Nuclear magnetic resonance acquisition and analysis of in vitro  
and ex vivo samples 
Frozen brain tissue samples from the glioma xenografts and U251 cell pellets were 
extracted using perchloric acid as described in detail previously (47). The 
neutralized extracts were lyophilized and kept at –80°C until being dissolved in 
600 µL of D2O. After final pH adjustments with potassium hydroxide (KOH), in vitro 
31P NMR spectra of extracts were acquired using a Bruker spectrometer (Bruker 
Avance III 600 MHz/54 mm US-Plus) equipped with a multinuclear QCI CryoProbe 
(Bruker BioSpin GmbH) operating at 243.5 MHz for 31P MRS. High-resolution 31P 
NMR spectra of the water-soluble metabolites were obtained with proton 
decoupling during acquisition, a 30° flip angle, 8,192 free induction decays (FID), 
TR = 4 seconds, spectral width of 14,577 Hz into 36,864 data points in time domain. 
31P HR-MAS spectroscopy was carried out using a 600-MHz spectrometer (Bruker 
Avance III 600 MHz/54 mm US-Plus) equipped with a triple 1H/13C/31P MAS probe 
(Bruker BioSpin GmbH). The frozen specimens from human brain tumors were 
thawed and cut on an ice-pad. Tissue samples were gently loaded into 30-µL 
disposable inserts filled with 3 µL 2H2O (Sigma-Aldrich GmbH) for the 
2H lock. The 
inserts were then placed into a 4-mm diameter ZrO2 MAS rotor (Bruker BioSpin 
GmbH). The MAS rotors were spun at 5 kHz and maintained at 4°C to minimize 
enzymatic activities within the tissue samples. All in vitro and ex vivo spectra 
were processed using the Bruker TopSpin V3.0 software (Bruker BioSpin GmbH). 
The accumulated FIDs were Fourier transformed after application of 3 Hz 
exponential line broadening. Automatic phase and linear baseline corrections 
were performed. The GPC peak (at 3.04 ppm) in 31P MR spectra was used as 
references for chemical shift calibration. Following standard processing, peak 
areas of phosphorylated metabolites were calculated by peak fitting (PeakFit V4.12; 
SeaSolve Software Inc.) using a combination of Gaussian–Lorentzian lineshapes 
(Voigt area). Metabolite concentrations were calculated from peak areas.
Statistical analysis 
The difference in the mean value of selected metabolite ratios were statistically 
assessed using a two-tailed unpaired Mann–Whitney test (Prism GraphPad V 4.03 
Software Inc.) and the differences were considered statistically significant for P 
values < 0.05. All results are represented as mean ± standard deviation (SD).
Results In vivo 3D 31P MRSI of human glioma xenografts 
Tumors in the brain present as hyperintense signal areas on T2-weighted MR 
images (compare the tumor-containing brain in Fig. 2A with the normal brain in 
Fig. 2B), and we used these images for voxel positioning. The 31P MR spectra of 
voxels of interest selected from the 3D MRSI dataset of this brain showed resolved 
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Figure 2  31P MRSI of the mouse brain with and without tumor. Orthogonal T2-weighted 
MR images of a mice brain with an E434 tumor (top, A) and a normal mouse brain (bottom, 
B) in axial, coronal, and sagital views, and corresponding 31P MR spectra of 27 mm3 nominal 
voxels from the 3D 31P MRSI data (C and D). E and F, bar plot of the (PC + GPC + PE + GPE)/ATP 
(E) and PCr/ATP (F) signal ratios of tumor types growing in mouse brain (n = 19) and of normal 
mouse brain (Ctrl, n = 3). Chemical shift is referenced to the GPC resonance at 3.04 ppm. 
The assigned peaks are (from left to right); PE, phosphoethanolamine; PC, phosphocholine; 
Pi, inorganic phosphate; GPE, glycerophosphoethanolamine; GPC, glycerophosphocholine; 
PCr, phosphocreatine; ATP, adenosine tri-phosphates. *, P < 0.05.
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resonances for a number of compounds, including ATP, phosphocreatine (PCr), 
GPC and GPE, inorganic phosphate (Pi), PC, and PE. The 31P-spectral profiles of 
tumor voxels in all four xenograft models differed from those obtained from 
voxels in comparable brain areas in non–tumor-bearing animals (compare Fig. 2C 
with 2D). The relative phosphor signal integrals of choline and ethanolamine 
compounds were increased, as represented by a significantly higher (PC + GPC + PE 
Figure 3  IDH1-mutated E478 xenografts show a distinct 31P-spectral pattern. A, in vivo 
31P MR spectra obtained from four human glioma xenograft tumor lines growing in the 
mouse brain (IDH1-mutated xenograft E478, and IDH1-WT E434, E473, and E468). In the 
IDH1-mutated xenograft, GPC is highly elevated and PE decreased compared with the 
wild-types. B, representative in vitro 243.5 MHz (1H-decoupled) 31P MR spectra of tissue 
extracts of these tumors; from top to bottom the IDH1-mutated E478, and the IDH1-WT lines 
E434, E468, and E473. The chemical shift reference is the GPC resonance at 3.04 ppm.
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+ GPE)/ATP ratio for all tumor types (P < 0.05; Fig. 2E). This total relative phospholipid 
content was not different among the tumor models. In addition, a significantly 
decreased PCr/ATP signal ratio was observed in tumor tissues compared with the 
healthy mouse brain tissues (P < 0.05; Fig. 2F). 
 Among the four human glioma lines, the E478 tumor exhibited a deviating 
spectral profile in the 2 to 8 ppm range (Fig. 3A and B). For a quantitative assessment, 
we first determined for each metabolite resonance its integral normalized to the 
sum of those of all phospholipid metabolite resonances (see Fig. 4A and B). This 
revealed a significant decrease of the PE resonance of the IDH1-mutant E478 
xenograft compared with those of the IDH1-WT xenografts (P = 0.003). A significant 
increase was observed for the GPC resonance of E478 compared with IDH1-WT 
tumors (P = 0.003). Furthermore, the PC peak of E478 showed a trend for an increase 
compared with the PC of the other tumors (P = 0.08). The GPE resonance did not 
differ between the tumors. In concordance with the in vivo results, we observed 
very similar differences between 31P NMR spectra of tumor extracts from 
IDH1-mutant and wild-type xenografts (Fig. 3B). Again, PE was reduced and GPC 
increased in E478 extracts compared with those of the other models (P = 0.004 and 
0.01 respectively; Fig. 4B) 
 These findings suggest that sensitive biomarkers associated with the presence 
of IDH1 mutations would be represented by the peak ratios PC/PE, GPC/GPE, GPC/
PE, and (PC + GPC)/(PE + GPE). A quantitative assessment of mean in vivo metabolite 
ratios obtained from all xenograft models showed that these ratios in the E478 
xenograft were more than 2-fold higher than those of the other xenografts (P < 
0.01 for all ratios; Fig. 4C). Similar findings were observed for these ratios obtained 
from spectra of tumor tissue extracts (Fig. 4D).
Phospholipid metabolite ratios involving PE and GPC are similarly 
altered in cell lines and human glioma with an IDH1 mutation 
To investigate how specific the phospholipid metabolite changes are for the IDH1 
mutation, we measured in vitro 31P NMR spectra of extracts of a set of U251-MG 
cell lines overexpressing either wild-type or mutant IDH1 (see Fig. 5A–C). The 
IDH1-R132H–expressing U251-MG cells showed significantly higher PC/PE and 
GPC/GPE levels than U251-IDH-WT (P < 0.001) and U251-MG control cell lines 
(P < 0.01 for both ratios; Fig. 5B). The U251-R132H also showed a significantly higher 
(PC + GPC)/(PE + GPE) ratio (P < 0.01; Fig. 5B). Finally, we investigated if these 
IDH-mutant specific spectral findings could be validated in human gliomas. For 
this purpose, we obtained 31P HR-MAS spectra of human glioma specimens. Again, 
31P spectral profiles in IDH1-mutant gliomas (Fig. 5D–F) were obtained that were 
characterized by significant elevations in PC/PE, GPC/GPE, and (PC + GPC)/(PE + GPE) 
ratios (P < 0.01 for all ratios) as compared with IDH1-WT glioma specimens (Fig. 5E).
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Figure 4  Relative tissue levels of MR detectable phospholipids in brain xenograft models. 
Metabolite signal integrals normalized to the total integral of detectable phospholipids 
signals in 31P MR spectra obtained from (A) in vivo mutant glioma xenograft E478 (n = 4) and 
wt xenografts (n = 5 for each) and (B) from tissue extracts of xenograft tissue extracts (n = 4 
for E478 and n = 5 for the other tumor lines). Values are presented as mean ± SD. Scatter plot 
of metabolite ratios obtained from 31P spectra measured (C) from tumors in mouse brain and 
(D) from extracted tumor tissue. The metabolite ratios of IDH1-WT tumor lines; E473 + E468 
+ E434 (orange, n = 15) were compared with the IDH1-mutated tumor line E478 (green, n = 4). 
The y-axis values indicate the mean and SD; **, P < 0.01.
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Discussion 
In this study, we tested the hypothesis that IDH1 mutations affect the phospholipid 
metabolite profile of tumors by using IDH1-R132H E478 xenografts (41). Our major 
finding is that gliomas with an IDH1 mutation indeed have a phospholipid profile, 
which differs from that in gliomas with wild-type IDH1. This is reflected most 
clearly in relatively higher GPC and lower PE tissue levels, resulting in more than 
two-fold higher PC/PE, GPC/GPE, and GPC/PE ratios for the IDH1 mutants. 31P 
Figure 5  31P NMR spectra of U251MG cell extracts and 31P HR-MAS MR spectra of surgical 
biopsies from patients with glioma. A, representative 31P NMR spectra of cell extracts show 
similar 31P-spectral features as observed for the in vivo growing brain xenografts. Relatively 
decreased PE and increased GPC resonances identify the mutant cell line (U251-R132H) from 
wild-type cell lines (U251-WT) and U251MG control cells (U251). The green and orange 
colored spectra are shifted to the right for a better visualization. B, the PC/PE, GPC/GPE, and 
(PC + GPC)/(PE + GPE) ratios are significantly increased in the U251-R132H cell line compared 
with the U251-WT and U251 cells. C, phospholipid levels measured from 31P MR spectra of 
U251 cell extracts. D, representative 31P HR-MAS MR spectra of glioma patient biopsies. 
E, the levels of PC/PE, GPC/GPE, (PC + GPC)/(PE + GPE) ratios in IDH1-R132H glioma patients 
are consistent with preclinical results. F, phospholipid metabolite levels measured in glioma 
patient tissues samples. The y-axis values indicate the mean and SD; *, P < 0.05; **, P < 0.01.
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nuclear magnetic resonance (NMR) of tumor tissue extracts obtained from the 
same animals confirmed the in vivo findings. Moreover, 31P NMR of extracts of 
U251 cells, stably expressing recombinant IDH1-R132H also yielded increased PC/
PE and GPC/GPE ratios compared with IDH-WT cells, proving that these changes 
are related to the IDH1 mutation. Finally, 31P HR-MAS of surgical biopsies of human 
brain tumors identified similar IDH mutation–specific phospholipid metabolite 
patterns. An increased GPC level has been detected by mass spectrometry in oligo-
dendroglioma cells expressing the IDH1 mutation as compared with wild-type 
cells (14), and a positive correlation of GPC with 2-HG was found by HR-MAS of ex 
vivo biopsies of low-grade tumors with the mutation (18). Elevated GPC has been 
associated with grade 2 and 3 gliomas (32–34). Because the majority of these have 
the IDH1 mutation and elevated GPC is associated with 2-HG (18), this suggests that 
GPC levels have a causal relationship with the mutation, which is in agreement 
with our findings. There is much less known for PE. Its resonances in 1H MR spectra 
are not well resolved. Data from 31P HR-MAS studies of biopsies indicate that PE is 
decreased in low-grade gliomas (34, 48), but the only report describing PE in 
relation to the IDH1 mutation indicates a positive correlation with 2-HG, as 
detected by 1H HR-MAS (18). As 31P NMR of the GBM cell line GS-2 also showed low 
PE to PC and high GPC to GPE ratios (49), it would be of interest to investigate 
whether this line also carries the IDH mutation. For all tumors in the mouse brain, 
we detected a decreased PCr/ATP ratio, which is in line with findings in 31P MRS of 
human tumors and indicates an altered energy metabolism (37, 50). IDH1 
mutations are confined to low-grade and secondary high-grade glioma GBM (4, 5) 
and confer a relatively good prognosis to patients suffering from these tumors (6, 
7, 51). Despite their frequent occurrence, glioma xenografts carrying these 
mutations are very scarce (41, 52, 53), and in vitro propagation of IDH1-mutated 
glioma cell lines is challenging (54). Interestingly, and in line with clinical 
observations, E478 xenografts present with lower proliferation rates than IDH-WT 
counterparts, as established via the Ki67 index, and mice carrying these xenografts 
have a longer survival time than mice carrying IDH-WT xenografts (see 
Supplementary Materials). A correlation between longer survival, lower Ki67, and 
lower PC/GPC ratio has also been observed in human patients with glioma (32, 34).
31P MRSI of brain tumors and imaging biomarkers for IDH1 mutation 
In this study, we demonstrate that 31P MR spectra of the mouse brain can be 
obtained with a good signal-to-noise ratio (SNR) by 3D MRSI on a 7 T magnet with 
a dedicated 31P coil. Moreover, at this field strength, resolved signals for individual 
choline- and ethanolamine-containing metabolites can be detected. This is also 
possible for human brain at clinical field strengths (1.5–3 T) using 1H decoupling 
(35, 37) and 1H-31P polarization transfer to enhance sensitivity (55, 56). Thus, it is 
599
worthwhile to investigate if ratios of PE and GPC signals can be used as biomarkers 
to assist in the noninvasive metabolic characterization of IDH mutations in 
patients with glioma brain tumors. This may be used in the assessment of the 
effect of inhibitors of the mutated IDH enzyme (57). It is known that human glioma 
cells with an IDH1 mutation accumulate 2-HG (12–14). We confirmed the presence 
of 2-HG in our E478 model and in IDH-R132H–overexpressing U251 cells, by both 
LC/MS (41) and 1D and TOCSY 1H MRS (see Supplementary Materials). This 
accumulation enables the detection of 2-HG by 1H MRSI, by which patients with 
this mutation can be identified (15, 17). However, spectral overlap hampers 
discrimination of 2-HG signals from those of glutamine, glutamate, and 
gamma-amino butyric acid, even with peak fitting using prior knowledge and 
optimal echo times. This may be overcome by spectral editing or 2D 1H MRS, but 
at the expense of increased complexity and longer scan times or low SNR (17). 
Moreover, in clinical practice, all these methods to detect 2-HG may fail due to 
suboptimal field homogeneity. As the resolved detection of 31P signals is less prone 
to field inhomogeneities, the distinct phospholipid metabolite profiles in 
IDH1-mutated gliomas may have a role in the identification of this mutation.
Biologic meaning of the change in phospholipid levels in 
IDH1-mutated glioma 
Many enzymes that are involved in lipid biosynthesis depend on appropriate levels 
of cytosolic NADPH and acetyl-CoA. The activity of IDH1 is an important source for 
cytosolic NADPH in the brain (ref. 51; see also Fig. 1A) and only for this reason, 
mutations in this enzyme are expected to affect lipid synthesis. This impact will 
be augmented by the fact that IDH1 is also involved in the reductive carboxylation 
of αKG to isocitrate, especially under hypoxic conditions, isocitrate being the 
building block for lipids via generation of acetyl- and succinyl-CoA. In mutated 
IDH1, this activity is lost (11). Evidently, according to this model, IDH1-mutated 
tumor cells are subject to high metabolic stress, and cells need to adapt to this 
stress to facilitate survival and tumor progression (58). In a previous report we 
described that E478 xenografts, despite the IDH1 mutation, do not have significantly 
decreased αKG levels and present with densely packed mitochondria. On the basis 
of these findings, we postulated that IDH1-mutated tumor cells rescue the IDH1 
defect by upregulating mitochondrial biosynthesis and concomitantly IDH2 
activity, followed by transport of mitochondrial αKG and NADPH to the cytosol 
(41). To accommodate mitochondrial biosynthesis, membrane synthesis is required. 
The altered steady-state levels of some phospholipid metabolites in IDH1-mutated 
gliomas may be related to rapid incorporation of precursors in phosphatidylcho-
line (PtdCho) and phosphatidylethanolamine (PtdEtn), the most abundant 
membrane compounds (59). An interesting question that directly follows, is 
100
whether energy production in IDH1-mutated gliomas is balanced more toward 
oxidative phosphorylation than to aerobic glycolysis (the Warburg phenomenon; 
ref. 60). Such considerations may eventually lead to therapeutic handles. In 
conclusion, we provide evidence that IDH1 mutations result in distinct alterations 
in lipid metabolism that can be detected noninvasively by 31P MRSI. These may 
serve as a complementary biomarker to characterize the metabolic status of 
IDH1-mutated gliomas during evaluation of anticancer targeted therapies and in 
tumor diagnosis. Increased availability to higher field strength MR systems (3 and 
7 T) and dedicated 31P coils hold promise for clinical translation of the 31P MRSI 
method. Further research is needed to fully elucidate the roles of PE and GPC, such 
as their involvement in mitochondrial membrane synthesis.
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Histopathology
Formalin fixed paraffin embedded brains were cut into 4 µm sections, transferred 
to glass slides and subjected to haematoxylin and eosin (H&E) staining or immuno-
histochemical (IHC) analysis according to standard procedures. Ki67 IHC was 
performed to visualize proliferating tumor cells. Primary Ki67 antibody (clone Sp6, 
Thermo Fisher Scientific, Waltham, MA, USA) incubations were done overnight at 
4˚C. Appropriate biotinylated secondary antibodies were used for detection using 
the ABC-method (Vector Laboratories, Burlingame, CA, USA). Specific signals were 
visualized by staining with 3-amino-9-ethyl-carbazole solution (Scytek Laboratories, 
Logan, UT, USA). All sections were counterstained with heamatoxylin and mounted 
in lmsol Mounting medium (Klinipath BV, Duiven, The Netherlands).
 Quantification of Ki67 positive nuclei was done using KS400 software (Carl 
Zeiss AG, Oberkochen, Germany) with a custom written macro. Proliferation indices 
were measured in 5 random non-overlapping tumor containing microscopic fields 
(magnification × 200).
1H NMR of extracted tissues of glioma xenografts and U251 cells
1H NMR spectra were acquired using a NOESY sequence with a 90° flip angle, 512 
FIDs, TR = 7.73 s, spectral width of 12019 Hz into 65536 data points. The spectral 
feature of the 2-HG metabolite in extracts of cultured U251-R132H cells and E478 
tissue samples was identified in both one-dimensional (1D) 1H NMR spectra (Figs. 
S3A and B respectively, compare to spectra from parental U251 cells in Figs. S3C 
and D) and 2D J-coupled total correlation spectroscopy (TOCSY) (Figs. S3E-H). 
TOCSY spectra were acquired with water pre-saturation, 128 transients, spectral 
width of 7202 Hz, a 40 ms mixing time in the direct dimension (F2), 128 increments 
in the indirect dimension (F1) for a total acquisition time of 5 hrs.
 All in vitro and ex vivo spectra were processed using Bruker TopSpin V3.0 
software. The accumulated FIDs were Fourier transformed after application of 3 
Hz exponential line broadening.  Automatic phase and linear baseline corrections 
were performed. Processing steps for 2D TOCSY spectra included; Fourier transform 
(FT) along both F1 and F2, linear prediction forward complex (LPfc) in F1, and 
square-sine window function in both directions. Cr peak (at 3.026 ppm) in 1H MR 
spectra was used as reference for chemical shift calibration.
Human IDH1-mutated gliomas in the mouse brain proliferate less 
and mice with these gliomas survive longer
Mutations of IDH genes are associated with a longer survival in glioma patients 
(4-8). We therefore evaluated the correlation between malignancy (as reflected in 
the proliferation index) and survival time (post tumor implantation). Proliferation 
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Figure S1  Evaluation of proliferation in the glioma xenograft models. (A) shows a representative 
microscopic field for each xenograft model of Ki67 IHC. Haematoxylin counter staining (blue) of 
the nuclei was done, while Ki67 positive cells were visualized using 3-amino-9-ethyl-carbazole 
solution (red staining). Representative H&E-stainings of overviews of the same xenografts 
are depicted in the insets. Quantification was done by software analysis of the number of 
Ki67 positive nuclei, compared to the total number of nuclei per microscopic field (5 fields 
per animal brain, Size bars: Ki67 100 µm, H&E 2 mm). (B) Linear regression plot (confidence 
intervals of ± 95%, P < 0.001) depicts a significant correlation between Ki67 indices and 
survival (Spearman correlation coefficient = -0.74, P = 0.002). (C) Kaplan-Meier analysis of 
all xenografts shows a better prognosis in E478 xenografts compared with E434 (Log-rank 
P = 0.01) and E473 (log-rank P = 0.03).
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indices in our xenograft lines, as measured by the ratio of Ki67 positive tumor 
cells, correlated significantly with survival (Fig.  S1, r = -0.74, P = 0.002). Survival 
plot demonstrated a longer survival in E478 xenografts compared with the other 
xenografts (Fig. S1C). Significant differences were found between E478 versus E434 
(P = 0.01) and E473 (P = 0.03) xenografts. Survival of mice with E434 and E473 
xenografts (both with proliferation indices of 75%) was significantly shorter than 
that of mice carrying E468 and E478 xenogafts (proliferation index of 28 %, median 
survival of 42 and 80 days, respectively).
 Spearman correlation analysis (GraphPad Software V 4.03 Inc.) was performed 
to assess the correlation between the proliferation index and survival time. 
Survival outcome were investigated by the Kaplan-Meier method and the survival 
distributions were compared with the log-rank (Mantel-Cox) test.
Figure S2  Western blot showing expression of IDH1 and IDH1-R132H protein in U251 glioma 
cell lines. Low levels of endogenous IDH1 protein are observed in the U251 parental cells 
while recombinant IDH1 wild type (U251-IDH1) and IDH1-R132H are readily overexpressed 
in U251-IDH1 and U251-IDH1-R132H cells, as evidenced via western blot using a pan IDH 
antibody and a IDH1-R132H-specific antibody.  Tubulin was used as loading control.
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Figure S3 Detection of 2-HG resonances in 1D and 2D MR spectra of IDH1-mutated 
xenografts and U251-R132H cell models. 2-HG resonances were detectable between 1.8 - 2.3 
ppm and 4.01 ppm in 1D 1H MR spectra of extracts from (A) U251-R132H cell line and (B) E478 
xenograft tissue but not in (C) U251-wt and (D) U251MG cell lines. In 2D TOCSY spectral 
maps the chemical shifts of the cross peaks of 2-HG are indicated by red boxes. Resolved 
cross peaks for 2-HG resonances were identified in TOCSY spectra of (E) U251-R132H extracts 
and (F) E478 xenograft at 1.82, 1.98, 2.24, and 4.016 ppm representing Hβ, Hβ, Hδ, and Hα 
respectively but not in the extracts obtained from (G) U251-wt and (H) U251MG cells.
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Figure S3 Continued.
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Abstract
Purpose The aim of this study was to produce a version of the tissue hypoxia 
marker pimonidazole (PIMO), that is suitable to image hypoxia both in vivo by 
19F MR and ex vivo by immunohistology. For this purpose pimonidazole was 
synthesized with a -CF3 group attached to the piperidine ring.  
Methods Molecular properties, toxicity and cellular uptake at normoxia and 
hypoxia, of trifluoro-pimonidazole (TF-PIMO) were determined. 19F MR spectroscopic 
imaging (MRSI) was applied to in vivo tumors in the mouse after administration of 
TF-PIMO for non-invasive assessment of the spatial distribution of the compound. 
Immunohistochemistry was performed on the same tumors to validate the presence 
of TF-PIMO. 
Results The addition of the –CF3 moiety to PIMO has little effect on the measured 
molecular properties. No cellular toxicity was observed at the levels applied in 
vivo. The cell uptake study showed that TF-PIMO can be detected by PIMO antibodies 
and that TF-PIMO accumulates significantly more in hypoxic than in normoxic cells. 
Non-invasive examination of hypoxic tumors by 19F MRSI also showed accumulation 
of TF-PIMO in the tumors. This was validated by ex vivo PIMO anti-body staining. 
Conclusion These results demonstrate that TF-PIMO can be used as an alternative 
to PIMO in staining hypoxic tissue, but with the added potential of enabling 
non-invasive imaging of hypoxia in the same tissue.  
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Introduction
Inadequate oxygen supply or hypoxia is a common condition for malignant tumor 
tissue. Oxygen may not reach tumor cells because of limited perfusion, due to 
unstable or immature blood vessels, or because of large diffusion distances from 
perfused blood vessels (1). Hypoxia is associated with tumor progression (2), 
increased aggressiveness (3), enhanced metastatic potential (4) and a poor prognosis 
(5). Moreover it negatively affects radiotherapy and chemotherapy outcome (6). 
Reducing hypoxia or targeting hypoxic cells in tumors has become a complementary 
treatment option (7,8). Thus for diagnosis and treatment, the measurement of 
hypoxia in tumors is important. 
 To measure hypoxia both invasive and non-invasive approaches are available 
(9–11). Non-invasive techniques either employ endogenous markers or exogenous 
(chemical) markers. Only few chemical hypoxia markers have entered limited 
clinical application (12,13). Non-invasive imaging of hypoxia in humans and in 
animals is often performed by positron emission tomography (PET), single photon 
computed tomography (SPECT) or magnetic resonance imaging (MRI) (14,15). 
 A major class of exogenous compounds for PET, SPECT and MR imaging of 
hypoxia are the 2-nitroimidazales. At low oxygen levels the 2-nitroimidazole moiety is 
enzymatically reduced in the cell into reactive products that form adducts with –
SH containing molecules such as glutathione and/or various proteins. The first 
step of the reduction pathway is reversible preventing intracellular compartmen-
talization eventually leading to clearance of the compound (Fig. S1). In the presence 
of adequate oxygen the 2-nitroimidazoles are either conjugated or oxidized before 
being reduced (16).
 Over twenty 2-nitromidazole based hypoxia labels have been reported for use 
in PET, SPECT, MRI and histology (14,17). Only few of these markers have entered 
(pre-) clinical application. The PET derivative of misonidazole (MISO), i.e. 18F-fluoro-
misonidazole (F-MISO), is most often used for imaging hypoxia in vivo (18). One of 
the drawbacks of this compound and other 18F PET variations of 2-nitroimadazole 
compounds is the trade-off between the nuclear half life of the fluorine isotope 
(about 110 minutes) vs time needed for injection and uptake and/or clearance from 
the bloodstream (5 x t½ plasma about 110 minutes) as observed for these compounds 
(19) A further problem is the failure to develop an antibody for immunohistochem-
ical staining of MISO (20). 
 Compounds labeled with fluor are suitable for MR as 19F has a relative high MR 
sensitivity (0.83 that of 1H) and in biological tissues a natural 19F background is 
absent. In addition 19F MR can be easily combined with conventional 1H MRI for 
detailed anatomical and functional background images. In addition, 19F labeled 
compounds can be administered repeatedly, effectively loading cells with the 
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drug before commencing imaging. With an MR analog of MISO with three 19F 
atoms (TF-MISO) the first spatially resolved hypoxia maps were made by 19F MR 
spectroscopic imaging (MRSI) (21). Earlier, in an attempt to increase sensitivity the 
MISO derivative CCI-103F with six fluorine atoms was developed (22).  Another 
imidazole based hypoxia marker designed for MR is SR-4554 with three 19F atoms 
(23–25), which was entered in a phase I study as a potential candidate for clinical 
MRI (12,26). Unfortunately no anti-body to correlate the in vivo findings with 
histology exists for these compounds.  
 Pimonidazole (PIMO) is a 2-nitroimidazole that was developed for immunohis-
tochemical staining of hypoxic tissues. After its administration tumor tissue is 
harvested by a surgical procedure, which is then stained with an antibody to 
assess hypoxia (16). Currently, this is considered the ‘gold standard’ to determine 
chronic hypoxia (27). A major drawback of this compound is that it can only be 
detected after the tissue has been excised. Thus, having a 2-nitro-imidazole 
compound suitable for both in vivo imaging and immunohistochemical staining 
would be very relevant. 
 Our principal goal was to develop a fluorinated pimonidazole suitable for both 
non-invasive imaging and immonostaining of hypoxic tissue. Such an analog is 
particularly attractive because there is ample experience with pimonidazole in 
animal tumor models (28). Furthermore, pimonidazole has been used in the clinic 
as hypoxia marker and its presence correlates with poor treatment outcome (29). 
We present the synthesis of trifluoro pimonidazole (TF-PIMO) for which the 
immunostaining with the same antibody as for pimonidazole appeared applicable 
and demonstrate that it can be employed for non-invasive MRI of hypoxia.
  
Materials and Methods
TF-PIMO synthesis
Although the structure of TF-PIMO (1-(2-nitro-1H-imidazol-1-yl)-3-[4-(trifluorometh-
yl)-piperidin-1-yl]propan-2-ol) is hinted in a patent by Raleigh et al. (30), the actual 
synthesis of TF-PIMO (structure XII in the mentioned patent) has not been described 
yet. We chose a two-step synthesis process where an imidazole epoxide is combined 
with a fluorinated piperidine to form TF-PIMO. 
 All solvents and reagents were used as received from commercial suppliers 
unless stated otherwise. The reaction progress was monitored by thin layer 
chromatography (TLC) performed on polgram SIL G/UV254 plastic backed plates 
or aluminium plates coated with kieselgel F254. Visualization was achieved by a 
combination of ultraviolet light (254 nm) and staining with potassium permanganate. 
Combined liquid chromatography-mass spectrometry (LC-MS) and high resolution 
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mass spectrometry (HR-MS) analyses were conducted on an Agilent 1200 series 
equipped with an Agilent 6210 Time of Flight Mass Spectrometer detector. Flash 
chromatography was performed using silica gel (Merck 60 (0.015–0.040 mm)), 
eluted with the indicated solvent. NMR spectra were recorded on a Bruker AV500 
NMR machine.
 Step 1 Production of imidazole epoxide: 2-nitroimidazole (500 mg, 4.42 mmol) 
and potassium car-bonate (60 mg, 0.434 mmol) were suspended in neat epichloro-
hydrin (15 mL) and heated to 100 °C. After 3.5 h the clear yellow solution was 
cooled to room temperature (RT), 20-25°C, and the solvent evaporated. The crude 
product was dried under high-vacuum overnight and dissolved in dichlorometh-
ane (DCM, 20 mL). Aqueous NaOH (2 M, 20 mL) was added and the biphasic system 
was stirred vigorously at 0 °C for 4 h.  The reaction was neutralized with 
concentrated HCl and extracted with chloroform (3 × 25 mL). The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and the solvent 
evaporated. The crude product was purified by flash chromatography (silica gel, 
EtOAc/c-Hex: 1:4 to 1:1) to give imadazole epoxide. 
 Step 2 Production of TF-PIMO: Diisopropylethylamine (0.164 mL, 0.940 mmol) 
was added to a sus-pension of the imidazole epoxide (see above) (53 mg, 0.313 
mmol) and 4-trifluoromethylpiperidine HCl (71.3 mg, 0.376 mmol) in ethanol at RT 
and the resulting solution was stirred at RT for 16 h. HCl (700 µL, 0.875 mmol, 1.25 
M in iPrOH) was added dropwise to the solution resulting in the slow precipitation 
of the product TF-PIMO (Fig. 1). After filtration and washing with ethanol and 
ether the product was obtained as a white solid.
Characterization of TF-PIMO
The molecular structure of TF-PIMO was validated by NMR. The value of its acid 
dissociation con-stant, pKa, was determined by means of neutralization titration. 
The logP and logD (partition and distribution ratios), were determined by correlating 
Figure 1  Molecular structure of trifluoro-pimonidazole or TF-PIMO (1-(2-nitro-1H-imidazol-1-yl)-
3-(4-(trifluoro-methyl)-piperidin-1-yl)propan-2-ol hydrochloride) as produced by a two-step synthesis.
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TF-PIMO retention time in an HPLC  column with similar compounds with known 
log P values. The optical absorption characteristics of TF-PIMO were assessed for a 
range of pH values. 
Cellular uptake of TF-PIMO under hypoxic conditions
Before use in cell assays and in vivo (see below) the TF-PIMO salt was dissolved in 
saline (0.9% NaCl) to a concentration of 12.6 mg/ml. C38 murine colon carcinoma 
cells were cultured in standard culture medium consisting of Dulbecco Modified 
Eagle Medium (DMEM) with 10% dialyzed fetal calf serum (FCS), 2 mM L-glutamine, 
20 mM HEPES buffer, 10 U/ml penicillin, 10 µg/ml streptomycin, with nonessential 
amino acids (NEAA) at 37 ˚C with 5 % CO2. Cells were grown on glass cover slides 
inside a 24-well plate and treated with 10 µg/ml TF-PIMO. For hypoxic incubation 
(0.1% O2) the cells were transferred into a hypoxic culture chamber (H35 
hypoxystation, Don Whitley Scientific, West Yorkshire, UK) for 6 or 24 hours. Cells 
were fixed with 2% paraformaldehyde and permeabilized with 0.1% Triton X-100. 
TF-PIMO staining was performed using rabbit-anti-pimonidazole (gift from J.A. 
Raleigh, Chapel Hill, NC, USA) and donkey-anti-rabbit conjugated with Alexa488 
(Molecular Probes, Leiden, the Netherlands). All nuclei were stained using Hoechst 
33342 (Sigma Chemical, St. Louis, MO, USA) and slides were enclosed on a 
microscope glass using Fluorostab (ICN pharmaceuticals Inc. Zoetermeer, the 
Netherlands). Microscopic images were acquired using IP-Lab for Macintosh 
software (Scanalytics Inc., Fairfax, VA, USA) in combination with a monochrome 
CCD camera (Retiga SRV, 1392 x 1040 pixels) and a RGB filter (Slider Module; 
QImaging, Burnaby, BC, Canada) attached to a motorized microscope (Leica DM 
6000, Wetzlar, Germany) at a 400x magnification.
Toxicity assessment of TF-PIMO
Toxicity of the synthesized compound was determined from cell viability of HeLa 
and RAW 264.7 cells after exposure to TF-PIMO under normoxic conditions. The 
cell viability was assessed by means of a 3-(4.5-dimetyl-2-tiazolil)-2.5-diphenyl- 2H-
tetrazonium bromide (MTT) assay (31,32). This colorimetric assay measures the 
activity of cellular enzymes that reduce MTT (yellow) to formazan (purple). The 
assay measures the viability and the proliferation of cells. 
 HeLa and RAW 264.7 cells were harvested on a 96-well ELISA plate with a 
density of 100,000 cells/mL in DMEM complemented with 1% simulated body fluid (SBF) 
during 24 hours. TF-PIMO was added to the cells in a wide range of concentrations, 
from 10 to 4400 ug/mL for a period of 24 hours cultured under normoxic conditions. 
Subsequently the medium was removed and the precipitated formazan crystals 
were dissolved in dimethyl sulfoxide (DMSO) 100 µL, and the plates were read at 
570 nm using an ELISA plate reader. In this assay we assumed no competition 
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between the nitroimidazole moiety of TF-PIMO and tetrazole moiety of MTT 
although both the reduction of MTT as that of TF-PIMO under hypoxic conditions 
rely on the same group of mitochondrial reductases. There is no reason to assume 
any competition in this assay as the reductases and oxygen are abundant.
Tumor models, TF-PIMO application and anesthesia
Female C57Bl6 mice (22-25 gram, age 8-10 weeks) were obtained from the institutes’ 
animal facility and were used for serial passage and growth of tumors. The C38 
murine colon carcinoma tissue was previously obtained from the department of 
Radiation Oncology of the same institute as described earlier (28) and stored at -80 °C. 
The tissue was defrosted and fragments were bilaterally implanted subcutaneously 
(s.c.) into the back of a cohort of host mice. After 4 weeks, the tumors were harvested 
and tumor tissue grafts of 1-3 mm were implanted s.c. in the upper leg of another 
cohort animals. In compliance with the local ethical committee recommendations 
and the national code of practice for animal use in cancer research these tumors 
were grown to a maximum size of 2 cm3 before the MR investigations. 
 Athymic female BALB/c nu/nu mice (18-25 gram, age 6-8 weeks) were kept 
under specified pathogen free conditions and received food and water ad libitum. 
E98 glioblastoma cells derived from subcutaneous xenograft tumors were injected 
intracranially (i.c.) as described previously (33). Animals were closely monitored 
and selected for MR investigations when evident signs of tumor burden (e.g. weight 
loss >20%, severe neurological abnormalities) were observed. 
 The C38 colon carcinoma bearing mice were injected with 200 mg/kg TF-PIMO 
intraperitoneally (i.p.), three hours before the MR experiments. The E98 gliobla - 
stoma bearing mice were injected with two times 200 mg/kg TF-PIMO i.p. 16 and 
three hours before MR experiments. To avoid interference of the 19F signals from 
the more commonly used fluorinated anesthetics these were replaced by a single 
i.p. injection of 0.2 ml 150 mM urethane (Sigma Chemical, St. Louis, MO, USA), 
providing stable anesthesia for up to 10 hours. 
 All experiments were approved by the local institute’s ethical committee for 
animal research. Animals were kept according to institutional guidelines for 
animal care complying with Dutch law. 
Magnetic resonance imaging and spectroscopy 
MR experiments were performed on a 7 T small bore animal MRI system (ClinScan, 
Bruker BioSpin GmbH, Ettlingen, Germany), using a homebuilt double tunable 
two-turn solenoid volume coil, tunable to 19F (282.3 MHz) and 1H (300.4 MHz). The 
coil was 25 mm long and 20 mm in diameter and fitted a mouse for the subcutaneous 
and brain tumor recordings. The loaded coil quality factor Q was on average 115 
when tuned to 19F and 90 when tuned to 1H.
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 After acquisition of 1H localizer images (gradient echo (GRE) with the following 
settings: echo time (TE) of 4.15 ms, repetition time (TR) of 43 ms and a 25° flip 
angle, field of view (FOV) of 30 mm2 and a slice thickness (Thk) of 1 mm, a matrix 
192 × 192 points was acquired), high resolution anatomical images in 3 
perpendicular directions of the tumor were acquired (turbo spin echo (TSE) TE 46 
ms, TR 2750 ms, FOV 25 mm, Thk 0.7 mm, matrix 256 × 256). Guided by the 
anatomical images a volume of interest (VOI) for spectroscopy was selected 
including the tumors. The magnetic field homogeneity was optimized using a 3D 
GRE shimming sequence, resulting in line widths of the water signal at half 
maximum below 80 Hz (1H free induction decay (FID) with TR 5 s).
 Successful injection of the TF-PIMO was validated by an unlocalized adiabatic 
excitation 19F FID sequence with TR of 597ms, number of averages (N) 512 and a 
total measurement time of 5 m 12 s. Spatial distribution of TF-PIMO was determined 
by a 3D 19F MRSI acquisition (FID-MRSI SinCos Adiabatic Half Passage pulse (AHP)), 
TR of 597 ms, 256 averages, FOV of 32 × 32 × 32 mm3 and encoded in an 8 × 8 × 8 
grid resulting in 4 mm cubic voxels, 512 points were sampled and weighted phase 
encoding was applied. A 25 ms acquisition allowed for a bandwidth of 20 kHz. A 
Hamming filter was applied to the data before reconstruction. For 19F MR 
experiments the carrier was positioned at a +29395 Hz offset from the calculated 
19F frequency using the 1H water reference frequency and respective gamma ratios 
(γ19F / γ1H). 
 19F nuclear magnetization recovery times of TF-PIMO in vitro and in vivo were 
estimated using saturation recovery series. The measurements were implemented 
by using a train of single BIR4 45° pulses with changing TR between excitation 
pulses. The signal after each pulse (after a steady-state condition was reached) is 
given by:
MTR / M0 = 1 - e
(-TR / T1) 
where MTR is the longitudinal nuclear magnetization, M0 is the equilibrium nuclear 
magnetization, and T1 is the nuclear spin-lattice relaxation time. By doing experiments 
with different TR values, the longitudinal 19F nuclear magnetization recovery 
curves of TF-PIMO both in vivo and in vitro at 37 °C were measured. The T1 values 
were then obtained by fitting the measured data point of varying TR with an 
exponential curve (see equation above). In vivo T1 relaxation of 19F spins of TF-PIMO 
in the tumor was determined using saturation recovery experiments. The T2* 
relaxation time was estimated from the line width of the TF-PIMO signal of the 
MRSI.
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MR data processing
All MR data were exported offline for further processing. MRI data were Fourier 
transformed and stored as magnitude data. MR spectra were unprocessed and 
saved in complex raw form. All MR data were further analyzed using homebuilt 
scripts implemented in MATLAB®. The relative TF-PIMO concentrations were 
obtained by integrating the 19F peak after phase and baseline correction. Integrated 
MRSI data were plotted spatially over MR images at the correct position to obtain 
metabolic maps. 
Immunohistochemical staining
After MR investigations, the colon carcinoma mice were injected with 0.2 ml 
Hoechst 33342 (Sigma Chemical, St. Louis, MO, USA) and sacrificed within 1 
minute. Immediately thereafter the tumors were excised and snap frozen in liquid 
nitrogen. The tumors were then sectioned and sliced for staining. Between all 
consecutive steps of the staining procedure, the sections were rinsed three times 
for 5 min in 0.1 M phosphate buffered saline (PBS), pH 7.4. The sections were first 
fixed in cold acetone (4° C) for 10 min. After rehydration of the tissue sections in 
PBS during 20 min, they were incubated with rabbit anti-pimonidazole diluted 
1:1,000 in primary antibody diluent (PAD, Abcam, Cambridge, UK) for 30 min. 
Sections were then incubated with donkey anti-rabbit-Alexa488 (Molecular Probes) 
diluted 1:400 in PBS for 30 min. Finally, sections were mounted with Fluorostab 
(ICN pharmaceuticals Inc.) 
 For the E98 glioma mice brains were removed, formalin-fixed, and cut in five 
to six coronal slices of approximately 2 mm before embedding in paraffin blocks, 
allowing simultaneous analyses of tissue on five to six levels. Sections of 4 µm were 
subjected to haematoxylin and eosin (H&E) or immunohistochemical staining 
using rabbit-anti-pimonidazole antibodies. 
Results
TF-PIMO synthesis
TF-PIMO was synthesized in two steps as described in the material and methods 
section. First an imidazole epoxide (Fig. S2), a colourless solid, was produced from 
2-nitromidazole and epichlorohydrin. In this step 554 mg of the intermediate 
product was formed corresponding to a yield of 74%.
 The intermediate epoxide was bound to 4-trifluoromethylpiperidine to form 
TF-PIMO (Fig. 1). After filtration and washing with ethanol and ether, 76 mg of the 
product was obtained as a white solid, corresponding to a yield of 68%.
 The identity of the intermediate and final end product was confirmed by high 
resolution 1H and 19F NMR at 500MHz (see supplementary material). Next to the 19F 
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singlet originating from TF-PIMO, small impurities (<1.4% of the main 19F signal) 
were detected in the 19F NMR spectrum, likely remains of the production process, but 
considered non interfering with neither MR or histological quantification (Fig. S3). 
TF PIMO characterization
To estimate the distribution properties of TF-PIMO in fat and in muscle its partition 
coefficient was measured using high performance liquid chromatography (HPLC). 
The partition coefficient of TF-PIMO is 10.1 (Log P 0.976 ± 0.186), the non-fluorinat-
ed conventional PIMO has a partition coefficient of 8.0 (34,35) making TF-PIMO 
slightly more lipophilic in comparison to its counterpart. 
 The acid dissociation constant (pKa), a measure for the acidity of TF-PIMO, was 
determined by titration and found to be 4.48 ± 0.02.
 The optical absorption spectrum of TF-PIMO in water resembles the typical 
pattern common to structures containing an imidazole ring and has a peak at 311 
nm with little pH dependence (Fig. S4). 
Cellular uptake of TF-PIMO under hypoxic conditions
To test the capacity of TF-PIMO for staining of hypoxic cells we assessed the uptake 
of the compound under normoxic and hypoxic conditions. Fluorescence microscopy 
of C38 colon carcinoma cells after incubation showed a clear difference in TF-PIMO 
uptake (Fig. 2). The fluorescence intensity was significantly different for normoxic 
and hypoxic cells both after six (p = 0.069) and twenty four hours (p = 0.0015) of 
incubation. There is some background in normoxia as TF-PIMO is passively taken 
up in cells also under normoxic conditions as it is always present in the culturing 
medium. This is in contrast with the in vivo situation where it is cleared via the 
bloodstream when not reduced. 
From the MTT toxicity assay (Fig. S5) it follows that TF-PIMO starts to be toxic above 
about 800 ug/mL in RAW 264.7 cells, and at about 400 ug/mL for HeLa cells. This is 
about a factor 10 above the concentrations used for the in vivo experiments in this 
study.
MR relaxation of TF-PIMO in vitro and in vivo 
The T1 relaxation time of 19F in TF-PIMO was estimated by saturation recovery , 
varying the TR be-tween 250 and 2000 ms. After fitting the signal integrals with 
an exponential curve we found the 19F T1 value to be 608 +/- 89 ms in vitro and 447 
+/- 77 ms in vivo in a C38 colon carcinoma tumor (Fig. 3A).
 The T2* relaxation time was estimated from the line width of the TF-PIMO 
signal and determined to be 3.5 +/- 0.005 ms in vitro and 1.6 +/- 0.13 ms in vivo in 
C38 colon carcinoma tumor for the extend of the experiment time. In previous 
studies on some imidazole compounds used to measure hypoxia MR line broadening 
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was observed (21). To assess whether this also occurred for TF-PIMO we recorded 
the line width of the observed signal over several hours in two animals (Fig. 3B). No 
line broadening was observed in the time span of the experiment. 
Figure 2  Cellular uptake of TF-PIMO under hypoxic and normoxic conditions.  Immunohisto-
chemical staining of TF-PIMO using PIMO specific antibody (green) and nuclei (blue) in C38 
colon carcinoma cells after incubation for 24 hours under normoxic (A) and hypoxic (B) 
conditions. C. Quantitative difference of PIMO antibody fluorescence signal after 6 and 24 
hours of incubation under normoxic and hypoxic conditions.
Figure 3  Realxation time measurements for 19F in TF-PIMO.  A. T1 relaxation measurements 
with TF-PIMO in vivo and in a phantom. The decline of the signal intensity of the TF-PIMO 
resonance upon increased repetition time was fitted with a mono-exponential function to 
obtain values for T1. The T1 for TF-PIMO in a phantom was determined to be 608 +/- 89 ms 
and 447 +/- 77 ms in vivo. B. Line width of the single 19F resonance originating from TF-PIMO 
in a C38 colon carcinoma plotted against the time of injection of the agent. For the complete 
time course of the experiment the line width did not increase.
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In vivo 19F MRSI of TF-PIMO
Finally we tested the feasibility to use TF-PIMO for in vivo MR mapping of hypoxia 
in C38 colon carcinoma tumors implanted on the hind leg of a mouse and in a 
human brain tumor model E98 growing in the mouse brain. The hypoxic fraction 
of the C38 colon carcinoma tumors is known to be 0.14 on average (29) and that of 
the E98 intracranial tumors is ranging up to 0.13 (33) making them valuable 
models for testing hypoxia agents. 
 From in vivo 3D 19F MRSI measurements of the C38 tumor and surrounding 
muscles, performed 4h after the administration of TF-PIMO, the spatial distribution 
of 19F signal was mapped (Fig.4). It indicates that TF-PIMO is located in the tumor 
graft and not outside (Fig. 4). The tumor to muscle ratio was determined to be 
approximately 4 after initial clearance of the excess TF-PIMO from the blood.  Also 
from the 3D 19F MRSI of the brain harboring the E98 tumor, performed 3 hours 
after the administration of TF-PIMO, a map of 19F signal intensity was made (Fig 5). 
For the brain no reference tissue was in the volume of interest and TF-PIMO 
concentrations were visualized relative to peak value (Fig. 6A). 
Figure 4  19F MRSI of C38 colon carcinoma. A: TF-PIMO distribution overlayed on the 
corresponding anatomical T2w image of a C38 colon carcinoma, 4 hours after injection of 
200 mg/kg TF-PIMO. Spectra: B: Highest intensity voxel in the complete tumor,  C: Control 
spectrum taken outside of the animal showing average noise. D: Spectrum of TF-PIMO residual 
in muscle tissue (partial volume effect).
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Immunohistochemistry
Immunohistochemical staining of excised C38 tumor tissue, harvested after the 
in vivo MRS meas-urement, with rabbit-anti-pimonidazole antibody confirmed the 
uptake of TF-PIMO in tumor tissue. The green staining reflects the extend and 
spatial distribution of the TF-PIMO antibody in hypoxic areas (Fig 5). 
 Immunohistochemical staining of E98 glioma tissue that was harvested after 
the in vivo MRS meas-urement and stained with rabbit-anti-pimonidazole 
confirmed the uptake and binding of TF-PIMO (Fig. 6D). The brown staining reflects 
the extend and spatial distribution of hypoxic areas. The binding of the TF-PIMO 
antibody nicely matched with the GLUT1 binding in hypoxic areas.
Figure 5  Immunohistochemistry of C38 tumor.  TF-PIMO staining by PIMO antibody (green) 
and nuclei staining by Hoechst 33342 (red) of C38 murine colon carcinoma tissue implated 
s.c. on the upper leg of C56Bl6 mice harvested immediately after the 19F MRSI experiments. 
Dose 80 mg/kg TF-PIMO.
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Discussion
In this study we demonstrated the successful synthesis of trifluoro-pimonidazole 
(TF-PIMO), a new tissue hypoxia marker suitable for both in vivo 19F MR and in 
vitro immunohistochemistry. TF-PIMO is a 19F labeled analogue of the gold 
standard tumor marker for hypoxia, pimonidazole (PIMO). The new compound has 
similar properties as PIMO as reflected in its lipophilicity, which is only slightly 
different from that of PIMO, and in its similar pKa value and optical properties 
(16). A hypoxia marker should be lipophilic for homogeneous biodistribution in all 
tissues including tumors but at the same time should have an hydrophilic 
character for its tissue elimination, resulting in a relatively large tumor to normal 
tissue ratio (36). PIMO has favorable tissue uptake properties as compared to other 
2-nitroimidazoles developed as hypoxia markers (34).
 In a cellular assay we demonstrated that TF-PIMO accumulates in hypoxic 
tumor cells. We showed that the agents presence in hypoxic tumor tissue can be 
visualized by using the same antibody as used for pimonidazole. This implies that 
we have produced a compound very similar to pimonidazole, but with the added 
value of having a 19F group that can be exploited for the in vivo assessment and 
Figure 6  19F MRSI of E98 tumor in mouse brain 3 hours after iv TF-PIMO administration. A: 
19F MRSI of 80 mg/kg TF-PIMO in an E98 glioma at twice the matrix resolution. B: 19F MRSI 
filtered and interpolated to MR image resolution. C: T2w MR image. D: Anti-pimonidazole 
stained immunohistochemical section of a matched brain section. For corresponding H&E, 
GLUT1 and MCT4 see fig. S6.
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imaging of hypoxia. As a demonstration of this added value we show that the 
presence of the compound in hypoxic xenograft tumors can be imaged by 3D 19F 
MRSI. The correlation with the immunohistology indicates that the 19F MRS 
images reflect hypoxia caused bound and not unbound TF-PIMO. Thus with this 
approach we can assess hypoxia of a tumor in vivo on a macroscopic scale and 
subsequently of the same tumor with immune-staining at the cellular level. In 
principle it would also be possible to image hypoxia in tumor tissue by 3D 19F MRSI 
ex vivo at much higher resolution than feasible in vivo, which could then be used 
as an in-between step for these two assessments.
 With conventional phase encoding 19F MRSI as applied in this study we clearly 
could discriminate hypoxia in the experimental tumor but the 4 mm spatial 
resolution did not allow to resolve heterogeneity further at the scale of the mouse 
tumor. Improvements are possible by more optimized pulse sequences, using 
higher magnetic fields and/or better RF probes (e.g. local receive coils or 
cryo-probes). As TF-PIMO only has one 19F resonance its visualization by 
conventional MR imaging sequences is straightforward. However, translation to 
the clinic requires dedicated 19F coils and some adaptation of the MR system 
scanner, but this is not difficult due to the small difference in Larmor frequency 
between 1H and 19F. For clinical applications of TF-MISO it was estimated that 
target volumes of about 500 mm3 would be feasible at 3 T for superficial lesions (21) 
and similar volumes then would also apply to TF-PIMO. MR imaging of multi-reso-
nance fluorine hypoxia markers like EF5 require  more complex acquisition 
methods (37).  
 It is of interest to compare further 19F MR properties of TF-PIMO with those of 
other fluorinated imidazole, in so far these are reported.  TF-MISO shows a similar 
line width change as TF-PIMO going from in vitro solution to in vivo tumor tissue, 
i.e from about 90 to 150 Hz (at 7 T), 2 hours after administration (21). However, it 
increased to 300 Hz in 6 hours, which we did not observe for TF-PIMO over time, 
which remained at a constant line width of about 200 Hz. For SR-4554 line widths 
were not explicitly reported but from the published 19F MR spectra one can deduce 
a line width in the order of 200 – 300 Hz at 4.7 T (25). Another hypoxia marker EF5 
showed smaller line widths going from 30 – 40 Hz in solution to 70 – 100 Hz in in 
vivo tumor tissue, at 4.7 T, which may be related to the higher mobility of the -CF3 
group on this compound (37). However, the authors reported that ultimately the 
19F resonances of EF5 became so broadened that its intensity dropped below the 
detection limit. Finally, for the compound CCI-103F we also deduce line widths of 
about 100 - 200 Hz at 2.35 T from the published spectra (38). 
 For TF-PIMO a moderate decrease in T1 value of the 19F spins was observed 
going from its presence in solution to in vivo tumor tissue (about 0.45 s), in contrast 
to TF-MISO for which its T1 value dropped more dramatically from 2.5 s (solution) 
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to 0.37 s (in vivo). The T1 difference in solution can be due to the particular solution 
conditions affecting T1 relaxation. The less pronounced changes in the T1 and T2 
relaxation times of TF-PIMO compared to TF-MISO upon tissue uptake may be 
related to a difference in structure, i.e. in TF-PIMO the tri 19F group is extended 
further away from the imidazole group by a piperidine ring which, because of its 
conformational flexibility (39), may give additional mobility to the tri-fluor group. 
 The 19F signals of TF-MISO, SR-4554 and EF5 in experimental tumors show a 
substantial decline over a period of about 5 hours (12,21,37). This is not observed 
for TF-PIMO in C38 tumors pointing to a long retention time. Hydralazine 
application to P22 tumors in SCID mice, increasing the amount of hypoxia in these 
tumors, also caused prolonged retention times for SR-4554 (25). This indicates that 
TF-PIMO in C38 tumors reflects the presence of a substantial amount of hypoxia in 
these tumors. It is also known that pimonidazole is among the more rapidly and 
extensively binding 2-nitroimidazoles (34).
 MRI of TF-PIMO presence, like that of other fluorinated 2-nitroimidazoles, only 
gives a time averaged non-invasive representation of hypoxia. To examine dynamic 
changes in oxygen levels (e.g. in acute or perfusion limited hypoxia) other MR 
methods like relaxometry of 19F in perfluorcarbons are better suited (40,41). 
Therefore it would be of interest to explore if the T1 relaxation time of 19F in 
TF-PIMO is sensitive to oxygen levels.    
In comparison to the hypoxia marker TF-MISO (21), TF-PIMO has the advantage 
that it can also be stained using immunohistochemistry after tissue excision. In 
addition, the binding characteristics of PIMO are more advantageous as those of 
MISO. It has been observed that the initial uptake of 18F-MISO/ TF-MISO is 
dominated by perfusion (43). The octanol/water partition coefficient logP of 
TF-PIMO is larger than most other nitro-imidazoles, including PIMO, that may lead 
to longer circulation/clearance times likely due to the largely un-ionized state of 
TF-PIMO. 
 In this study we showed that TF-PIMO levels well below the LC50 values in a 
cellular MTT assays were sufficient for in vivo 19F MRSI. The toxicity of PIMO also 
has been assessed (31), but with a different assay, so that only a qualitative 
similarity can be concluded.  
 As there is no measured added toxicity effect or loss of characteristics of 
TF-PIMO compared to PIMO we suggest its use in pre-clinical hypoxia experiments 
and warrant further investigation towards possible clinical application.
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Chemical shifts of trifluoro-pimonidazole measured by 1H  
and 19F NMR  at 11.7 T 
Chemical shifts are given in parts per million and referenced to the appropriate 
non-deuterated residual solvent signal. J-values are reported in Hertz.
 1H NMR characterization of imidazole epoxide (1H NMR (DMSO-d6, 500 MHz) 
d 2.56 (dd, J = 2.5, 4.4 Hz, 1H), 2.92 (t, J = 4.2 Hz, 1H), 3.40 (tq, J = 2.5, 4.0, 6.5 Hz, 1H), 
4.19 (dd, J = 6.6, 14.7 Hz, 1H), 5.03 (dd, J = 2.5, 14.7 Hz, 1H), 7.16 (d, J = 1.1 Hz, 1H), 7.18 
(d, J = 1.1 Hz, 1H). 13C-NMR (DMSO-d6, 125 MHz) d 45.6, 50.1, 51.8, 126.6, 128.7, 
144.8. HRMS m/z (ESI+) [M+H]+ C6H7N3O3 calc 170.0560, found 170.0555.) and 1H 
NMR characterization of TF-PIMO (1H-NMR (DMSO-d6, 500 MHz) d 1.89 (dq, J = 3.0, 
13.0 Hz, 1H), 1.94–2.04 (m, 3H), 2.64 (br s, 1H), 2.99–3.10 (m, 3H), 3.22 (dd, J = 5.1, 12.8 
Hz, 1H), 3.62 (t, J = 11.4 Hz, 2H), 4.41 (dd, J = 7.2, 16.9 Hz, 1H), 4.42 (s, 1H), 4.56 (dd, J = 
7.2, 16.9 Hz, 1H), 6.09 (br s, 1H), 7.19 (d, J = 0.9 Hz, 1H), 7.66 (d, J = 0.9 Hz, 1H), 10.34 
(br s, 1H). 19F-NMR d  72.6 HRMS m/z (ESI+) [M+H]+ C12H17F3N4O3 calc MW 
323.1326, found MW 323.1325.)
Figure S1  [2]-nitroimidazole reduction mechanism Reduction mechanism of a [2]-nitroimi-
dazoles based molecule in the presence and absence of adequate oxygen.
Figure S2  Imidazole epoxide Intermediate product of the first step of TF-PIMO production, 
imidazole epoxide (2-nitro-1-(oxiran-2-ylmethyl)-1H-imidazole).
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Figure S3  Spectrum 19F HR-NMR spectrum (470 MHz) of TF-PIMO.
Figure S4  Optical absorption characteristics A. Optical absorption spectrum of TF-PIMO in 
water. The absorption of the nitro-imidazole ring is maximum at a wavelength of approximately 
311 nm just outside of the boundaries of conventional ELISA readers. B. pH dependency of 
TF-PIMO optical absorption spectrum.
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Figure S5  MTT cellular toxicity Cellular toxicity assay of HeLa (white bars) and RAW 264.7 
cells (gray bars). TF-PIMO LC50 was determined to be >800 ug/mL for Hela and >1600 ug/mL 
for RAW 264.7 cells.
Figure S6  Complementary Immunohistochemistry A: Hematoxylin and Eosin (H&E) antibody 
staining. B: Glucose transporter type 1 (GLUT1) antibody staining. C: Monocarboxylate 
(mainly lacatate) transporter type 4 (MCT4) antibody staining.
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Abstract
A method to achieve NMR of dilute samples in the earth’s magnetic field by 
applying para-hydrogen induced polarization is presented. Maximum achievable 
polarization enhancements were calculated by numerically simulating the 
experiment and compared to the experimental results and to the thermal 
equilibrium in the earth’s magnetic field. Simultaneous 19F and 1H NMR detection 
on a sub-milliliter sample of a fluorinated alkyne at millimolar concentration 
(~1018 nuclear spins) was realized with just one single scan. A highly resolved 
spectrum with a signal/noise ratio higher than 50:1 was obtained without using 
an auxiliary magnet or any form of radio frequency shielding.
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Introduction
NMR spectroscopy is a powerful analytical tool for non-destructive investigations 
in material science, chemistry and biology. The resolving power of the technique 
depends on the chemical shift dispersion, which is linearly dependent on the 
magnetic field strength. Recent applications of low field NMR [1], [2] and [3] 
nevertheless demonstrated the possibility of obtaining analytical information in 
the absence of strong magnetic fields. In contrast to using chemical shift, as is 
common in high field NMR, the information at low field is obtained from 
heteronuclear couplings resolved with high accuracy. The main disadvantage of 
NMR at such low fields is its inherent low sensitivity; therefore, concentrated 
samples (typically 1021–1025 nuclear spins) pre-polarized at higher magnetic fields 
are required.
 The aim of this study was to develop a method to measure low field NMR on 
dilute samples by exploiting the sensitivity gain provided by nuclear spin hyperpo-
larization. Several techniques [4-6] and [7] are nowadays available to increase the 
population differences of the nuclear spin states far beyond thermal equilibrium. 
Here, we present a theoretical description and report on the results of an NMR 
measurement performed at earth’s field, using Para-Hydrogen Induced Polarization 
[8, 9] and [10] (PHIP) as hyperpolarization method. The NMR data we present have 
been acquired with just one scan on a sub-milliliter sample at millimolar 
concentration (~1018 nuclear spins).
Theory
PHIP requires a fast chemical reaction between the para- spin isomer of molecular 
hydrogen (p-H2) and an organic substrate (typically an alkene or an alkyne) [4-6, 8] 
and [11]. Depending on the magnetic field strength during the hydrogenation, 
PHIP experiments are classified as PASADENA [8, 11] and [12] (high field) or 
ALTADENA [9] and [13] (low field). Recently, optimized versions of PHIP have been 
proposed relying on RF irradiation [10] and [14] or magnetic field cycling (FC) [13] 
and [15] to convert the proton spin order of the p-hydrogenated product into 
longitudinal magnetization. Noticeably, nuclear hyperpolarization has been 
recently obtained also via reversible association of an organic substrate with p-H2 
[16], thereby lifting the stringent requirement of a p-hydrogenation reaction.
 The conversion of spin order to proton and heteronuclear longitudinal 
magnetization in a FC experiment has been discussed in the original paper of 
Jóhannesson et al. [15]. In Fig. 1A we summarize his conclusions for the specific 
case of a 1H, 19F spin system. For simplicity we present a reduced spin system 
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consisting of two protons from p-H2 and a single 
19F nuclear spin. The energy 
diagrams in Fig. 1A were drawn considering a 100% p-H2 enrichment and assuming 
the same scalar coupling network (3JHH = 12.5 Hz, 
3JHF = 8.4 Hz, 
4JHF ~ –0.8 Hz) as 
found in the hydrogenated product, 4,4,4-trifluoro but-2-enoate, used in the 
experiment (see below). The eigenstates at zero field and earth’s field (γB0/2π: 
1H = 
2152 Hz, 19F = 2020 Hz) are expressed below in the Zeeman eigenbasis; expressions 
for the value of the coefficients can be found in [15].
at zero field and
at earth’s field.
After p-hydrogenation and sudden jump to zero field, only energy levels corresponding 
to eigenstates with a total magnetic quantum number Mz = +/–½ are populated [15]. 
For an in-depth discussion about the eigenstates of a three-spin system at low-field 
and the population distribution after p-hydrogenation see [17] and [18]. The 
population distribution within these energy levels depends on the strength of 
H–H as well as H–F scalar coupling interactions. In the case of our spin system, ca. 
80% of the total population is equally distributed between the Ф1– and Ф2– 
eigenstates (circles black and white in Fig. 1A). For the sake of clarity, the remaining 
20% population (almost uniformly distributed among the other energy levels) is 
not displayed in Fig. 1A and not further considered.
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 During adiabatic remagnetization, the eigenstates smoothly follow the 
Hamiltonian change while the populations of the corresponding energy levels are 
left unperturbed. As a consequence, only two energy levels remain considerably 
populated during the whole remagnetization process.
Figure 1  (A) Energy diagram at zero field and at earth’s field (50.50 µT) of a (1H, 1H,19F) spin 
system; the energy values were calculated assuming the same H–H and H–F coupling 
constants as found in 4,4,4-trifluoro but-2-enoate and by using the expressions given in Ref. 
[15]. The populations of the Ф1– and Ф2– eigenstates are represented with a black and white 
circle, respectively. The gray arrows indicate the transitions corresponding to the signals 
observed in the earth’s field NMR spectrum (B) Field dependence of the coefficients defining 
the eigenstates Ф1– (left) and Ф2– (right) in the Zeeman eigenbasis.
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 The eigenstates transformation from zero field to earth’s field can be followed 
by numerical methods. In Fig. 1B, the conversion of the two highly populated 
eigenstates at zero field (i.e. Ф1– and Ф2–) is shown. Ф1– (black circle) transforms to 
|ααβ>, in agreement with the emissive 19F signal in the earth’s field NMR spectrum 
of Fig. 3, which corresponds to the transition |ααβ > → |ααα>. In contrast, Ф2– 
(white circle) transforms to eigenstate ψ2–: this is consistent with the 
1H absorptive 
signal in the earth’s field NMR spectrum of Fig. 3, originating from the transition 
ψ2– → |βββ>.
 The optimal magnetic field profile during remagnetization depends on the 
scalar coupling network as well as on the gyromagnetic ratios of the nuclear spins 
in the p-hydrogenated molecules. Adiabatic remagnetization of (1H, 13C) spin 
systems has been previously achieved with a linear or exponential profile of 
approximately 1–5 s duration [15] and [19]. In the present case, where both 1H and 
19F T1 relaxation times at earth’s field are on the order of 1 s, a faster remagnetiza-
tion is desirable. We therefore calculated the shortest possible remagnetization 
trajectory satisfying the general requirements posed by the approximate adiabatic 
criterion [20] and [21] within a 0.01 tolerance (see below). The time dependence of 
the magnetic field during remagnetization was determined for the hyperpolarized 
spin system of 4,4,4-trifluoro but-2-enoate (i.e. three equivalent 19F spins and two 
1H spins). The ramp from low to high field (Fig. 2A) was divided in 100 steps of 
equal amplitude; the duration of each individual step was determined under the 
condition that the transition probability between any pair of eigenvectors [20] be 
less than 0.01. Our approach resulted in a remagnetization profile of approximately 
Figure 2  (A) Profile of the magnetic field strength B0 versus time for the adiabatic remagneti-
zation. The curve was calculated with a 0.01 tolerance (see text). (B) Buildup of 1H and 19F 
longitudinal magnetization during the remagnetization assuming an adiabatic process (dashed) 
or solving the Liouville–von Neumann equation in steps of 20 µs (full). The calculations were 
carried out neglecting the effects of spin relaxation and assuming a p-H2 enrichment of 80% 
as used for the experiment (see below).
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210 ms, substantially shorter than 1H and 19F T1. The nuclear magnetization for 1H 
and 19F during the remagnetization, calculated under the assumption of an 
adiabatic process, is shown in Fig. 2B (dashed curve): a spin polarization of ca. 60% 
(i.e. twice the expectation value <Iz>, see [15]) is predicted for both nuclear species 
at the end of the trajectory. Comparable results were obtained by numerically 
solving the Liouville–von Neumann equation to determine the evolution of the 
density matrix during the remagnetization. The oscillations of the longitudinal 
magnetization displayed in Fig. 2B (full curve) are due to the evolution of 
off-diagonal terms of the density matrix [10]. Given the short duration of the re-
magnetization the effects of longitudinal- and cross relaxation were assumed 
negligible and, therefore, not included in the calculation.
Experimental results and discussion
Hyperpolarization of both 1H and 19F nuclear spins was obtained using a diabat-
ic-adiabatic field cycling (FC) scheme [15] following p-hydrogenation. We chose a 
fluorinated compound as it allows for simultaneous detection of both 
hyperpolarized nuclear species at earth field [22]. We could therefore compare the 
attained hetero nuclear polarizations and validate our results against our 
theoretical prediction. In addition, our choice simplified the experimental setup 
as the 1H–19F strong coupling condition required during the field cycling (see 
above) can be achieved already at magnetic field strengths of a few microTesla.
 The NMR sample we used consisted of 310 µl of oxygen-free solution of 4,4,4-
trifluoro but-2-enoate (2) 9 mM in deuterated acetone. It was obtained by p-hydroge-
nation of 4,4,4-trifluoro but-2-ynoate (1) using 15 mM [Rh(cyclo-octadiene) dyphe-
nyl-phosphanyl butane)] [BF4] as catalyst and 80% enriched p-H2 at 0.2 MPa (2 bars). 
The reaction (Scheme 1) was carried out in 5 s, resulting in a 95% yield, as 
established by conventional high field 1H NMR after the earth’s field (EF) NMR 
experiment.
Scheme 1  Production of 4,4,4-trifluoro but-2-enoate (2) from 4,4,4-trifluoro but-2-ynoate (1).
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 An NMR spectrum of 4,4,4-trifluoro but-2-enoate (2) with signals substantially 
above the noise level was acquired at earth’s field (50.5 µT) in a single scan (Fig. 3). 
Two signals with comparable integrals and opposite sign are found in the spectrum, 
experimentally confirming the prediction about opposite polarizations reported 
earlier [15]. The multiplet structure of 1H and 19F signals results from H–H and H–F 
couplings (3JHH = 12.5 Hz, 
3JHF = 8.4 Hz, 
4JHF ~ –0.8 Hz). The two signals roughly 
resemble a quartet and a triplet with a splitting of ca. 3.5 Hz. A more careful 
analysis of these “deceptively simple” structures [23] reveals a complex peak 
pattern, consistent with the H–H (and partially H–F) strong coupling regime. A 
linewidth of ~0.7 Hz was estimated for the multiplets components, illustrating the 
magnetic field homogenenity within the sample. This is quite remarkable, 
considering that the spectrum was acquired indoor without sample shimming, in 
close proximity to armed concrete floor and ceiling. The shape and relative 
Figure 3  Single-scan earth’s field NMR spectrum (in black) of 310 µl hyperpolarized 4,4,4-
trifluoro but-2-enoate (2), 9 mM in perdeuterated acetone. A signal/noise ratio higher than 
50:1 was estimated from peak intensities and RMSD noise of the spectrum (0.03 µV/Hz). The 
multiplets displayed in red are obtained by simulating the complete field cycling experiment 
(i.e. para-hydrogenation + adiabatic remagnetization + excitation + detection at earth’s 
magnetic field). Insert. FID acquired at earth field (50.50 µT) after hydrogenation of 4,4,4-
trifluoro but-2-ynoate (1) with 80% enriched parahydrogen and diabatic–adiabatic field 
cycling. 1H and 19F signals were acquired for 2 s after a RF pulse of 0.7 ms, corresponding to 
a ~90° flip angle, and with a pre-acquisition delay of 25 ms.
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intensity of the two multiplets is in very good agreement with the result of a 
simulation of the complete FC experiment (Fig. 3 in red), using standard 
propagation methods (relaxation not included). This supports the notion of sca-
lar-couplings [15], [24] and [25], rather than cross-relaxation, as being the driving 
force of the hyperpolarization process by diabatic FC.
 The core of the NMR setup consists of a solenoid coil used for RF excitation and 
signal detection. The solution containing 4,4,4-trifluoro but-2-ynoate (1) was 
centered on the axis of this coil in a small glass sphere (ca. 350 µl) connected to an 
evacuated chamber of ca. 12 ml. Whilst placed inside the coil this reaction chamber 
was instantaneously filled with 80% enriched p-H2 to form 4,4,4-trifluoro 
but-2-enoate (2). After the p-hydrogenation, the magnetic field was reduced from 
150 µT to approximately zero field (<3 µT) in less than 1 ms. The field strength was 
then adiabatically increased up to earth’s field. During the adiabatic remagnetiza-
tion the spin order originating from p-H2 evolves coherently in 
19F and 1H 
longitudinal magnetization. RF irradiation and signal detection take place in situ, 
with no additional dead time for sample transfer. While non-inductive detection 
systems (e.g. SQUID [1]) could have offered a higher sensitivity, we have here 
privileged the simplicity and portability of a conventional inductive coil.
 The spin polarization experimentally obtained using the calculated magnetic 
field profile, was estimated by comparison with the earth’s field 1H NMR spectrum 
of a sample of 3.9 ml water (~1023 proton spins). This reference spectrum was 
acquired in 16 scans, repetitively polarizing the water protons at 15 µT for 5 s, 
while keeping all other experimental parameters unchanged. From the comparison 
of the signal integrals, a spin polarization of ca. 3% was estimated for both 1H and 
19F, corresponding to a 108-fold polarization enhancement with respect to thermal 
equilibrium. In part, the discrepancy with the (20 times larger) predicted 
enhancement might be explained in terms of singlet–triplet mixing during the 
reaction, which converts the long-lived state originating from p-H2 [18] into faster 
relaxing terms (i.e. H–F longitudinal spin order). Such interconversion between 
singlet and triplet states could be prevented by selective proton irradiation [10], 
[26] and [27] during the reaction.
Conclusion
A method to measure earth’s field NMR on dilute samples, exploiting the sensitivity 
gain provided by PHIP, was presented. PHIP dramatically lowers the requirements 
for earth’s field NMR to sample volumes and concentrations common to high field 
NMR investigations. The method has enabled us to measure earth’s field NMR even 
under non-ideal conditions (e.g. indoor and using a conventional coil).
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Experimental
Para-hydrogen (p-H2) was produced at 20 K in the presence of iron oxide and stored 
at a pressure of 0.2 MPa (2 bars) in an aluminum bottle for later use [28]. The level 
of p-H2 enrichment was assessed by recording a high field 
1H NMR spectrum using 
a Varian UnityINOVA (500 MHz, 1H frequency) before starting the earth’s field 
NMR experiment.
 For NMR a B1 and an optional polarization coil were positioned exactly in the 
isocentre of a Helmholtz pair. The magnetic field strength through the sample was 
modified with the Helmholtz pair, oriented approximately 67° from the horizontal 
plane set to produce a magnetic field parallel or opposite to the earth’s magnetic 
field. The accuracy of the alignment between earth’s magnetic field and the 
Helmholtz field was determined not to be better than 2.7°, which determined a 
small field component oriented perpendicular to the earth’s magnetic field. 
Numerical simulations indicate a modest decrease (ca. 5%) of 1H and 19F spin 
polarization at the end of the remagnetization step due to this residual magnetic 
field (approximately 2 µT, corresponding to ν(1H) – ν(19F) ~ 6 Hz immediately after 
the jump from earth field to low field). The setup allows for in situ measurement 
of NMR spectra, without additional “dead periods” for sample transfer to an NMR 
spectrometer.
 Chemicals were purchased from Sigma–Aldrich. Care was taken to degas all 
chemicals and glassware used in the experiment. For activation 160 µl of the 
catalyst solution was injected into the evacuated reactor and pressurized with 0.2 
MPa (2 bars) H2. After 60 s of gentle mixing the catalyst was assumed activated and 
the reactor was evacuated once more before introducing 150 µl of the substrate 
solution.
 Before starting the para-hydrogenation reaction and field cycling experiment 
the reactor, now containing the activated catalyst and substrate, was connected to 
the p-H2 vessel (0.2 MPa/2 bars) and inserted into the NMR coil setup (see above).
 Immediately after the remagnetization, performed using the calculated 
adiabatic trajectory (see above), an NMR spectrum of the hydrogenated product 
was acquired at earth’s field.
 The NMR spectrum of the hydrogenated product was acquired following a 0.7 
ms (~90°) RF pulse at a frequency of 2090 Hz (exactly between 19F and 1H Larmor 
frequencies at earth’s field) and a 25 ms B1 coil ring-down delay. Total acquisition 
time was 2 s in which a total of 32 k real points was recorded. The free induction 
decay (FID) was processed with scripts implemented in MATLAB® using 90° shifted 
square sine-bell apodization, prior to zero-filling to 64 k real points, and Fourier 
transformation.
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 The evolution of the hyperpolarized spin system during field cycling, RF 
irradiation and detection period was calculated by standard propagation methods, 
with a full non-truncated Hamiltonian. The simulation was carried out as 
numerical integration of the Liouville time-dependent differential equations in 
constant time steps of 20 µs (for the 210 ms adiabatic remagnetization), 0.7 µs (for 
the 0.7 ms RF pulse) and 200 µs (for the acquisition period) using MATLAB®. The 
effects of relaxation were not accounted for in these simulations. The calculated 
FID was processed in a similar fashion as the acquired FID (see above).
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Summary
This thesis describes several novel MR methods for the assessment of biological 
characteristics of preclinical tumor models with the aim to improve the imaging 
of gliomas via mapping of tumor perfusion, hypoxia and metabolites. It includes 
the presentation of applications of these methods focusing on brain tumor models, 
such as the establishment of MR biomarkers in the diagnosis of these tumors and 
imaging the effect of anti-angiogenic therapies.
With time-of-flight and phase contrast angiography fast flowing spins can be 
depicted. These methods are less sensitive to visualize small veins for example in 
tumors. Susceptibility weighted imaging (SWI) can be used to depict small veins 
but, due to a lack of susceptibility changes, does not visualize small arteries. 
Contrast enhanced SWI (CE-SWI) is based on the added susceptibility effect of 
a contrast agent to also depict vascular volume in tumors. A combination of SWI 
and CE-SWI using USPIOs may therefore give important information on vascular 
characteristics of cancers and may predict susceptibility to anti-angiogenic 
therapy chapter 2.
Targeting tumor blood vessels and blood vessel formation through the use of 
 anti-angiogenic compounds is becoming more common in cancer therapy. Blood 
vessel formation can be inhibited by targeting vascular endothelial growth factor 
(receptors) VEGF(R), and vessel maturation can be inhibited by PDGFRß platelet 
derived growth factor receptor-ß targeting compounds. Previous work has shown 
that inhibition of VEGFR signaling does not have an anti-tumor effect in diffuse 
glioma xenografts models, presumably because in diffuse infiltrative areas in 
glioma there is no involvement of angiogenesis. It is shown that additional 
targeting of PDGFR signaling does not improve anti-tumor responses. These data 
are in line with the concept that diffuse infiltrative areas in gliomas are 
intrinsically resistant to anti-angiogenic therapy. These results have recently been 
confirmed for clinical glioma, as two large phase III trials for glioma using the 
anti-VEGF antibody bevacizumab failed to show improved survival [1].
Finally this study showed that anti-angiogenic compounds (VEGF and/or PDGRFß 
targeting compounds) reduce vessel leakage in compact tumor areas, resulting in 
decreased detectability of these, mostly infiltrative, xenografts in Gd-DTPA 
contrast enhanced MRI scans chapter 3. 
As glioblastomas are (partially) invisible in conventional contrast-enhanced MRI, 
especially after anti-angiogenic treatment , exploration of other MR methods to 
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visualize these cancers, is of high importance . Magnetic Resonance Spectroscopic 
Imaging (MRSI) allows for visualizing metabolic profiles in relatively small voxels, 
which can be exploited to identify and map tumor-containing voxels, based on 
aberrant metabolism of cancer cells. . 1H MRSI is superior to CE-MRI for a reliable 
noninvasive evaluation of therapeutic effects of anti-angiogenesis on gliomas and 
yields additional information about tumor metabolism that may be exploited for 
individualized treatment. In addition MRSI revealed that infiltrating glioma cells 
in  glioma brain tumor models did not display the glycolytic phenotype that has 
been suggested to be a hallmark of tumors (ie, the Warburg effect) chapter 4.
In addition to 1H MRSI more insight into tumor energy metabolism and lipid 
metabolism is achieved by 31P MRSI. Mutations in the metabolic enzyme isocitrate 
dehydrogenase 1 (IDH1), that occur very frequently in grade II and III gliomas and 
secondary glioblastomas and that have prognostic value, result in distinct 
alterations in lipid metabolism in brain tumors that can be detected non-invasively 
by 31P MRSI. These may serve as a complementary biomarker to non-invasively 
identify IDH-mutated glioma chapter 5.
The accumulation of pimonidazole (PIMO) in hypoxic cells is commonly used to 
identify hypoxia in preclinical tumors ex vivo. To evaluate the possibility of in vivo 
hypoxia imaging we synthesized tri-fluoro PIMO (TF-PIMO). Molecular characteris-
tics of TF-PIMO were determined and compared to those of PIMO. As there is no 
measurable added toxicity effect or loss of characteristics compared to PIMO its 
use is of interest in pre-clinical hypoxia experiments. We showed that this 
compound allows for in vivo 19F-MR imaging of hypoxia in tumor xenografts 
(glioma and colon carcinoma) and can also be measured ex vivo, similar to PIMO 
chapter 6.
As low signal to noise ratios still is a major issue in preclinical MRS, new approaches 
to enhance the signal were investigated. A method to measure NMR of dilute 
samples in the magnetic field of the earth, exploiting the sensitivity gain provided 
by parahydrogen induced polarization (PHIP), is presented. PHIP dramatically 
lowers the requirements for earth’s field NMR to sample volumes and concentrations 
common to high field NMR investigations. The method has enabled us to measure 
earth’s field NMR even under non-ideal conditions (e.g. indoor and using a 
conventional coil). The system presented takes us a step further toward the goal of 
obtaining a more general and simple approach to characterize dilute samples by 
just using the earth’s field and opens up the way of translation of this technique to 
preclinical applications chapter 7.
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Clinical translation
A general discussion on potential clinical translation of the work described in the 
preceding chapters will be given here, followed by some future perspective of the 
presented work.
Some of the techniques presented in this thesis can be translated to humans 
without significant alterations. Both CE-SWI as applied in chapter 2 and CE-MRI 
as applied in chapter 3 can be directly translated from preclinical to clinical 
application. Both methods make use of iron oxide particles that for a long time 
were not available for routine human use but have recently been reintroduced [2]. 
Also there is no major technical hurdle of applying the 1H MRSI techniques to 
assess gliomas during anti-angiogenic therapy, as explained in chapter 4, in the 
clinic. The expertise needed in the interpretation and performance of 1H MRSI 
might nevertheless limit its application to centers of expertise. The X-nucle-
us-based MRS techniques of chapter 5 and chapter 6 are less likely to be translated 
to routine clinical application on short term as specific coils for X-nuclei are not 
routinely available in clinical MR centers. This may change if for instance 31P 
metabolites turn out to be ‘killer’ biomarkers in diagnosis or therapy evaluation. 
In addition higher fields (e.g. 7 T) may be helpful for higher sensitivity and spatial 
resolution.  
In chapter 7 initial steps of parahydrogen induced polarization were presented. 
The application of hyperpolarized agents in the clinic is still challenging. The 
production of short-lived hyperpolarized agents for in vivo application is 
complicated and costly. However, recently the first clinical trial with dynamic 
nuclear polarization (DNP) of pyruvate in human prostate was presented [3]000-fold 
enhancement in signal relative to conventional magnetic resonance (MR and a 
commercial DNP polarizer for clinical applications is now available (SpinLab).
Future perspectives
Although radiological MR practice is still largely focusing on anatomy and 
structure, new methods to monitor function, physiology and metabolism and even 
genetic mutations through phenotype, are becoming more important. This is 
especially relevant in a heterogeneous disease as cancer, where the detection of 
early changes can be essential to obtain a personalized diagnosis and to tailor the 
treatments. 
158
Work described in this thesis was performed at a preclinical small bore 7 T MR 
setup. Over the last few years more and more 7 T human whole body MR machines 
have been installed for human research purposes [4] although the majority operate 
at magnetic fields of 1.5 T and below (i.e. about 70%. The step from 3 T to 7 T brings 
enhanced sensitivity and higher spectral resolution at the cost of more RF 
inhomogeneity and power deposition, less contrast in T1 weighted images and 
more susceptibility artifacts. Susceptibility-weighted imaging nevertheless 
benefits from the higher main magnetic field strength. The technique has recently 
been used for detecting and grading intracranial gliomas in humans [5]. The lack 
of standardization of the SWI technique remains an obstacle in its integration into 
mainstream grading of gliomas. SWI for now plays an important role in detecting 
gliomas and guiding biopsies. The goal of noninvasive accurate grading of tumors 
is yet to be realized. 
In addition to histological assessments of tumor tissue obtained by biopsies and T1 
weighted CE-MRI, improved grading of brain tumors is now possible with 1H MRSI. 
New database tools allow radiologists with a minimum knowledge of what an MR 
spectrum is to compare their acquired spectra to a standardized database and 
analyze them [6]. The system is expected to help in the categorization of MRS from 
any abnormal brain mass. 
Upon categorization of a tumor, an appropriate treatment, targeting individual 
characteristics of the tumor, can be started. For instance antibodies are currently 
being introduced to target specific cancer signaling pathways [7]. The efficacy of 
antibodies for treatment of gliomas still needs to be determined. Recently, a IDH1 
mutated specific vaccine has been developed that stops the further growth of IDH1 
positive (preclinical) tumors [8]. In addition novel nano materials also aimed to 
destroy malignant glioma are being introduced. The latter have the added 
advantage that they also provide a potential platform for MR imaging, for instance 
by labeling the particles specifically with 19F atoms [9].  
Fluorine is also still the most likely candidate to enable hypoxia imaging with MR. 
New ways to assess hypoxia by MR are also being explored, e.g. [10] . A better 
understanding of the mechanisms of tumor hypoxia with non-invasive imaging 
will provide a basis for improved radiation therapeutic practices [11]. 
One of the exciting new MR fields, for which also work is described in this thesis, 
is the field of hyperpolarization. With the use of hyperpolarized compounds MRI 
can be performed with orders of magnitude higher sensitivity. Recently, the first 
19F MR image produced by PHIP was obtained [12] for which also polarization, 
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transfer of 1H to 19F was employed  [13]. Although promising, the PHIP method is 
lacking behind in development to hyperpolization MRI with DNP. To translate 
PHIP to biological applications requires complicated chemistry, which makes it 
very probe specific. A knew PHIP approach called SABRE is explored to make it 
more universal applicable [14].
However, this PHIP variant is still far away from the biomedical potential of DNP 
for the hyperpolarization of many biological compounds. Currently DNP MRI is 
mainly applied with the use of 13C labeled compounds. With respect to its kinetics 
and interpretation of results the DNP technique resembles PET [15]. Although the 
use of hyperpolarized agents increases MR sensitivity enormously (into the nM 
range) it is not expected to reach PET sensitivity (pM to even fM range). Therefore 
DNP is not seen as a method for direct receptor imaging, but the unique point of 
DNP MRI is that it can image a range of metabolic conversions and therefore is very 
suitable to assess key metabolic pathways in tumor and other cells or tissues. 
A widespread concept in modern biomedical imaging is multi-modality, which 
implies the use of different complementary imaging techniques to solve a 
biomedical problem. A successful combination in clinical practice is PET-CT and 
the new combination of PET with MR may also prove to be important for imaging 
in cancer research [16]. 
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Samenvatting
In dit proefschrift wordt de ontwikkeling en toepassing van een aantal in vivo 
magnetische resonantie (MR) methoden beschreven, met name gericht op 
onderzoek van hersentumoren (glioma’s) in de muis, als model voor deze tumoren 
in de mens.  Met deze non-invasieve methoden zijn hun biologische karakteristiek-
en in kaart gebracht, nieuwe diagnostische tumor biomarkers gevonden en 
groei-remmende behandelingen van bloedvaten in tumoren geëvalueerd. In het 
bijzonder zijn de doorbloeding van de tumoren, hun eventuele zuurstoftekort en 
de verdeling van verschillende metabolieten over tumor- en hersenweefsel 
bestudeerd. 
Met behulp van de MR technieken time-of-flight en fase contrast angiografie kan 
stromend bloed afgebeeld worden. Deze MR technieken zijn echter relatief 
ongevoelig en daarom minder geschikt om kleine capillairen in tumoren  af te 
beelden. Susceptibiliteit gewogen imaging (‘susceptibility weighted imaging’, 
SWI) kan wel gebruikt worden voor dit doel vanwege de aanwezigheid van het 
paramagnetische deoxyhemoglobine, met name in de venen. Omdat het niet-para-
magnetische oxyhemoglobine doorgaans domineert in arteriën kunnen deze niet 
zichtbaar gemaakt worden met deze techniek. We laten zien dat door intraveneuze 
toediening van een ijzerhoudend contrastmedium een susceptibiliteitsverander-
ing veroorzaakt wordt zodat met SWI zowel kleine venen als arteriën afgebeeld 
kunnen worden. Door bloedvaten in tumoren met een combinatie van SWI met 
contrast versterkte SWI te karakteriseren is het misschien mogelijk de gevoeligheid 
van tumoren voor een bloedvat remmende (anti-angiogene) therapie te voorspellen 
hoofdstuk 2.
Anti-angiogene therapie heeft inmiddels een belangrijke rol verworven in de 
klinische praktijk voor een aantal tumortypes. Bloedvatvorming in tumoren kan 
worden voorkomen via remming van zogenaamde vascular endothelial growth 
factor (VEGF-A)  of VEGF receptoren (R). Verdere maturatie van de bloedvaten kan 
worden geremd door blokkade van platelet derived growth factor receptor’) 
PDGF(R). De remming van VEGFR signalering heeft geen anti-tumor effect op 
diffuse glioma xenografts modellen, waarschijnlijk omdat diffuus infiltratief 
groeiende tumorcellen voldoende hebben aan de pre-existente bloedvaten in het 
brein voor hun bloedvoorzieningen er geen  angiogenese nodig is. Ook additionele 
remming van de PDGF signalering leidt niet tot een verbeterde anti-tumor respons. 
Deze gegevens zijn in overeenstemming met het concept dat diffuus infiltratief 
groeiende gliomacellen intrinsiek resistent zijn tegen anti-angiogene therapie. 
Deze resultaten zijn onlangs bevestigd in twee grote fase III studies waar de 
162
behandeling van gliomas met het anti-VEGF-antilichaam bevacizumab geen 
verbeterde overleving opleverde. We tonen aan dat anti-angiogene therapie de 
defecte bloed-hersenbarrière in tumoren herstelt wat resulteert in verminderde 
detecteerbaarheid van deze  tumoren in Gd-DTPA contrast gewogen MRI-scans 
hoofdstuk 3.
Omdat de verspreiding van glioblastoma in de hersenen (gedeeltelijk) onzichtbaar 
is in conventionele Gd contrast gewogen MRI (CE-MRI), in het bijzonder na 
anti-angiogene therapie, is het van groot belang andere MR methoden te 
ontwikkelen om deze kankers te visualiseren. Met magnetische resonantie spec-
troscopische beeldvorming (‘proton magnetic resonance spectroscopic imaging’, 
1H MRSI) kunnen metabole profielen in relatief kleine voxels worden bepaald. Met 
behulp van deze techniek is het mogelijk om tumor bevattende voxels op basis van 
hun afwijkend metabolisme te identificeren en in kaart te brengen. 1H MRSI is 
superieur aan CE-MRI voor een betrouwbare niet-invasieve evaluatie van de 
therapeutische effecten van anti-angiogene therapie en levert daarnaast 
aanvullende informatie over tumor metabolisme wat benut kan worden voor een 
geïndividualiseerde behandeling. Bovendien bleek met MRSI dat de infiltratieve 
component van glioma’s veel minder glycolyse vertoont dan verwacht op basis van 
het Warburgeffect hoofdstuk 4. 
Naast het gebruik van 1H MRSI is het mogelijk om met fosfor (31P) MRSI op een 
non-invasieve manier inzicht te verkrijgen in de energiehuishouding en het 
vetmetabolisme van een tumor. Met behulp van deze techniek is het mogelijk om 
o.a. verschillende fosfolipide metabolieten te detecteren. We hebben voor het eerst 
31P MRSI op de hersenen van de muis uitgevoerd en daarmee orthotoop groeiende 
tumoren van humane glioma cellen met en zonder mutaties in het enzym isoci-
traatdehydrogenase 1 (IDH1) onderzocht. De tumoren met het gemuteerde IDH1 
vertoonden een specifiek spectraal patroon voor metabolitieten betrokken in het 
fosfolipid metabolisme. De resultaten laten zien dat IDH1 een bijzondere rol heeft 
in dit metabolisme en dat het specifieke spectrale patroon als biomarker kan 
dienen voor de indirecte identificatie van de IDH-status. Dit laatste is van belang 
omdat patiënten met deze mutaties, die zeer vaak voorkomen in klasse II en III 
glioma’s en in secundaire glioblastoma, een betere prognose hebben. 31P-MRS 
metingen kunnen ook bijdragen aan de evaluatie van nieuwe behandelingen van 
de gemuteerde tumoren hoofdstuk 5.
De accumulatie van pimonidazole (PIMO) in weefsel dat een laag zuurstofniveau 
heeft, wordt vaak gebruikt om ‘radiotherapeutische’ hypoxie te identificeren in 
tumoren bij proefdieren. De bepaling vindt ex vivo plaats via immunohistochem-
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ische detectie op uitgenomen weefsel. Om te onderzoeken of het ook mogelijk is 
om hypoxie behalve ex vivo ook in vivo kan worden afgebeeld, hebben we tri-fluor 
PIMO (TF-PIMO) gesynthetiseerd. De fluor spins in dit molecuul kunnen met MR 
gedetecteerd worden. De moleculaire kenmerken van TF-PIMO zijn vergeleken met 
die van PIMO. Beide stoffen vertonen een vergelijkbare (lage) toxiciteit en 
accumulatie in hypoxisch weefsel. We toonden aan dat TF-PIMO middels 19F-MRI 
goed in vivo te detecteren is in hypoxische tumoren (glioma en coloncarcinoma) 
aanwezig in muizen. Daarna konden we hypoxie in het uitgenomen tumorweefsel 
ex vivo vaststellen door het aan te kleuren met een antilichaam volgens het 
reguliere  PIMO protocol. Met TF-PIMO kan dus van hetzelfde weefsel zowel 
macroscopisch in vivo als microscopisch ex vivo de mate van hypoxie worden 
bepaald hoofdstuk 6.
Een relatief lage signaal-ruis verhouding beperkt de gevoeligheid en het oplossend 
vermogen van in vivo MRS. Momenteel worden verschillende nieuwe benaderingen 
om het signaal te versterken middels hyperpolarisatie onderzocht. Wij zijn 
nagegaan in hoeverre met parawaterstof geïnduceerde polarisatie (‘parahydrogen 
induced hyperpolarization’, PHIP) het (N)MR signaal kan worden versterkt. Het 
blijkt dat PHIP drastisch de gevoeligheid van NMR kan doen toenemen. Zo werd 
het  mogelijk om in het aardmagnetisch veld NMR toe te passen op opgeloste 
stoffen bij concentraties en in volumes waarvoor  het normaliter nodig is een veel 
hoger magneetveld te gebruiken. 
NMR met de PHIP methode in het aardmagnetisch veld kon zelfs onder niet-ideale 
omstandigheden worden uitgevoerd (bijvoorbeeld in een gebouw met potentieel 
veld verstorende constructies en met het gebruik van een conventionele RF spoel). 
Het gepresenteerde systeem is een stap in de richting van een algemene en 
eenvoudige benadering om monsters met zeer lage spin hoeveelheden te 
karakteriseren in het aardmagnetisch veld. De techniek heeft daarom ook 
potentieel voor  toepassingen in (pre-)klinische onderzoek hoofdstuk 7.
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